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Abstract 
Meningococcal meningitis from the causative organism Neisseria meningitidis is 
the leading cause of meningitis globally. This bacterium is among a limited 
number of pathogens that have the propensity to cross the blood brain barrier 
(BBB) vasculature causing meningitis. It has been recently demonstrated that 
Neisseria meningitidis targets the laminin receptor (37 LRP/67 LR) on the surface 
of human brain microvascular endothelial cells, and two meningococcal outer 
membrane proteins, PorA and PilQ, have been identified as bacterial ligands. 
Interestingly, this interaction is hypothesized to underlie meningococcal tropism 
for the central nervous system (CNS). There are two isoforms of laminin receptor; 
monomeric 37 kDa laminin receptor precursor (37 LRP) and mature 67 kDa 
laminin receptor (67 LR). The relationship between the 67 LR and its precursor 
37 LRP is not completely understood, but previous observations have suggested 
that 37 LRP can undergo homo- and/or hetero- dimerization with Galectin-3 (Gal-
3) to form mature 67 LR. Gal-3 is the only member of the chimera-type group of 
galectins, and has one C-terminal carbohydrate recognition domain (CRD) that is 
responsible for binding the ß-galactoside moieties of mono- or oligosaccharides 
on several host and bacterial molecules, including neisserial lipooligosaccharide 
(LOS). 
To identify the LOS-independent meningococcal ligands that bind Gal-3, binding 
of lactose liganded Gal-3 and CRD with meningococci was investigated using 
ELISA assay. Neisseria meningitidis bound lactose liganded Gal-3 significantly 
more than H. pylori, which is known to bind Gal-3 via LPS. This binding was not 
inhibited by increasing concentrations of lactose. Also the lactose liganded CRD 
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of Gal-3 bound meningococci but to a lesser extent than full molecule. 
Importantly, binding of Gal-3 was conserved among 25 meningococcal clinical 
isolates tested in the current study. A meningococcal mutant lacking the 
glycosyltransferase required for chain elongation from the core lipid A-(KDO)2-
Hep2 showed reduced binding to lactose-liganded Gal-3, but binding was not 
abolished indicating that the meningococcal-Gal-3 binding was not entirely LOS-
dependant. 
Using a re-tagging approach, meningococcal PilQ and PilE proteins were 
identified as Gal-3 binding ligands. Mutation of the genes encoding either of these 
two molecules in strain MC58 led to a significant reduction in Gal-3 binding. 
PilQ is not known to be glycosylated, therefore its interaction with Gal-3 is likely 
to be protein-mediated. PilE is post-translationally glycosylated and deletion of 
the pilin glycosylation genes pglC and/or pglL dramatically reduced bacterial-
Gal-3 binding.  
Given the binding of meningococcal PilQ to 37 LRP/67 LR and Gal-3, this study 
sought to investigate possible dimerization between 37 LRP and Gal-3 to form 67 
LR. Double immunofluorescence staining of endogenous receptors revealed 
colocalization of 67 LR with its precursor and both of them with Gal-3 in 
HBMECs, astrocyte and COS7 cells. Moreover, co-expression of 37 LRP and 
Gal-3 fused to different fluorescent proteins indicated colocalization of these 
receptors in COS7 cells. Using bimolecular fluorescence complementation (BiFC) 
assays, the presence of 67 LR in homo- and hetero-dimer forms with Gal-3 has 
been confirmed in different cell lines. In addition, the recombinant laminin 
receptor bound Gal-3 and its CRD to comparable level. Further investigation for 
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Gal-3 and 37 LRP dimerization mechanism revealed that the conserved cysteine 
(C173A) within the CRD of human Gal-3, which is known to abolish disulphide-
mediated dimerization of murine Gal-3, is critical for Gal-3 homo- and hetero-
dimerization with 37 LRP, whereas neither of the two cysteines on 37LR (cys148 
and cys163) are required for dimerization. 
To examine the role of Gal-3 in meningococcal interaction with host cells, the 
adhesive and invasive capacities of meningococci were compared between Gal-3 
transfected and non-transfected neuroblastoma cell line (N2a) cells. Transient 
expression of Gal-3 in mouse N2a cells significantly enhanced meningococcal 
invasion when compared with non-transfected cells. Moreover, infection of 
CD46-expressing transgenic mice with meningococcal strain MC58 significantly 
increased the expression of Gal-3 and 37 LRP in the brain.  
This work also attempts to study whether the 37 LRP/67 LR meningococcal 
ligands (rPorA, loop 4 of PorA and rPilQ) have any influence on the surface level 
of 67 LR and Gal-3. As indicated by flow cytometry analysis, recruitments of 67 
LR and Gal-3 to the surface of HBMECs were increased in cells incubated with 
rPilQ, Loop 4 of PorA and more prominently rPorA. To examine these results in 
more detail, effect of each of these ligands on 37 LRP expression was 
investigated using qPCR. Loop4 of PorA and rPilQ induced 37 LRP expression 
significantly more than PBS. Although there was a trend for an increase in 37 
LRP expression with treatment with rPorA, the difference was not statistically 
significant (p = 0.1507). Further investigation in future study for the effect of 
these bacterial adhesins on Gal-3 gene expression will be of great value. 
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Collectively, these data revealed the capacity of Gal-3 to target meningococcal 
PilQ and PilE, as well as the previously known LOS and showed the importance 
of Gal-3 in the meningococcal-host cell interaction. This interaction may be part 
of host-cell defence against the organism, and/or, conversely, it may be part of a 
strategy adopted by the organism to modulate the host response and facilitate its 
invasion. Remarkably, the current findings also demonstrated the existence of 67 
LR as homo- and hetero- dimer with Gal-3. This dimerization of two 
meningococcal host receptors may help to extend spectrum of their bacterial 
adhesins which may act cooperatively or synergistically at different stages of 
infection. Besides, the expression pattern of these receptors may suggest specific 
receptor repertoire in the BBB which might contribute in meningococcal tropism 
for the CNS. 
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1. Chapter 1: General introduction 
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1.1. Bacterial meningitis 
Bacterial meningitis is the most common type of bacterial infection in the central 
nervous system (CNS) and one of the top ten infectious causes of death 
worldwide (WHO, 2004).  
1.2. Definition 
Bacterial meningitis is defined as an inflammation of the meninges, the 
membranes surrounding the brain and spinal cord. It causes an infection of the 
pia, the arachnoid and the CSF (cerebro spinal fluid), which results in 
leptomeningeal inflammation. 
1.3. Aetiology 
The majority of cases are caused by Streptococcus pneumoniae, Haemophilus 
influenzae and Neisseria meningitidis (Somand & Meurer, 2009). Other bacteria, 
such as E. coli K1, group B streptococci and Listeria monocytogenes, can also 
cause meningitis. Importantly, Neisseria meningitidis is known to be the leading 
cause of meningitis globally (Kim, 2008). 
1.4. Historical background of meningococcal disease 
Meningococcal disease, which is known as cerebrospinal fever, was first reported 
by Vieusseux in 1805 in the city of Geneva (de Souza & Seguro, 2008). After 
this, several outbreaks of a similar disease were reported in different countries (de 
Souza & Seguro, 2008). However, it was not until 1887 that the Austrian 
pathologist Anton Weichselbaum elucidated the aetiological nature of 
meningococcal disease by demonstrating for the first time that there was a 
connection between bacteria (at that time it was known as Diplococcus 
intracellularis meningitidis) and epidemic cerebrospinal meningitidis (de Souza & 
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Seguro, 2008). Eventually, the name of the bacteria was changed to N. 
meningitidis, after the German scientist and clinician Alberet Neisser, who 
discovered the related bacteria, Neisseria gonorrhoeae (the gonococcus) 
(Ala'Aldeen, 2006). 
1.5. Cultural and biochemical characteristics of N. meningitidis 
N. meningitidis (meningococcus) is a Gram-negative, oxidase and catalase 
positive, non-sporing, aflagellate, aerobic diplococcus of approximately 0.8 µm in 
diameter. Meningococci belong to the genus Neisseria in the family 
Neisseriaceae. This genus consists of 19 species of commensal Gram-negative 
bacteria that colonize the mucous membranes of many mammals. 15 of these are 
human originated species and only two are pathogenic: Neisseria meningitidis and 
Neisseria gonorrhoeae (Ala'Aldeen, 2006; Lee et al., 2010). The rest of the 
Neisseria species, such as N. lactamica and N. polysaccharea, are commensal 
bacteria that may cause disease in immunocompromized patients (Ala'Aldeen, 
2006). 
N. meningitidis is a fastidious microorganism that requires enriched media to 
grow in, including blood, chocolate, the modified New York City medium and 
Muller-Hinton agar (Ala'Aldeen, 2006). Colonies of N. meningitidis are 
transparent, non-haemolytic, non-pigmented and convex. Optimally, 
meningococcus grows at 35-37°C in a moist environment containing 5-10% CO2 
at pH 7.0-7.4 (Ala'Aldeen, 2006).  
1.6. Genetic characteristics of N. meningitidis 
Up to now, the complete genome sequence of N. meningitidis serogroup A (strain 
Z2491), B (strain MC58) and C (strains FAM18 and 053442) has been reported 
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(Bentley et al., 2007; Parkhill et al., 2000; Tettelin et al., 2000). An analysis of 
the sequence has revealed that the average genome size for these strains is 2.2 
megabase pair (Mbp) with an average G + C content of 51% (Tettelin et al., 
2000). 
Meningococcal genomes have several distinguishing characteristics, including the 
presence of the repetitive DNA element, a high level of genome fluidity and a 
high capacity for phase variation. Regarding the first characteristic, the repetitive 
DNA sequences within the meningococcal genome range in size from short 
(10bp) sequences, which are involved in DNA uptake, to large (39 kb) gene 
duplications and prophage sequences (Ala'Aldeen, 2006). In addition, the 
neisserial genome possesses highly repetitive small nucleotide sequences, known 
as Correia elements, which have transposon-like properties (Siddique et al., 
2011).   
The second characteristic of the meningococcal genome is its high fluidity, which 
results from different mechanisms involving natural transformation, horizontal 
gene transfer, recombination and spontaneous mutation (Schoen et al., 2007). 
This characteristic enables the bacteria to adapt to different environmental 
changes. In this context, the chromosomal DNA of MC58 is larger than that of 
strains Z2491 and FAM18 by almost 100 kb (Schoen et al., 2007). This is due to 
the acquirement of two horizontal genomic islands of 17.1 kb and 32.6 kb and the 
duplication of the 30 kb coding sequence (Schoen et al., 2007).  
Finally, many of the N. meningitidis genes (more than 60) are subject to a phase 
variation process (Ala'Aldeen, 2006). In this process, the translational or 
transcriptional control of the expression reversibly switches the gene expression 
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on and off or changes the level of gene expression, respectively (Virji, 2009). 
Phase variation is considered to be one of the mechanisms that is used by 
meningococcus to evade the immune system (Virji, 2009). 
1.7. Epidemiology of meningococcal disease 
Despite the availability of effective vaccines, therapeutic choices and the 
sensitivity of the N. meningitidis to several antibiotics, a significant number of 
patients either die of the disease or suffer long-term neurological complications 
such as epilepsy, neurological damage and deafness (Dawson et al., 1999; 
Grimwood et al., 2000). Out of the estimated 500,000 cases, 50,000 deaths are 
thought to occur annually worldwide (Girard et al., 2006). N. meningitidis is 
classified into 13 serogroups based on immune specificity and the structure of 
capsular polysaccharide; however, only six of them cause invasive disease 
(serogroups A, B, C, W-135, X and Y) (Stephens et al., 2007). It is also classified 
into 20 serotypes and 10 serosubtypes based on the outer membrane porins (PorB 
and PorA), respectively, and into different immunotypes depending on its LPS 
(lipopolysaccharide) (Frasch et al., 1985). In addition, variations in seven 
housekeeping genes are used to classify the meningococcal strain into STs 
(sequence types) using MLST (multi-locus sequence typing) (Brehony et al., 
2007).  
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Figure 1.1: Worldwide distribution of invasive meningococcal disease. 
Worldwide distribution of major meningococcal serogroups and outbreaks of serogroup 
B by serotype (shaded in purple). The meningitis belt (dotted line) of Sub-Saharan Africa 
and other areas of substantial meningococcal disease in Africa are shown. Reproduced 
from (Stephens et al., 2007). 
N. meningitidis serogroup A is the most common cause of meningococcal disease 
in what is known as the African Meningitis Belt and some areas of Asia (Schoen 
et al., 2007). The African Meningitis Belt is a region in Africa that expands from 
Senegal to Ethiopia and it has a high rate of meningococcal disease (Figure 1.1), 
while the meningococci serogroups B and C are responsible for the majority of 
cases in Europe and the United States (Stephens et al., 2007). Meningococcal 
disease caused by serogroup Y has emerged recently in the United States (Schoen 
et al., 2007). Meningococcal serogroup W135 accounted for large outbreaks 
among Hajj pilgrims in Saudi Arabia in 2000 and 2001 and also in Burkina Faso 
in 2002 (Schoen et al., 2007). 
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1.8. Virulence factors of N. meningitidis  
In this section, the most important meningococcal virulence factors that have been 
utilized by bacteria to develop the infection or evade the immune system will be 
highlighted and illustrated in a schematic presentation (Figure 1.2).  
 
Figure 1.2: Prominent outer membrane components of N. meningitidis that 
influence bacterial interaction with host cells. (A) Pili traverse the capsule and are 
the most prominent adhesions of encapsulated N. meningitidis. In addition, the integral 
outer membrane (OM) adhesions, Opa and Opc, are also known to mediate interactions 
with specific host cell receptors. LPS may interfere with the adhesion functions of OM 
proteins, but can also contribute to cellular interactions by interacting with various 
cellular receptors. (B) A cross-section of a pilus fibre showing that variable domains (V) 
and glycans (G) as well as other substitutions (not shown) are located externally, whereas 
the constant domains are buried within the fibre and protected from the host environment. 
Reproduced from (Virji, 2009). 
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1.8.1. Capsule  
The polysaccharide capsule is considered to be one of the major virulence factors 
for N. meningitidis, as the majority of meningococci isolated from patients 
infected by invasive meningococcal disease are capsulated and express capsules 
belonging to serogroups A, B, C, Y and W-135 (Stephens et al., 2007). In 
serogroups B, C, Y and W-135, WKHFDSVXOHV¶VWUXFWXUHVDUHFRPSRVHGRISRO\PHUV
of sialic acid (N-acetylneuraminic acid, NANA) derivatives (Ala'Aldeen, 2006). 
The composition of sialic acid in meningococcal capsules differs among 
VHURJURXSV WKH VHURJURXS % FDSVXOH FRQVLVWV RI Įĺ-linked NANA, the 
VHURJURXS&FDSVXOHFRQVLVWVRIĮĺ-linked NANA, the serogroup Y capsule 
consists of alternating D-glucose and NANA and the serogroup W-135 capsule 
consists of D-galactose and NANA (Ala'Aldeen, 2006). On the other hand, the 
serogroup A capsule is non-sialyated and consists of N-acetyl mannosamine 
residues (Ala'Aldeen, 2006). Sialylation of meningococcus capsules provides a 
protective mechanism for the bacteria against the host immune system, since 
sialic acid exists on the host cell surface (Hill et al., 2010). In the context of 
molecular mimicry, only the serogroup B capsule of N. meningitidis is similar in 
structure to a component of the human NCAM (neural cell-adhesion molecule). 
Because of this similarity, the meningococcal serogroup B capsule is poorly 
immunogenic and this is considered to be one of the obstacles for vaccine 
development (Diaz Romero & Outschoorn, 1994). The meningococcal capsule 
also has anti-phagocytic and anti-bactericiadal activities through the prevention of 
complement activation and antibody recognition, which enables bacterial survival 
in the blood stream and CSF (Nassif, 1999). It is not only the infection process 
that the meningococcal capsule is involved in; it also promotes meningococcal 
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transmission by hindering bacterial attachment to the respiratory mucus 
membrane, facilitating bacterial spreading from one person to another. It also acts 
as a hydrating shield that protects bacteria from environmental factors such as 
desiccation during transmission (Diaz Romero & Outschoorn, 1994). 
The cps locus is responsible for meningococcal capsular expression, which 
consists of the genes required for the biosynthesis and polymerization of the 
polysaccharide, and surface translocation (Frosch et al., 1989). N. meningitidis 
has the ability to switch capsule type through the horizontal transfer of the siaD 
gene in the cps region. This phenomenon has been reported by previous studies 
where meningococci switch capsules from serogroups B to C, Y to B and C to W-
135 (Beddek et al., 2009; Tsang et al., 2005). In addition, meningococcal capsular 
expression is subject to reversible on/off phase variation. This results from 
slipped strand mispairing (SSM) and the reversible insertion of mobile elements 
(Hammerschmidt et al., 1996; Hill et al., 2010). 
1.8.2. Lipooligosaccharide (LOS) 
As opposed to other Gram-negative bacteria, meningococcal LPS lacks an O-
antigen repeating unit; thus it is known as an LOS (Kahler & Stephens, 1998). It 
is composed of inner and outer oligosaccharide cores attached to lipid A (Figure 
1.3) (Jennings et al., 1999). As demonstrated in Figure 1.3, the inner core 
comprises two heptoses (HepI and HepII) linked to lipid A by one of the two 
KDOs (2-keto-3-deoxy-d-manno-2-octulosonic acids), and the outer core consists 
of variable lengths of oligosaccharides extending from the HepI UHVLGXHWRIRUPĮ
and ß chains (Jennings et al., 1999). The outer core extension of meningococcal 
LOS is regulated by glycosyltransferases that are encoded by lgt genes (Figure 
  
10 
 
1.3) (Jennings et al., 1999). Meningococcal lipid A and the inner core are 
embedded in the cell membrane while variable oligosaccharide chains are surface 
exposed. 
 
Figure 1.3: Representation of the structure of N. meningitidis LOS. The 
meningococcal LOS consists of lipid A and inner and outer cores. Variations in both the 
+HS,Į-FKDLQH[WHQVLRQV*OF*DO*OF1$F*DODQGVLDOLFDFLGDQGWKH+HS,,ȕ-chain 
extensions (GlcNAc, PEA and Glc) determine the different immunotypes of LOS. TKHĮ-
chain structures of the L3, L7 and L8 immunotypes are shown. The genes encoding the 
glycosyltransferases responsible for outer core extension are indicated as lgt A, B, E and 
F (Jennings et al., 1999). The addition of PEA in the indicated position of Hep II is 
mediated by enzymes encoded by lpt3 and lpt6. Sialylation of terminal galactose in 
LNnT residue is mediated by WKHSURGXFWRIWKHOVWJHQHWKHĮ-2,3-sialyltransferase. The 
Į-chain structures of the L3, L7 and L8 immunotypes are indicated. The residues are as 
follows: Kdo is 2-keto-3-deoxy octulosonic acid, Hep is L-glycero-D-manno heptose, 
Glc is glucose, Gal is galactose, GlcNAc is 2-acetamido-2-deoxy-glucose and PEA is 
phosphoethanolamine. Reproduced from (Hill et al., 2010). 
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According to the composition of the outer core oligosaccharides, meningococci 
are classified into 12 immunotypes, designated by L1-L12 (Mandrell & Zollinger, 
1977). Some of these immunotypes, such as L2-5, L7 and L9, have a lacto-N-
neotetraose motif (LNnT: galactose, N-acetylglucosamine, galactose and glucose) 
in the chain of variable glycan moiety linked to the Hep I residue (Figure 1.3) 
(Jennings et al., 1995). LNnT mimics human antigens expressed on human 
erythrocytes, thus facilitating bacterial evasion from the immune system. 
Interestingly, invasive meningococcal isolates have LNnT in their LOS but not 
carriage isolates (Scholten et al., 1994). In addition, LNnT acts as an acceptor for 
sialic acid; thus some meningococci bearing LNnT in their LOS are subjected to 
sialylation addition of sialic acid to the terminal galactose residue of LNnT 
(Gilbert et al., 1996). Importantly, the sialylation of meningococcal LOS 
enhances bacterial resistance to the complement-mediated bactericidal activity 
and to opsonophagocytosis by means of human neutrophils (Estabrook et al., 
1997; Vogel et al., 1997). 
Like the meningococcal capsule, LOS is also subject to phase variation, mainly in 
the gene encoded enzymes responsible for the extension of sugar chains. For 
example, immunotype L8 results from phase variation in the lgtA gene (Figure 
1.3) (Jennings et al., 1999). Such variations change the antigenic properties of the 
LOS and allow switching between immunotypes (Hill et al., 2010; Jennings et al., 
1999). 
Lipid A of meningococcal LOS is responsible for the stimulation of inflammatory 
cytokine release during sepsis (Brandtzaeg et al., 2001). In addition, an in vitro 
study has found that LOS is toxic for human endothelial cells (Dunn et al., 1995). 
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Of interest, the observed LOS toxicity is enhanced by the pili, revealing a 
cooperative mechanism between the LOS and pili to induce signalling in 
endothelial cells (Dunn et al., 1995). 
1.8.3. Type 4 pili 
Neisseria meningitidis has hair-like projections that extend beyond the capsule, 
known as pili (Strom & Lory, 1993). Meningococcal pili belong to the Type 4 pili 
(T4p) family that undergo a rapid cycle of extension and retraction. They are thin 
(4-6 nm in diameter) and flexible and can extend several micrometres in length 
from the bacterial surface and can also aggregate laterally to form bundles of pili 
(Mattick, 2002).  
Meningococcal pili initiate bacterial adhesion to epithelial and endothelial cells 
(Pujol et al., 1997). It has been suggested (Kallstrom et al., 1997) that CD46, a 
PHPEUDQH ERXQG FRPSOHPHQW &¶ UHJXODWRU LV WKH KRVW FHOO UHFHSWRU IRU 7S
However, another study (Kirchner et al., 2005) has reported CD46-independent 
adhesion , which necessitates further investigation of T4p initial adhesion to the 
host cell.  
There are other multiple functions mediated by neisserial T4p, including 
twitching motility and DNA uptake during transformation (Mattick, 2002). In 
addition, it has been shown that the interaction of N. meningitidis T4p with the 
host cell leads to an induction of the signal transduction pathway, and increases 
the calcium level (Kallstrom et al., 1998).  
Recently, 15 proteins, designated pilC-pilX and ComP, have been identified as 
being involved in the pilus biogenesis through systemic genetic analyses (Virji, 
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2009). The structural model of meningococcal pili is based on the reported crystal 
structure of the related gonococcal (GC) pilus filament (Craig et al., 2006). The 
biogenesis of the T4p is resolved in four steps: assembly, functional maturation, 
emergence on the cell surface and counter-retraction (Figure 1.4). In this review, 
pilus biogenesis will be described briefly (Figure 1.4), and the focus will be on 
Type IV pili components, which have been reported to be involved in 
meningococcal-host interaction. 
 
Figure 1.4: Implication of the N. meningitidis pili components in the different 
steps of T4p biogenesis fibre assembly, functional maturation and counter 
retraction of fibres, retraction powered by the PilT protein and emergence of 
the fibres on the cell surface. At the inner membrane-periplasm interface, the pilin 
subunits (PilE) are assembled from a platform complex (PilD, PilF, PilM, PilN, PilO and 
PilP) and the growing fibre is translocated to the cell surface via the secretin (PilQ). It has 
been recently demonstrated that PilP, which co-purifies with the inner membrane, 
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interacts with PilQ. Two inner membrane ATPases, PilF and PilT, promote pilus 
elongation and pilus retraction, respectively. Different components are required to 
counteract pilus retraction (PilC1/C2, PilG, PilH, PilI, PilJ, PilK and PilW). PilC1/C2 and 
PilW are located in the outer membrane whereas PilG is in the inner membrane. Some 
components are important for pilus function (PilC1, PilW, PilI, PilJ, PilK, PilX, PilV and 
ComP). Among the minor pilin components (PilH, PilI, PilJ, PilV, PilX and ComP), 
PilV, X and ComP are incorporated into the fibre. Adapted from (Carbonnelle et al., 
2009). 
 
1.8.3.1. PilE 
PilE is the major pilus subunit, the pilin, which is arranged in a helical 
configuration to form pilus fibre (Craig et al., 2006). Neisserial pilins are encoded 
by the pilE gene, which is subject to antigenic variation as a result of a genetic 
recombination with one or more of the truncated silent pilin genes (pilS) (Segal et 
al., 1986).  
First, pilin is synthesized as a precursor (prepilin) in the cytoplasm, which is 
inserted into the inner membrane by the Sec machinery. The N-terminal leader 
sequence (first seven amino acids) is cleaved by the inner membrane prepilin 
peptidase (PilD) in order to generate the mature pilin (Strom & Lory, 1993) 
(Figure 1.4). The resulting mature pilin, which is approximately145-160 amino 
acids in length, is also methylated at the N-terminal phenylalanine by PilD; 
however, a lack of methylation does not appear to have a dramatic effect on the 
pilus assembly (Pepe & Lory, 1998). At the inner membrane, the processed PilE 
subunits are assembled into a helical filament by complex machinery consisting 
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ATPase PilF (Carbonnelle et al., 2006). T4p emerge at the surface via outer 
membrane secretin PilQ. Another cytoplasmic ATPase protein called PilT powers 
pilus retraction (disassembly) to counteract the pilus extension (assembly) 
mediated by PilF (Wolfgang et al., 1998) (Figure 1.4). The remainder of the 15 
proteins mentioned earlier as being involved in pilus biogenesis play a role after 
pilus assembly by antagonizing pilus retraction (Carbonnelle et al., 2006). 
The crystal structure of highly homologous PilE from N. gonorrhoeae (Figure 
1.5) has been resolved (Craig et al., 2006); therefore, it has been predicted that all 
T4p pilins, including meningococcal pilin, have fairly similar structures. Based on 
a crystal structure study of GC pilin, PilE protein is elongated and is ladle shaped 
(Figure 1.4A) (Craig et al., 2006). The PilE structure is composed of a conserved 
N-WHUPLQDOĮ-KHOL[VXUURXQGHGE\ȕVKHHWVDQGDK\SHUYDULDEOH&-terminal (blue 
LQ)LJXUH7KHKHOL[NQRZQDVĮLVGLYLGHGLQWRWZRSDUWVWKHK\GURSKRELF
N-WHUPLQDOKDOIĮ-N) protrudes from the protein and the C-WHUPLQDOKDOIĮ-C). 
7KHĮ-C has two faces: a hydrophobic face, which is surrounded by four anti-
SDUDOOHO VWUDQGHG ȕ VKHHWV WR IRUP WKH JOREXODU GRPDLQ DQG D K\GURSKLOLF IDFH
which is embedded in the assembled pilus (Craig et al., 2006). The globular head 
domain is conserved and flanked by two variable regions that are exposed at the 
VXUIDFHWKHĮȕORRSFRQQHFWVĮZLWKWKHȕVKHHWVDQGWKH'-region contains two 
conserved cysteine residues, which form a disulphide bond, linking the C-
WHUPLQDO WR WKH ȕ VKHHWV 7ZR SRVW-translational modifications, a 
phosphethanolamine and a disaccharide, can be seen LQWKHĮȕORRSRI3LO(ZKLFK
will be described below. The disulfide bridge in the D-region is involved in the 
formation of the surface accessible, variable and immune dominant part of the 
pilus (Craig et al., 2006; Philippe C morand, 2006; Schaechter, 2009).   
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It is worth noting that N. meningitidis produces two types of pilins, known as 
class I and class II pilins (Virji et al., 1989). Class I pilins are recognized by their 
immunoreactivity to the monoclonal antibody SM1, which is specific for epitopes 
49-53 of N. gonorrhoea strain MS11 pilin, whereas Class II pilins are not (Virji et 
al., 1989).   
 
Figure 1.5: Full-length gonococcal (GC) pilin crystal structure and sequence 
alignment with MC pilin. (A) X-ray crystal structures of full-length N. gonorrhoeae 
*&SLOLQ7KHĮ-loops are coloured green and the D-regions are coloured magenta. The 
conserved regions among the type IV pilins (grey), including the extended N-terminal Į-
helix Į (comprised of Į-N and Į-C), the ß sheet and the disulfide-bonded cysteines 
A B
C
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(cyan), plus the structurally variable D region (pink) and the Į-loops (green) with the 
disaccharide Gal-DADDGlc at Ser63 and phosphoethanolamine (PE) at Ser68. (B) 
Schematic representation of the pilins, indicating the relevant regions and residues. (C) 
Sequence alignment of GC (N. gonorrhoeae strain C30) and MC (N. meningitidis MC58) 
pilin with the identical (orange) and conserved (yellow) residues highlighted. The 
structural features of GC pilin are shown as follows: disulfide cysteines, cyan; Ser63 
disaccharide, green arrowhead; Ser68 phosphoethanolamine, orange arrowhead; Ser69 
and Thr71 sequence differences from the previous structure, asterisks; ß strands, arrows; 
Į loop, green bar; and D region with hypervariable loop (pink and magenta bars, 
respectively). Reproduced from (Craig et al., 2006; Craig & Li, 2008). 
 
Post translational modification of PilE 
Meningococcal PilE is known to be post-translationally modified at several serine 
residues by O-linked JO\FRV\ODWLRQ DW SRVLWLRQ  DQG Į-glycerophosphate at 
position 93 (Stimson et al., 1995; Virji et al., 1993b; Virji, 1997). In addition, 
substitutions of residue at position 68 with phosphate, phosphoethanolamine or 
phosphorylcholine have been reported (Hegge et al., 2004; Weiser et al., 1998). 
Previous studies have suggested that pilin glycosylation is involved in influencing 
bacterial cellular interaction, perhaps by affecting the agglutination of bacterial 
pili (Stimson et al., 1995; Virji et al., 1993b). It has also been suggested that pilin 
glycosylation might promote the secretion of the soluble pilin, called S pilins, 
since no production of S pilins was observed with the meningococcal strain 
producing non-glycosylated pilin (Marceau et al., 1998). Secreted pilins are not 
assembled into pili and could have functions in immune diversion and/or adhesion 
(Marceau et al., 1998). Glycosylation also can be involved in the interaction of 
the bacteria with the immune system, as suggested by a previous study (Hamadeh 
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et al., 1995), where complement mediated lysis was shown to be interfered by a 
naturally occurring antibody directed against the terminal galactose of 
meningococcal PilE. 
The modification of meningococcal pilin with glycans is regulated by a pgl (6-
phosphogluconolactonase) gene cluster, which is initially identified by sequence 
homology searches (described in Chapter 3). Although the genetics of glycan 
biosynthesis, modification and transfer to protein have been described, 
polymorphisms and the phase variation of protein glycosylation enzymes 
contribute to the observed variations in the glycan structure of PilE (Power et al., 
2003).  
Over and above the glycosylation at position 63, meningococcal pilin is modified 
by phosphorylcholine or phosphoethanolamine at position 68. Such modifications 
have the potential to affect cellular interactions and immune recognition owing to 
their alteration of the charge in the substituted position of PilE (Virji, 2009). The 
presence of phosphorylcholine on the bacterial surface may lead to bacterial 
clearance by promoting their targeting by CRP (C-reactive protein) and anti- 
phosphorylcholine antibodies. In addition, phosphorylcholine resembles the 
platelet activating factor, which might enhance bacterial adhesion by binding to 
the PAF (platelet-activating factor) receptor and neutralizing the host 
antimicrobial peptide in the nasopharynx (Lysenko et al., 2000). It is interesting 
to note that, in commensal Neisseria species and H. influenzae, phosphorylcholine 
is attached to the LPS not the pili (Serino & Virji, 2002; Weiser et al., 1997). 
Both phosphorylcholine and phosphoethanolamine are added to the Neisserial 
pilins by a single pilin phosphor-form transferase enzyme (PptA).  
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Recently, the enzyme responsible for the addition of phosphoglycerol to the 
meningococcal pilin at serine 93 has been identified, which is the pilin 
phosphotransferase B (PptB) (Chamot-Rooke et al., 2011). Interestingly, the 
expression of PptB is found to be upregulated during the attachment of 
meningococci to the host cells, which increases the addition of phosphoglycerol 
to PilE and leads to the separation of the bundled pili into single strands (Chamot-
Rooke et al., 2011). Such an increase in pilin modifications results in a loss of 
bacterial aggregation and allows bacterial migration across the host cells and 
dissemination to other hosts (Chamot-Rooke et al., 2011). 
1.8.3.2. PilQ 
The PilQ secretin is required for the extrusion and retraction of N. meningitidis 
T4p (Carbonnelle et al., 2006; Drake & Koomey, 1995). It is a member of the 
secretin family of outer membrane proteins with conserved C-terminals that are 
involved in type II secretion, including type IV pilus biogenesis and type III 
secretion (Genin & Boucher, 1994). PilQ forms a multimeric ring-like structure as 
revealed by the transmission electron microscopy (TEM) examination of purified 
protein (Collins et al., 2004; Frye et al., 2006). PilQ secretin oligmer is composed 
of 12 identical monomers, forming pores through which pilus are extruded 
(Collins et al., 2004; Frye et al., 2006). Three features distinguish meningococcal 
PilQ from other bacterial secretins: its abundance in the outer membrane, the sole 
secretin in N. meningitidis and the presence of an octapeptide repeat 
PAKQQAAA, called a small basic repeat (SBR), in its N- terminal (Tonjum et 
al., 1998).  
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In a recent study, meningococcal PilQ has been identified as an adhesin for 
laminin receptor 37 LRP/67 LR (Orihuela et al., 2009). 
1.8.3.3. PilC 
It has been suggested that meningococcal PilC is located at the tip of T4p (Rudel 
et al., 1995). The PilC protein plays a crucial role in pilus expression on the 
bacterial surface, transformation competence and adhesion to human cells (Nassif 
et al., 1994). Two PilC variants, known as PilC1 and PilC2, have been found to be 
expressed by meningococci (Jonsson et al., 1995). Although both variants of PilC 
mediate bacterial piliation and transformation competence only PilC1 is found to 
be involved in bacterial adhesion to endothelial and epithelial cells (Nassif et al., 
1994; Ryll et al., 1997). In contrast, a recent study reported by Morand et al. 
(2009) showed that PilC2 also mediates meningococcal adhesion; however, both 
versions of PilC display different effects on the host cells (Morand et al., 2009).  
1.8.3.4. Prepilin-like proteins 
The major subunit of T4p, PilE, has a hydrophobic N-terminal, which is involved 
in the polymerization of the pilin subunit to form T4p fibre, as mentioned earlier. 
There are seven proteins in pathogenic Neisseria, which share the same N-
terminal domain of PilE and are termed prepilin-like proteins: PilH, PilI, PilJ, 
PilK, ComP, PilV and PilX (Koomey, 1995). Among the prepilin-OLNHSURWHLQV¶
ComP, PilV and PilX, which have canonical PilD cleavage motifs and mature 
lengths similar to PilE, play a role in T4p related function but not directly in pilus 
biogenesis. ComP was the first pre-pilin protein to be identified and it is 
important for DNA transformation (Wolfgang et al., 1999). PilV is involved in 
the modulation of bacterial adhesion to epithelial cells (Winther-Larsen et al., 
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2001). Based on the fact that both PilC and PilV can be copurified with T4p and 
that purified T4p from the PilV null mutant reduces the level of PilC, it has been 
suggested that the role of PilV in adhesion is mediated via the functional display 
of PilC in the pilus (Philippe C morand, 2006; Winther-Larsen et al., 2001). 
Recently, PilV has been shown to be involved in meningococcal resistance to 
shear stress forces through the induction of cholesterol recruitment to form 
cortical plaques in the endothelial cells (Mikaty et al., 2009). PilV also 
antagonizes ComP transformation competence and modulates the level of 
phosphorylcholine or phosphoethanolamine in the pili (Aas et al., 2002; Hegge et 
al., 2004).  
Meningococcal PilX is necessary for bacterial aggregation and adhesion (Helaine 
et al., 2005). The abolition of PilX leads to a loss of bacterial autoaggregation 
ability, which subsequently affects bacterial adhesion to the host cell. 
1.8.4. Major outer membrane proteins  
1.8.4.1. PorA and PorB  
Two distinct porins, PorA (class 1 protein) and PorB (class 2 or class 3 protein) 
are expressed by N. meningitidis3RULQVDUHȕ-barrel proteins that assemble into 
trimer forming pores in the bacterial outer membrane. These pores regulate the 
exchange of ions between the bacteria and the surrounding environment. PorA is 
approximately a 45 kDa protein, highly cation-selective and composed of 16 
WUDQVPHPEUDQHȕ-strands and 8 surface-exposed loops (van der Ley et al., 1991). 
Some variability of PorA sequence has been shown among meningococcal strains, 
mainly owing to the surface-exposed loops 1 and 4 (variable regions) (van der 
Ley et al., 1991). PorB is expressed as PorB1 (׽41 kDa) or PorB2 (׽38 kDa), the 
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expression of which is mutually exclusive and anion-selective and has a similar 
transmembrame loop structure to that of PorA (Minetti et al., 1997; Minetti et al., 
1998). Meningococcal PorB2 and PorB3 show sequence similarity with N. 
gonorrhoeae Por1B and Por1A, respectively (Derrick et al., 1999). Unlike PorB, 
there is no homology of PorA expressed in gonococci (Feavers & Maiden, 1998). 
Meningococcal PorA has been shown to interact with the complement regulator 
C4b-binding protein (C4bp), inhibiting complement activation, which 
subsequently enhances meningococcal serum resistance (Jarva et al., 2005). 
However, poly sialic acid capsules reduce the C4bp-PorA binding by 50% (Jarva 
et al., 2005). In addition, the involvement of PorA and PorB in bacterial entry has 
been suggested through the rearrangement of the cytoskeleton (Nassif et al., 
1999). Neisserial porins also are able to stimulate B-cells through TLR2 (toll-like 
receptor 2) in a MyD88 dependent pattern (Massari et al., 2002). Moreover, 
meningococcal PorB has been shown to interact with mitochondria and protect 
host cells from apoptotic stimuli (Massari et al., 2000). Interestingly, laminin 
receptor 37 LRP/67 LR has been shown to target meningococcal PorA (Orihuela 
et al., 2009).  
1.8.4.2. Opacity proteins 
Two types of meningococcal outer-membrane proteins, Opa and Opc, impart an 
opaque phenotype to agar-grown colonies (Hill et al., 2010). Opa and Opc, 
initially known as class 5 proteins, have similar molecular weights (27-31 kDa) 
but share a very limited sequence homology. Meningococci express three to four 
Opa proteins, while gonococci possess up to 12 Opa genes (Aho et al., 1991). 
Opa protein has eight transmembrane domains arranged in ȕ-parallel strands and 
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four surface-exposed loops. Three of these loops are highly variable within and 
among different N. meningitidis strains (Malorny et al., 1998). The gene encoding 
Opa is subjected to phase variation via different mechanisms: SSM, point 
mutations, insertion and deletion (Aho et al., 1991; Hill et al., 2010; Malorny et 
al., 1998).  
Opc expression only occurs in meningococci and Opc is encoded by a single 
opcA gene (Zhu et al., 1999). The expression of Opc is phase variable through 
transcriptional regulation (Sarkari et al., 1994). Structurally, Opc is also a b-
barallel protein that consists of 10 transmembrane domains producing five surface 
exposed loops (Zhu et al., 1999).  
It is worth noting that the opacity proteins play an important role in 
meningococcal±host interaction (Hill et al., 2010; Virji, 2009). In this context, 
Opa binds carcinoembryonic antigen-related cell-adhesion molecules 
(CEACAMs) family and heparan sulfate proteoglycans (HSPGs) (Virji et al., 
1996; Virji et al., 1999). Like Opa proteins, Opc interacts with HSPGs and it also 
binds the extracellular matrix (ECM), such as fibronectin, vitronectin and integrin 
(Unkmeir et al., 2002; Virji et al., 1994; Virji et al., 1995).  
1.8.5. Minor adhesins of N. meningitidis  
There are other minor adhesins that have been recently identified as a result of N. 
meningitidis genome sequencing, including NadA (Neisserial adhesinA), NhhA 
(Neisseria hia homologue A), App (adhesion and penetration protein) and MspA 
(meningococcal serine protease A). NadA belongs to the oligomeric coiled-coil 
adhesin (OCA) family of adhesins and interacts with human epithelial cells using 
an as yet unknown receptor (Capecchi et al., 2005). Interestingly, approximately 
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50% of disease isolates express NadA compared with ׽5% of carriage isolates 
(Comanducci et al., 2004).  
Both NhhA and App are homologous to the autotransporter proteins Hsf/Hia and 
Hap of H. influenzae, respectively. NhhA is expressed in most meningococcal 
disease isolates (Pizza et al., 2000). It has been reported that the NhhA mediates a 
low level of adhesion to epithelial cells, HspGs and laminin (Scarselli et al., 
2006). Both pathogenic and commensal Neisseria spp. express App (Serruto et 
al., 2003). Before App autocleavage, it helps in bacterial colonization and, after 
cleavage, in bacterial detachment and subsequent spreading (Serruto et al., 2003). 
MspA is homologous to App, which is expressed by several but not all virulent 
meningococcal strains, and it is reported to support bacterial adhesion and 
invasion into epithelial and endothelial cells (Turner et al., 2006). 
1.9. Pathogenesis 
Various steps in EDFWHULDíKRVW LQWHUDFWLRQ DUH LQYROYHG LQ WKH GHYHORSPHQW RI
bacterial meningitis. These consist of adhesion to the host, mucosal colonization 
of the upper respiratory tract, bacterial invasion of the intravascular space and 
survival/multiplication in the blood stream, resulting in bacteraemia (Hill et al., 
2010; Somand & Meurer, 2009). Pathogens then cross the blood brain barrier 
(BBB), survive and multiply in the subarachnoid space, which induces host 
inflammatory responses and pathophysiological changes such as pleocytosis and 
BBB disruption (Kim, 2008).  
1.9.1. Colonization and penetration of the respiratory mucosa 
N. meningitidis lives commensally in the nasopharynx, which serves as a reservoir 
for and source of meningococcal infection. The transmission of meningococci 
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from one person to another can occur by direct contact or respiratory droplets 
(Stephens & Farley, 1991). Virtually, meningococci are transmitted as 
encapsulated bacteria in order to enhance WKHEDFWHULD¶VDELOLW\WRVXUYLYHRXWVLGH
the host (Diaz Romero & Outschoorn, 1994). Colonization of the upper 
respiratory mucosal surface by N. meningitidis is the first step in the 
establishment of a human carrier state and invasive meningococcal disease 
(Stephens, 2009). To avoid the bacteria being washed by mucous, the firm and 
fast adhesion of bacteria to mucosal epithelial cells is assumed to be crucial (Hill 
et al., 2010). Type IV pili (T4p), which extend beyond the capsule, initiate the 
binding of encapsulated meningococci to non-ciliated epithelial cells 
(Scheuerpflug et al., 1999). It has been suggested that this initial attachment is 
mediated by the recognition of PilC by the CD46 receptor on the epithelial cells 
(Kallstrom et al., 1997). However, CD46-independent adhesion has been reported 
by another study (Kirchner et al., 2005). For efficient initial attachment, 
meningococci multiply and auto-aggregate with each other through pilus±pilus 
(PilX-PilX) interactions on the cell surface, forming tightly associated 
microcolonies (Merz & So, 2000). After the initial attachment, downregulation of 
T4p, dispersion of microcolonies and spreading of bacteria on the cell surface as a 
monolayer take place to initiate closer adhesion (Pujol et al., 1997). Both T4p 
downregulation and microcolony dispersal have been attributed to ATPase PilT 
(Pujol et al., 1999). Moreover, the expression of meningococcal capsules is 
downregulated (Deghmane et al., 2002), allowing intimate adhesion via opacity 
proteins (Opa and Opc) (Virji, 2009). In addition to opacity proteins, the 
engagement of other meningococcal adhesins, such as NhhA, App and NadA, 
may support bacterial colonization and the invasion of a mucosal barrier. 
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Meningococcal adhesins target host receptors, and Opa interacts with CEACAMs 
and HSPGs (Virji et al., 1996; Virji et al., 1999); Opc interacts with fibronectin, 
vitronectin and endothelial integrins (Unkmeir et al., 2002; Virji et al., 1994; Virji 
et al., 1995); and the receptors of recently identified meningococcal adhesins are 
not yet determined except for NhhA, which targets laminin and HSPGs (Scarselli 
et al., 2006). Such intimate adhesion mediated by the interaction of 
meningococcal adhesins with receptors in epithelial cells can trigger cell-
signalling events that lead to meningococcal internalization (Hill et al., 2010; 
Virji et al., 1994) (Figure 1.6).  
Both the antigenic variation of meningococcal surface proteins and invasion of 
meningococci into the epithelial cells enable the bacteria to evade the host 
immune system (Hill et al., 2010). 
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Figure 1.6: Overview of meningococcal interactions at the epithelial barrier 
of the nasopharynx. T4p mediates the initial attachment with epithelial cells via the 
interaction of PilC, which is located at the tip of pilus, with CD46. Intimate adhesion is 
mediated by the interaction of other non-pilus adhesins with their cognate receptors; for 
example, Opa proteins may bind CEACAM and HSPGs, and Opc proteins can target 
HSPGs and, via vitronectin and fibronectin, with their integrin receptor. Although some 
minor adhesins such as NhhA have been shown to interact with HSPGs, the receptors 
targeted by MspA, App and NadA have not yet been determined. Receptor-adhesin 
interactions result in meningococcal internalization into epithelial cells by triggering a 
variety of host cell-signalling mechanisms. Reproduced from (Hill et al., 2010; Trivedi et 
al., 2011). 
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1.9.2. Spread in the bloodstream 
After crossing the nasopharyngeal mucosa, meningococci can occasionally enter 
the blood stream, leading to a strong inflammatory response and activation of the 
complement and the coagulation cascade (Hill et al., 2010). Meningococcal LOS 
plays a vital role in the induction of inflammatory responses that lead to sepsis 
(Braun et al., 2002). A correlation between the amount of circulating LOS with 
the rate of morbidity and mortality associated with meningococcal bacteremia and 
meningitis has been shown (Brandtzaeg et al., 1989).  
The lipid A portion of meningococcal LOS is the moiety that induces the 
inflammatory response associated with meningococcal sepsis. Different 
inflammatory cytokines, including IL-6 and TNF-Į WXPRXU QHFURVLV IDFWRU-Į), 
and chemkines such as ROS (reactive oxygen species) and NO are released in 
response to meningococcal LOS. This induction results in part from the 
interaction of lipid A moiety with TLR 4 (toll-like receptor 4) (Chow et al., 
1999). 
In the blood, meningococci adopt different mechanisms to resist being killed by 
antibodies, complement-mediated lysis and opsonophagocytosis in the blood 
stream. Two important mechanisms are the N. meningitidis capsule and LOS, 
since disruption of the genes is involved in LOS and capsule synthesis increases 
meningococcal sensitivity to serum killing (Chow et al., 1999). Another 
mechanism is the negative regulation of the complement system, which enhances 
bacterial survival. In this context, meningococcal fHbp (factor H-binding protein) 
and PorA have been shown to bind factor H and C4bp, respectively, influencing 
bacterial resistance in the blood (Jarva et al., 2005; Madico et al., 2006). In 
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addition, the binding of meningococcal Opc to vitronectin, which inhibits the 
formation and insertion of a MAC (membrane attack complex) into bacterial 
membranes, increases bacterial resistance to serum-mediated killing (Virji, 2008). 
Meningococcal porins may act as an adjuvant, resulting in the stimulation of B-
cells through the interaction with TLR2 (toll-like receptor 2) (Massari et al., 
2002). Out of the minor adhesins, NadA, has been shown to induce high levels of 
IL-8 and TNF-ĮSURGXFWLRQIURPKXPDQPRQRcytes and macrophages (Franzoso 
et al., 2008). As a result it is not only meningococcal LOS and capsules but also 
several proteinaceous adhesins that can modulate the immune response (Hill et 
al., 2010).  
1.9.3. Traversal of the BBB and meninges invasion 
Many pathogens can survive and multiply in the blood stream but only certain 
bacteria, including Neisseria meningitidis, are able to traverse the BBB (Kim, 
2008; Somand & Meurer, 2009). The BBB is a highly specialized structure and 
acts as a barrier to protect the brain from any microbes and toxins and it controls 
the passage of molecules into and out of the brain (Kim, 2008). Different cell 
types that constitute the BBB, among them brain microvascular endothelial cells, 
represent the first line of defence against pathogens in the CNS. These brain 
endothelial cells are characterized by their tight junctions and low rates of 
pinocytosis. The interaction of N. meningitidis with endothelial cells is a crucial 
step for meningeal invasion. This step is greatly affected by the blood flow rate 
and shear stress. Post-mortem histological examination of meningitis patients has 
shown that meningococci adhere to capillaries with a low rate of cerebral blood 
flow (Mairey et al., 2006). To investigate this in vitro, Mairey, Genovesia et al. 
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(2006) used a model for meningococcal binding with brain endothelial cells in the 
presence of shear stress, mimicking the blood stream. The study revealed that 
meningococcal T4p plays an important role in maintaining bacterial adhesion 
under a high flow rate. Following bacterial adhesion, N. meningitidis induces the 
formation of membrane protrusion, filopodia-like structures that help to protect 
the bacteria against shear stress (Eugene et al., 2002). The development of a 
cellular projection after the attachment of meningococci to the host cell via T4p 
stems from the organization of a honeycomb lattice structure underneath the 
bacWHULDO PLFURFRORQLHV FDOOHG WKH ³FRUWLFDO SODTXH´ (Merz et al., 1999).The 
formation of the cortical plaque, which contains different structural proteins and 
membrane receptors, is a two-step process. First, there is the initial recruitment of 
one or several receptors following T4p mediated adhesion (Coureuil et al., 2012). 
Second, the activation of these receptors leads to the recruitment of other 
transmembrane components and the modification of the host cell cytoskeleton, 
which is also mediated by T4p (Coureuil et al., 2012).  
In the context of receptor recruitment or clustering, it has been suggested that the 
adhesion receptor for meningococci is CD46, as mentioned earlier (Kallstrom et 
al., 1997). However, subsequent studies have reported CD46-independent 
adhesion. Therefore, it is possible that one or several cellular receptors in addition 
to CD46 is/are responsible for the meningococcal T4p interaction with brain 
endothelial cells (Join-Lambert et al., 2010). Recently, 37 LRP/67 LR has been 
found to be an adhesion receptor for N. meningitidis (Orihuela et al., 2009). PorA 
and PilQ have been identified as meningococcal-laminin receptor ligands. In 
addition, the invasion of uncapsulated N. meningitidis into endothelial cells has 
been shown to be mediated by the interaction of Opc with integrin via fibronectin 
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(Unkmeir et al., 2002). However, meningococci are encapsulated in the blood 
stream; thus the relevance of such a binding in vivo is unclear (Kim, 2008). A 
recent study (Coureuil et al., 2010) KDVVKRZQWKDW WKHȕ-adrenergic receptor is 
recruited after the initial adhesion of N. meningitides to brain endothelial cells. 
Two meningococcal OLJDQGV KDYH EHHQ UHSRUWHG IRU WKH ȕ-adrenergic receptor, 
the major and minor pilin PilE and PilV, respectively (Coureuil et al., 2010). 
Interestingly, the involvement of the PilV in meningococcal resistance against 
shear stress has been reported recently. This effect results from the PilV induction 
of cholesterol recruitment to the cortical plaque in endothelial cells, protecting 
bacterial microcolonies from the shear stress of the blood stream (Mikaty et al., 
2009) (Figure 1.7). 
Turning to the second step of the cortical plaque formation, there are several 
cytoplasmic proteins that have been recruited to this niche, which will be 
illustrated briefly below. Ezrin and moeisn, members of the ERM (ezrin-radixin-
moesin) protein family, are key components in the formation of membrane 
protrusion (Doulet et al., 2006; Eugene et al., 2002; Lambotin et al., 2005). These 
proteins control the organization of the cortical actin cytoskeleton via their 
carboxy terminal F-actin binding sites. Furthermore, ERM proteins bind the 
cytoplasmic domain of numerous ERM binding transmembrane receptors such as 
CD44 and ICAM-1 and -2, acting as a linker between the actin cytoskeleton and 
the plasma membrane. In addition, the activation of cortical actin polymerization 
has been shown to be associated with cortical plaque formation, resulting in the 
elongation of membrane protrusions (Coureuil et al., 2012). This stimulation of 
cortical actin polymerization is due to the activation of RhoA and Cdc42 GTPases 
and PI3-K/Rac1signalling pathways involved in cortactin recruitment to the 
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membrane protrusions (Eugene et al., 2002; Lambotin et al., 2005). Cortactin 
(cortical actin binding protein) is a perinuclear cytoplasmic protein involved in 
the reorganization of the cell¶V cortical actin cytoskeleton. Not only is cortactin 
recruitment required for the formation of membrane protrusions at the 
meningococcal adhesion site but also its activation by phosphorylation (Coureuil 
et al., 2012; Join-Lambert et al., 2010). Phosphorylation of the cortactin in 
meningococcal infection has shown to be mediated by the activation of the host 
cell tyrosine kinase receptor ErbB2, which subsequently activates src kinase 
activity (Hoffmann et al., 2001). In addition, activation of the tyrosine kinase Src 
by direct interaction with ȕDUUHVWLQZKLFKDFFXPXODWHG LQ WKHFRUWLFDO SODTXH LQ
UHVSRQVH WR WKH DFWLYDWLRQ RI WKH ȕ-adrenergic receptor, also leads to the 
phosphorylation of cortactin (Coureuil et al., 2010) (Figure 1.7). 
It is important to note that it has been reported by Coureuil et al. (2009) that the 
adhesion of N. meningitidis to endothelial cells recruits several proteins involved 
in the formation and stabilization of adherens and tight junctions, to the cortical 
plaque. This effect is attributable to the recruitment of polarity complex proteins, 
namely PAR3, PAR6 and PKC, in response to meningococcal T4P binding to 
endothelial cells (Coureuil et al., 2009). Such recruitment of polarity complex 
proteins leads to the formation of ectopic domain, which has filopodia-like 
structures and is enriched with several junctional proteins; it is called the ectopic 
intracellular junctional domain (Coureuil et al., 2009). Several junctional proteins, 
such as V-cadherin, ZO-1 or claudin-5, are depleted from tight junctions and 
redistributed underneath bacterial microcolonies, leading to the disruption of the 
intercellular junctions and enabling meningococcal entry (Coureuil et al., 2009). 
In addition, the possibility that meningococci can cross the BBB through the 
  
33 
 
transcytosis route cannot be excluded (Hill et al., 2010). Alternately, damage to 
the endothelial cells caused by the cytotoxic effect of LOS may facilitate the 
meningococcal crossing of the BBB (Dunn et al., 1995). Other routes, such as 
direct inoculation into the cerebrospinal fluid and mechanical spread from the 
contagious source of infection, are less frequently attributed to microbial entry 
into the central nervous system (Kim, 2006) (Figure 1.7). 
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Figure 1.7: Formation of the cortical plaque and transmigration of Neisseria 
meningitidis. (A) Meningococcal T4p mediate the EDFWHULDO DGKHVLRQ WR WKH EUDLQ¶V
microvascular endothelial cells using an unknown adhesion receptor. Following the 
initial bacterial adhesion, T4p lead to the formation of membrane protrusions that result 
from the organization of a specific cytoplasmic molecular complex called the cortical 
plaque. The formation of the cortical plaque involves the clustering and activation of 
differenW UHFHSWRUV VXFK DV WKH ȕ-adrenergic receptor, and triggers their subsequent 
signalling events. The consequences of these events enable meningococcal 
transmigration between endothelial cells as result of the damaged barrier or it may also 
enable bacteria to transmigrate by endocytosis, which is something that is still unknown. 
(B) Signalling pathways induced by N. meningitidis lead to the formation of the cortical 
plaque and disruption of the junctional adhesion molecules. T4p mediated adhesion of N. 
meningitidis WR WKH HQGRWKHOLDO FHOOV LQFOXGLQJ WKH ȕ-adrenergic receptor, leads to the 
formation of membrane protrusions that result from the organization of a specific 
cytoplasmic molecular complex called the cortical plaque. (1) Endothelial cell 
protrusions are enriched in ezrin and ezrin binding receptors (CD44, ICAM-1 and -2), 
which are recruited in a phosphatidylinositol-4, 5-bisphosphate (PI(4,5)P2) dependent 
manner. (2) Actin polymerization requires the recruitment and phosphorylation of 
cortactin. The recruitment of cortactin is mediated by the activation of two signalling 
pathways: the PI3-Kinase/Rac1 GTPase signalling pathway and the Cdc42 GTPases that 
recruit the Par6/aPKC polarity complex and allow the recruitment of the p120-
catenin/Cortactin/Arp2/3 complex beneath the bacterial colonies. N. meningitidis induces 
phosphorylation of the cortactin by activating the host cell tyrosine kinase receptor 
ErbB2, which DFWLYDWHVGRZQVWUHDPWKHVUFNLQDVHDQGȕ-DGUHQHUJLFUHFHSWRUȕDUUHVWLQ
activated src. (3) Cdc42 mediated activation of Par3/Par6/aPKC elicits the recruitment of 
adherens and tight junction proteins from pre-existing junctional complexes. Reproduced 
from (Coureuil et al., 2012; Join-Lambert et al., 2010).  
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1.10. Clinical manifestations of meningococcal disease  
N. meningitidis causes a diverse disease spectrum, which usually occurs within 
the first week after acquisition (Stephens et al., 2007). The most common types of 
meningococcal disease are meningitis and septicaemia, which may co-exist 
(Kirsch et al., 1996). 
The progression of meningococcal disease from an initial mild clinical 
presentation to fulminant disease, multi-organ failure and death may occur within 
hours (Pace & Pollard, 2012; Stephens et al., 2007). The main factor contributing 
to the clinical manifestations of meningococcal disease is the extent of the 
activation of the host immune response, which is affected by bacterial factors 
such as the level of circulating endotoxin and the bacterial load (Darton et al., 
2009), and genetic variation in microbial recognition genes, such as the 
complement system and inflammatory response (Figure 1.8) (Brouwer et al., 
2010; Pace & Pollard, 2012; Wright et al., 2009).  
 
Figure 1.8: Interplay of factors contributing to the manifestations of 
meningococcal disease. Reproduced from (Pace & Pollard, 2012).   
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The initial symptoms of meningococcal disease are similar to the symptoms of 
upper respiratory tract infection, such as pharyngitis, fever, loss of appetite, 
nausea and vomiting (Thompson et al., 2006). Thus the early symptoms are non-
specific and usually misdiagnosed by the clinician. However, late manifestations 
are specific and suggestive of the development of meningitis or septicaemia (Pace 
& Pollard, 2012).  
Meningitis affects 30-60% of infected individuals and is commonly associated 
with the following symptoms: severe headache, fever, nausea, vomiting, stiff 
neck, lethargy, loss of consciousness and photophobia (CDC, 2009; Stephens et 
al., 2007). The resulting manifestation of meningitis is due to the inflammatory 
response triggered within the subarachnoid space in response to the 
meningococcal invasion (Brandtzaeg et al., 1992a).  
However, septicaemia represents 20-30% of meningococcal disease and is 
characterized by lower limb pain, cold peripheries and the appearance of a 
petechial or purpuric rash (CDC, 2009; Thompson et al., 2006). The release of 
large amounts of meningococcal LOS in the blood stream activates a massive 
immune response, leading to damage to the microvascular endothelium (Pathan et 
al., 2003). In severe cases, microvascular thrombosis, hypoperfusion, ischemia, 
multiple tissue injury and death might occur (Pathan et al., 2003).  
In rare cases meningococci infect other anatomical sites in addition to the 
meninges and blood stream, causing pneumonia, conjunctivitis, arthritis, 
pericarditis and myocarditis (Hart & Thomson, 2006; Pace & Pollard, 2012). 
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1.11. Diagnosis of meningococcal disease 
After the initial recognition of the above-mentioned clinical features, a confirmed 
diagnosis of meningococcal disease is achieved through microbiological testing 
(Stephens et al., 2007). These microbiological tests rely on obtaining samples of 
meningococci from the blood, CSF, nasopharyngeal throat, skin lesion and 
synovial fluid of infected patients (Cartwright & Ala'Aldeen, 1997; Nadel & 
Kroll, 2007). Cultured bacteria can be further characterized by Gram staining and 
antibiotic sensitivity tests. Among these diagnostic methods, the determination of 
CSF protein, glucose and the white cell count (WCC) through a lumbar puncture 
(if not contraindicated) is the method of choice for the diagnosis of 
meningococcal disease (Fitch & van de Beek, 2007; Somand & Meurer, 2009). 
Recently, PCR has been used extensively for the detection of meningococcal 
DNA in clinical samples (Carrol et al., 2000). Other non-specific laboratory tests, 
such as WCC and CRP, are commonly used in febrile children to distinguish 
between invasive bacterial infection from self-limiting viral infection (Bourke et 
al., 2010). 
1.12. Management of meningococcal disease 
Parenteral administration of ȕ-lactam antibiotics, such as cephalosporins and 
penicillins, is the drug treatment of choice for meningococcal disease (Chaudhuri 
et al., 2008). It is worth noting that the mortality rate from invasive 
meningococcal disease has been shown to decrease by the prehospital 
administration of antibiotics in suspected patients (Perea-Milla et al., 2009).  
Once a case of meningococcal disease has been confirmed, antibiotic treatment 
should be given to anyone in close contact with the patient to eradicate the 
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potential colonization of N. meningitidis (Gardner, 2006). In addition to the 
effective eradication of the meningococcal carriage, the administration of 
prophylactic antibiotics has shown to decrease secondary cases among close 
contacts (Bilukha & Rosenstein, 2005). Antibiotic regimens for prophylaxis 
against meningococcal disease include rifampin, ciprofloxacin and ceftriaxone 
(Gardner, 2006).  
1.13. Meningococcal vaccine 
1.13.1. Capsular polysaccharide vaccine 
The meningococcal polysaccharide capsule is an important virulence factor, 
which renders the bacteria serum resistance, and it is located in the surface of the 
bacteria. Therefore, capsule based vaccines have been used for the prevention of 
meningococcal disease caused by serogroups A, C, W-135 and Y for considerable 
periods of time (Gold et al., 1977). However, although these vaccines produce 
protective antibody responses against meningococcal disease, they have some 
limitations. First, these vaccines are poorly immunogenic in children younger 
than two years of age (Bilukha & Rosenstein, 2005). Second, they do not induce 
long-term memory (Gotschlich et al., 1969). Third, owing to their short-memory 
protection repeated doses of capsule based vaccines every three to five years are 
required, which may attenuate the serum bactericidal antibody response to N. 
meningitidis, known as hyporesponsiveness (Pollard et al., 2009). More 
importantly, there is no vaccine against the meningococcal serogroup B capsule, 
which is the most common serogroup in developed countries, because of its poor 
immunogenicity.  
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1.13.2. Meningococcal conjugate vaccines 
The short-lived memory problem of capsule based vaccines necessitates the 
consideration of other approaches to produce long-term protection against 
meningococcal disease (Pollard et al., 2009). One of the approaches that have 
been used in the Haemophilus vaccine, which has shown great efficacy and is 
based on the conjugation of capsular polysaccharides to a protein carrier to 
produce what is known as a conjugate vaccine (Stein, 1992). Such conjugation 
converts polysaccharide from the T-cell independent antigen into a T-cell 
dependent antigen, resulting in longer memory protection (Bilukha & Rosenstein, 
2005). There are several immunogenic protein carriers that have been linked to 
meningococcal polysaccharides, including tetanus or diphtheria toxoid and CRM 
197 (a non-toxin variant of the diphtheria toxin) (Granoff MD, 2008). 
In 1999, a conjugate vaccine against serogroup C polysaccharide (MenC) was 
first introduced into schedules for routine infant immunization in the United 
Kingdom, leading to a significant reduction in the disease and carriage cases 
caused by this serogroup (Maiden et al., 2008; Miller et al., 2001). Another 
conjugate vaccine against serogroup A (MenAfriVac) has been introduced in 
Africa (Moszynski, 2010). Recently, in the United States of America (USA) and 
the European Union (EU) two tetravalent conjugate vaccines (A/C/Y/1-135) have 
been licensed for use; these are called Menactra and Menveo, respectively 
(Bilukha & Rosenstein, 2005; Gasparini & Panatto, 2011). However, this 
approach cannot be implicated in the development of a vaccine against N. 
meningitidis serogroup B (Gasparini & Panatto, 2011). 
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1.13.3. Vaccines against meningococcal serogroup B  
The similarity between the meningococcal serogoup B capsule and host glycan 
hinders the generation of a capsule based vaccine as such a similarity may lead to 
a severe autoimmune disease. Thus other approaches have been adopted to 
develop vaccines to combat meningococcal serogroup B using non-capsular 
surface structures. In this context, several licensed non-capsular group B vaccines 
are based on detergent extracted OMV (outer membrane vesicle) preparation. The 
OMV is composed of a mixture of LOS and outer membrane proteins, which can 
be separated from meningococci or isolated as a membrane bleb that is released 
into the media during bacterial growth (Holst et al., 2009). It is necessary to treat 
the OMV with detergent in order to extract the LOS and decrease the endotoxin 
level (Holst et al., 2009). Although meningococcal OMV vaccines are safe and 
effective, they generate a strain-specific immune response to the protein PorA 
(Tappero et al., 1999). PorA is the immunodominant antigen in these vesicles and 
it is highly variable in different strains of N. meningitidis serogroup B (Tappero et 
al., 1999). This limitation renders meningococcal B OMV vaccines effective only 
in epidemics caused by a single PorA expressing strain (Tan et al., 2010). In an 
attempt to increase their limited coverage, OMV vaccines have been prepared 
from more than one strain (Sandbu et al., 2007). Another approach is to prepare 
OMV from mutants where the PorA gene is inactivated and other minor outer 
membrane proteins are overexpressed (Weynants et al., 2007). These minor 
proteins are usually expressed in low levels, such as transferrin-binding protein A, 
neisserial surface protein A (NspA) and outer membrane protein 85. 
In 2000, a genome based method called ³reverse technology´ was used to identify 
the potential novel meningococcal vaccine candidate (Pizza et al., 2000). More 
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than 600 potential meningococcal antigens have been identified based on the 
prediction that they will be recognized by a component of the immune system, 
and only 350 of them can be expressed in E. coli (Rappuoli & Covacci, 2003). 
These expressed proteins were injected into mice and their ability to produce 
bactericidal antibodies were evaluated (Rappuoli & Covacci, 2003). Of these 
proteins, the most promising five proteins, known as genome-derived neisserial 
antigens (GNAs), were selected for use in the formulation of a multivalent 
vaccine named rMenB. These GNAs are N. meningitidis adhesin A (NadA, or 
GNA1994), the factor H-binding protein (GNA1870), GNA2091, GNA2132 
(recently renamed the neisserial heparin binding antigen) and GNA1030. This 
vaccine has been shown to elicit murine bactericidal antibodies against 78% of 
the selected group B meningococcal strains (Giuliani et al., 2006; Tan et al., 
2010). Therefore, the reverse technology concept has been implicated in the 
current development of a universal vaccine against meningococcal serogroup B, 
and two promising vaccines are under study at the present time. One of these 
vaccines, known as Bexsero (4CMenB), is a multicomponent vaccine combined 
with OMV and is produced by Novartis (Tan et al., 2010). The other vaccine has 
been developed by Wyeth and contains two protein variants of fHbps (Tan et al., 
2010).  
1.14. Laminin receptor  
In 1983, three different laboratories identified and isolated the laminin binding 
receptor from different cell lines (Lesot et al., 1983; Nelson et al., 2008; Rao et 
al., 1983; Terranova et al., 1983). Laminin affinity chromatography was used to 
extract and purify 67 LR from the cell membrane. The isolated receptor displayed 
a single protein with an apparent molecular mass of approximately 67 kDa, as 
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estimated by SDS/PAGE. The receptor binds to laminin with specificity and high 
affinity; thus it is referred to as the 67 kDa laminin receptor (67 LR) (Malinoff & 
Wicha, 1983; Rao et al., 1983).  
Microsequencing analysis of the peptide obtained from the cyanogen bromide 
digestion of the purified 67 LR has revealed a unique octapeptide with the 
sequence MLAREVLR (Wewer et al., 1986). These octapeptides have enabled 
the identification and isolation of a cDNA clone encoding the protein since the 
direct sequence of the protein has not been determined, probably due to its 
blocked N-terminus (Wewer et al., 1986). Northern blot analysis has revealed that 
the mRNA encoding 67 LR is approximately 1700bp and contains an open 
reading frame of 888bp (Wewer et al., 1986). The resulting open reading frame 
encodes a protein of 295 amino acids in length and a calculated molecular mass of 
approximately 32 kDa. In a western blot, this protein is detected at approximately 
37 kDa and is considered to be the precursor for 67 LR; therefore, it is referred to 
as the 37 kDa laminin receptor precursor (37 LRP) (Nelson et al., 2008). 
Homologues of 37 LRP/67 LR are found in all five kingdoms (archaebacteria, 
eubacteria, fungi, plants and animals). The amino acid sequence of 37 LRP is 
highly conserved, with at least 98.3% similarity between mouse, bovine and 
human sequences, and 99% similarity between rat and human sequences (Menard 
et al., 1997; Nelson et al., 2008). The formation of 67 LR from its precursor 37 
LRP has only been described in vertebrates. However, the mechanism by which 
37 LRP is converted to 67 LR is not yet understood (described below). It is worth 
noting that the C-terminal of 37 LRP is highly conserved among vertebrates but 
very divergent in other organisms (Menard et al., 1997). Therefore, it has been 
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suggested that the C-terminal of 37 LRP might be involved in the biosynthesis of 
67 LR (Menard et al., 1997). 
1.14.1. Molecular structure and function 
The separation of 67 LR protein from the cell onto the denaturing polyacrylamide 
gel reveals that it is 67 kDa in size; however, the cDNA of this receptor encodes a 
protein that is transferred at approximately 37 kDa on SDS/PAGE and this is 
known as the laminin receptor precursor (37 LRP) (Wewer et al., 1986). The most 
common reason for such a difference in the molecular mass between 67 LR and 
37 LRP might be a posttranslational modification or the formation of homo- 
and/or heterodimers (Nelson et al., 2008).  
The translational protein resulting from 37 LRP cDNA does not have an N-linked 
glycosylation site or transmembrane domain, which is revealed through the 
absence of a recognizable signal sequence, at the N-terminus. On the other hand, 
there is a hydrophobic domain between amino acids 86-101 in the N-terminal 
region that has been proposed as a transmembrane domain (Rao et al., 1989) 
(Figure 1.9). This prediction for the transmembrane domain position is consistent 
with the immunofluorescence staining pattern of 67 LR using a panel of 
antibodies directed to various parts of the receptor (Castronovo et al., 1991b). 
However, the recent crystal structure of 37 LRP has suggested that this domain is 
an integral part of the protein fold and is unlikely to serve as an transmembrane 
helix (Jamieson et al., 2008). It should be noted that the published crystal 
structure of the 37 LRP represents amino acid residues from 1 to 220 (Jamieson et 
al., 2008) (Figure 1.9). 
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The extracellular C-terminal region contains 70 amino acid segments, which have 
five repeats of the (D/E)W(S/T) sequence and are characterized by their resistance 
to trypsin and a high negative charge (Nelson et al., 2008; Sylvie et al., 1997) 
(Figure 1.9). 
 
Figure 1.9: Schematic representation of 37 LRP. The 37 LRP is 295 amino acids 
in length and three functional domains within its C-terminal are exposed to extracellular 
space. The transmembrane domain is located between amino acids 86 and 101. The 
binding sites of laminin, heparin, prion, VEE virus and bacteria causing meningitis, 
including N. meningitidis, are located in the C-terminal of 37 LRP.  
The 67 LR is considered to be the mature form of the receptor, which it has been 
suggested to originate from homo- or heterodimerization of its precursor 37 LRP 
(Nelson et al., 2008; Sylvie et al., 1997). This receptor-precursor relationship has 
been revealed by the cross-reactivity of some antibodies raisied  against 37 LRP 
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with the mature form, 67 LR, using the western blot (Rao et al., 1989). In 
addition, a pulse chase experiment has shown that the radiolabeled 37 LRP is 
initially detected, followed by the appearance of a similarly labelled 67 kDa 
protein, which also supports the receptor±precursor relationship (Rao et al., 
1989). 
The reason for the observed variation in size between the mature (67 LR) and the 
precursor (37 LRP) forms is not fully understood. Many hypotheses attribute this 
to the post-translational covalent modification or dimerization of the precursor 
protein into the homo- or heteroform (Nelson et al., 2008). It has been shown that 
37 LRP is modified by post- translational acylation to form the surface exposed 
form of the receptor (67 LR) (Landowski et al., 1995; Simona Butò, 1998). The 
involvement of acylation has been revealed by the accumulation of the 37 LRP 
and either the inhibition or decrease in the formation of the 67 LR after using of 
fatty acid synthase inhibitor such as cerulenin (Simona Butò, 1998). In addition, 
the 67 LR has been subjected to methyl-transesterification and GC-MS (gas 
chromatography-MS) recognizes three covalently bound acylated fatty acids: 
palmitate, oleate and stearate in the 67 LR (Landowski et al., 1995). 
Moreover, there is no effect on the size of protein after O-glycanase, 
neuraminidase or Endo-F glycosidase treatments (Landowski et al., 1995; Nelson 
et al., 2008). This indicates that 67 LR maturation involves acylation but not the 
glycosylation process.  
The 37 LRP has been found to be associated with the 40S ribosome and bound to 
the nucleus; in addition, its function has been found to be a precursor for the cell 
surface laminin binding receptor 67 LR (Nelson et al., 2008; Sylvie et al., 1997). 
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In conclusion, lipid modification of the protein through fatty acid acylation might 
help to stabilize the two dimers of 37 LRP and target them as a 67 LR to surface 
of the cell membrane (Landowski et al., 1995; Nelson et al., 2008; Simona Butò, 
1998). On the other hand, lipids can participate in the conformational changes of 
the protein or enable protein binding with other components (Landowski et al., 
1995). 
1.14.2. Dimerization 
Several studies have suggested homo- or hetero- dimerization of 67 LR. The 
evidence supporting each hypothesis will be presented below.  
1.14.2.1. Heterodimerization 
It has been predicted that 67 LR is a heterodimer that results from dimerization 
between 37 LRP and the E-galactoside binding lectin known as Galectin-3 (Gal-3) 
(which is described in detail later on) (Castronovo, 1993). This model was first 
proposed by Castronovo in 1993 (Figure 1.10). Both Galectin-3 and 67 LR are 
non-integrin laminin binding proteins. Galectin-3, previously known as HLBP31 
(a 31 kDa human laminin-binding protein), binds to the poly-N-acetyl-
lactosamine residues of laminin (Castronovo, 1993; Nelson et al., 2008), while 
the binding of 37 LRP/67 LR to laminin involves the YIGSR, a short sequence 
IURPWKHȕFKDLQRIODPLQLQ(Nelson et al., 2008).  
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Figure 1.10: Speculative model for the 67 LR. In the proposed model, the 67 LR 
would be obtained through the association between the 37 LRP and Galectin-3. Laminin 
is a heWHURWULPHUSURWHLQDQGLVFRPSRVHGRIWKUHHVXEXQLWVĮ-FKDLQȕ-FKDLQDQGȖ-chain, 
found in five, four and three genetic variants, respectively. These chains assemble in 
various combinations to form at least 15 laminin isoforms. The laminin molecule has a 
cross-like structure with three short arms and one long arm. Galectin-3 binds the poly-N-
acetyl-lactosamine moiety of laminin. Residues 205-229 of 37 LRP/67 LR interact with 
QDQRSHSWLGHIURPWKHȕFKDLQRIODPLQLQ&'3*<,*65,QDGGLWLRQUHVLGXHV-180 
of 37LRP/ 67 LR (called peptide G) bind laminin.  
37 LRP
Galectin-367 LR
heterodimer
Laminin
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A proposed heterodimerization model between 37 LRP and Gal-3 is based on 
several findings. First, it has been shown that both Gal-3 and 67 LR can be eluted 
from the laminin affinity column by lactose, galactose and N-acetyllactoseamine 
(Castronovo et al., 1992). Second, antibodies generated against another lectin, 
known as HLBP14 (human laminin binding protein 14), also immunoreacted with 
lactose eluted 67 LR and Gal-3 in the western blot (Castronovo et al., 1992). 
Third, treating laminin with endo-ȕ-galactosidase, an enzyme that disrupts linear 
type 2 poly-N-acetyllactoseamine, abolishes its binding with 67 LR and Gal-3 
(Castronovo et al., 1992). As a result, it has been suggested that the recognition of 
laminin by 67 LR is dependent on the N-acetyllactoseamine moiety (Castronovo 
et al., 1992) (Figure 1.10). In 1998, further evidence backing up the 67 LR 
heterodimer model was reported by %XWȩHWDO. In their study the immunoblotting 
of a detergent-soluble extract from a human carcinoma cell, which has been 
proved to express 67 LR and 37 LRP, using a polyclonal antibody directed 
against Galectin-3 recognized a band at 67kDa, which is the same size as the 
mature 67 LR, but not at 37 kDa (Buto et al., 1998). In conclusion, all these 
findings indicate that 37 LRP might be associated with Gal-3 to form the 67 LR.  
1.14.2.2. Homodimerization 
In contrast to the heterodimerization hypothesis, it has been shown that the amino 
acid composition of 67 LR is found to be identical to that of 37 LRP (Landowski 
et al., 1995). Another study (Gauczynski et al., 2006) reported that both 67 LR 
and 37 LRP co-exist on the surface of N2a cells, cells that do not express Gal-3, 
based on the immunoblotting of the membrane fraction. These studies revealed 
that Gal-3 or any other lectin is not obligated to surface expression of 67 LR 
(Nelson et al., 2008).  
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1.14.3. Function of the laminin receptor 
1.14.3.1. Interactions with laminin 
It binds extracellular matrix glycoprotein laminin, collagen and elastin, which 
mediate the receptor role in cell differentiation, movement and growth. The 
expression of 67 LR is high in cancer and indicates an invasive and aggressive 
phenotype of tumour (Sylvie et al., 1997). 
1.14.3.2. Pathogen receptor  
In addition to its role as a membrane receptor for the adhesive basement-
membrane protein laminin, 37 LRP/67 LR has been targeted by many pathogens. 
These infectious agents, including viruses, bacteria, protozoa, cellular proteins 
and toxins, mainly infect the central nervous system. The Sindbis virus (Wang et 
al., 1992), Dengue virus (Thepparit & Smith, 2004), adeno-associated virus 
(Akache et al., 2006), tick-borne encephalitis virus and Venezuelan equine 
encephalitis virus (Ludwig et al., 1996) have all been found to bind with the 37 
LRP/67 LR of the host cell. Moreover, the prion protein PrP that causes prion 
disease uses 37 LRP/67 LR in its internalization pathway (Gauczynski et al., 
2006).  
Importantly, bacteria causing meningitis, including E. coli K1, S. pneumonia, H. 
influenza and N. meningitidis, have been reported to target 37 LRP/67 LR on the 
surface of HBMECs. All these bacteria interact with specific domains within 37 
LRP/67 LR, as shown in Figure 1.9. Interestingly, the binding of the three 
commonest bacteria causing meningitis, S. pneumonia, H. influenza and N. 
meningitidis, is thought to be within 263-282 domain, as the adhesion of these 
pathogens to the host cell is decreased by the antibody targeting this region 
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(Orihuela et al., 2009). As mentioned earlier, 37 LRP/67 LR helps to initiate 
bacterial adhesion to the BBB, which is a crucial step in meninges infection. The 
following bacterial adhesins, pneumococcal CbpA, meningococcal PilQ and PorA 
and OmpP2 of H. influenzae, are identified as bacterial ligands for 37 LRP/67 LR. 
Furthermore, E. coli K1 targets the same receptor via its cytotoxic necrotizing 
factor 1 (CNF1) (Kim et al., 2005). The interaction of CNF1 with 37/67-kDa LR 
provokes the enrolment of focal adhesion kinase (FAK) and paxillin into the 
67LR, leading to bacterial invasion into HBMECs (Kim et al., 2005).  
In conclusion, there are various ranges of ligands that share the common feature 
of infecting the CNS and utilize 37 LRP/67 LR to mediate their pathogenesis. 
This specific ligand-receptor interaction potentiates 37 LRP/67 LR to become a 
novel therapeutic target, particularly in the case of limited treatment or a 
prevention option for such as, bacterial meningitis.  
1.15. Galectin-3 
*DOHFWLQV DUH D JURXS RI ȕ-galactoside-binding lectins that share a conserved 
carbohydrate recognition domain (CRD) (Barondes et al., 1994a). Lectins are 
glycan binding proteins, in which galectins represent the most widely expressed 
type of lectins. Fifteen mammalian galectins have been described in the literature 
so far, 11 of which are expressed in humans (Cooper, 2002). According to the 
number of CRDs and structural differences, mammalian galectins are classified 
into three subgroups: proto, chimera and tandem repeat types (Barondes et al., 
1994b; Cooper, 2002) (Figure 1.11). Proto-type galectins (galectins 1, 2, 5, 7, 10, 
11, 13, 14 and 15) have one CRD while tandem repeat galectins (galectins 4, 6, 8, 
9 and 12) consist of two CRDs that are joined by a linker peptide. In the chimera-
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type galectins, one CRD is connected by a collagenase-sensitive domain, a region 
rich in proline, glycine and tyrosine, to the N-terminal. Galectin-3 is the only 
chimeric member of the family of galectins, and will be the focus of this review.  
 
Figure 1.11: Subtypes of the galectin family. Galectins can be divided into three 
subtypes based on their structure. Schematic examples of prototype galectins: Gal-1 has 
one carbohydrate recognition domain (CRD); Gal-3 is the only chimeric galectin with 
one CRD and it is a proline-, glycine- and tyrosine-rich repeating domain and the N-
terminus and tandem-repeat galectins (for example, Gal-9) consist of two CRDs joined 
by a short peptide. Reproduced from (Barondes et al., 1994b).  
1.15.1. Discovery 
Initially, Galectin-3 was identified as a Mac-2 antigen on the surface of murine 
macrophage (Ho & Springer, 1982). Later, Galectin-3 was described as CBP-35, a 
galactoside binding protein in mouse fibroblasts (Roff & Wang, 1983); L-34, a 
tumour surface lectin in oncogene-transfected rat embryonal fibroblasts (Raz et 
al., 1987); RL-29 or HL-29, lectins identified in the rat or human lung, 
respectively (Cerra et al., 1985; Sparrow et al., 1987); IgE-binding protein in rat 
basophilic leukaemia cells (Liu & Orida, 1984); and LBP, a laminin binding 
protein in macrophages (Woo et al., 1990). In 1994, all of these proteins were 
Prototype galectin
e.g. Galectin-1
Chimera type
Galectin-3
Tandem repeat
e.g. Galectin-9
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termed Galectin-3 (Gal-3) with the establishment of the nomenclature of galectins 
(Barondes et al., 1994a). 
1.15.2. Structure and specificity 
Galectin-3 is made up of three distinct structural domains: a short N-terminal 
domain, a repetitive collagen-like sequence and one CRD at the C-terminal 
(Barondes et al., 1994b).  
The N-terminal domain of Galectin-3 consists of 110-130 amino acids based on 
the species. It contains multiple homologues repeats of nine amino acids (Pro-
Gly-Ala-Tyr-Pro-Gly-X-XX). The N-terminal domain mediates Galectin-3 
multimerization and it is sensitive to proteolysis by certain matrix 
metalloproteinases, MMP-2 and MMP-9 (Ochieng et al., 1998). It has been 
shown that the first 12 amino acids of Galectin-3 N-terminal, also called the small 
N-terminal domain, are essential for Galectin-3 secretion and nuclear localization 
(Gong et al., 1999; Menon & Hughes, 1999). Within the small N-terminal 
domain, the highly conserved Ser6 residue has been shown to be involved in the 
anti-apoptotic activity of Galectin-3 (Seetharaman et al., 1998). The N-terminal 
domain of Galectin-3 lacks glycan binding activity; hence, it is referred to as the 
non-lectin domain. However, a modelling and mutagenesis analysis study has 
shown that the N-terminal domain Tyr102 residue is also attributed to the glycan 
binding activity of Galectin-3 (Barboni et al., 2000).  
The C-terminal domain of Galectin-3 is composed of approximately 130 amino 
acids. This domain is called the lectin-domain since it contains the glycan binding 
sites and is, therefore, responsible for the glycan binding activity of Galectin-3. 
The crystal structure of Gal-&5'KDV UHYHDOHG ILYH DQG VL[ VWUDQGHGȕ VKHHWV
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DUUDQJHG LQ D ȕ-sandwich (Seetharaman et al., 1998). One of the characteristic 
features of the Gal-3 CRD sequence is the presence of the NWGR (Asp-Trp-Gly-
Arg) motif, which is important for galectin-ELQGLQJWRȕ-galactoside (Akahani et 
al., 1997). Interestingly, this motif also exists in the B-cell lymphoma 2 Bcl-2 
family proteins, and is found to be responsible for the anti-apoptotic activity of 
Bcl-2 and Galectin-3 (Yang et al., 1996). In addition to glycan binding and anti-
apoptotic activities, the NWGR motif participates in the self-association of Gal-3 
through the CRD in the absence of carbohydrate ligands (Yang et al., 1998). 
Close to the NWGR motif, there is a single cysteine residue (Cys 186) that has 
been shown to be required for the dimerization of murine Gal-3 (Woo et al., 
1991).   
Galectin- ELQGV ȕ-galactoside containing glycan, preferably to galactose 
terminated glycans rather than to simple galactose (Agrwal et al., 1993; Sato & 
Hughes, 1992). For instance, lactose and N-acetyllactosamine (LacNac) bind 
Galectin-3 more strongly than galactose (Agrwal et al., 1993; Sato & Hughes, 
1992). The CRD of Galectin-3 has an extended binding site for glycan as revealed 
by crystal structure analysis when compared with other galectins (Seetharaman et 
al., 1998). This results in the increased affinity of Gal-3 for glycans with multiple 
lactoseamines and the substitution of the non-reducing terminal galactose moiety 
with ABH blood group oligosaccharides (Fuc 1,2, GalNAc 1,3 (Fuc 1,2) and 
Gal 1,3 (Fuc 1,2) (Seetharaman et al., 1998).  
Galectin-3 can form a homodimer and/or pentamer through intermolecular 
interactions involving the N-terminal domain, leaving the CRD free to interact 
with different glycans (Ahmad et al., 2004; Nieminen et al., 2007). The 
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multimerization of Galectin-3 leads to the crosslinking of different 
glycoconjugates. In the absence of glycan ligands, Galectin-3 can also form 
homodimer via CRD (Woo et al., 1991; Yang et al., 1998). 
1.15.3. Cellular localization and functions 
Galectin-3 presents in the cytosol, nucleus and cell surface but they are also 
excreted extracellulary by an unknown mechanism (Dagher et al., 1995; Hughes, 
1999; Sato & Hughes, 1994). 
The cellular localization of Gal-3 determines its biological activities. In 
cytoplasm, Galectin-3 interacts with several cytosolic proteins and is involved in 
a diverse range of intracellular events (Dumic et al., 2006). Among these binding 
proteins, apoptosis repressor Bcl-2 binds Galectin-3 and this binding mediates the 
anti-apoptotic effect of Gal-3 (Yang et al., 1996). Other binding proteins include 
CD95 (APO-1/Fas), Nucling and Alix/AIP1, GTP-bound K-Ras and Akt-protein, 
which are involved in the role of Gal-3 in apoptosis, proliferation and 
differentiation (Elad-Sfadia et al., 2004; Fukumori et al., 2004; Liu et al., 2004). 
Nuclear Galectin-3 acts as a pre-mRNA splicing factor through interacting with 
the nuclear protein Gemin4 (Dagher et al., 1995; Park et al., 2001). In addition, 
nuclear Galectin-3 is involved in the regulation of the gene transcription via 
enhancing the transcription factor binding with CRE and Sp1, the promoters for 
the cell cycle regulating gene cyclin D1 (Lin et al., 2002). 
Extracellularly, Galectin-3 plays a role in cell-cell adhesion and in adhesion to the 
extracellular matrix through binding with cell surface glycoproteins and the 
glycosyalted components of extracellular matrix (Dumic et al., 2006; Ochieng et 
al., 2004). In contrast to intracellular Galectin-3, extracellular Galectin-3 induces 
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apoptosis in activated T cells (Fukumori et al., 2003). In addition, extracellular 
Galectin-3 mediates cell activation by crosslinking its cell surface glycoconjugate 
ligands, leading to the formation of a lattice-like structure and induces cell 
signalling (Ahmad et al., 2004; Ochieng et al., 2004). It also acts as a 
chemoattractant and promotes the migration of monocytes and macrophages 
(Sano et al., 2000).  
The majority of interactions between Galectin-3 and intracellular host proteins are 
glycan independent (protein-protein interaction) (Dumic et al., 2006), while 
extracellular Galectin-3 binds a diverse range of glycosylated molecules on the 
cell surface in a glycan dependent pattern (Dumic et al., 2006).  
1.15.4. Galectins-3 in host-pathogen interactions  
Host defence against pathogens is achieved by two types of immune response: the 
innate and adaptive immune systems. Pathogens that invade the human host are 
initially recognized by their innate immunity. This recognition is accomplished by 
germline encoded pattern recognition receptors (PRRs). These receptors can 
recognize the microbial components, termed pathogen-associated molecular 
patterns (PAMPs), and subsequently activate the immune system (Akira et al., 
2006; Cerliani et al., 2011). Out of these receptors, members of the host C-type 
lectin family are used by the innate immune system as PRRs to recognize 
pathogens. Such recognition is mediated by binding the host C-type lectin to 
SDWKRJHQ JO\FDQV VXFK DV WKH PXOWLSOH WHUPLQDO PDQQRVH FOXVWHU RU ȕ-glucan, 
inducing the release of inflammatory cytokines and reactive oxygen intermediates 
(Cerliani et al., 2011; van Kooyk & Rabinovich, 2008). Other host lectins, such as 
DC-SIGN, selectins and siglecs, bind microorganisms carrying host-like glycans 
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(Cerliani et al., 2011). For instance, DC-SIGN and the mannose receptor bind to 
the ManLAM of Mycobacterium tuberculosis, N-linked high mannose-type 
glycans attached to HIV-1 gp120, and Lewisx and Lewisy on H. pylori (Cerliani et 
al., 2011; Sato et al., 2009; van Kooyk & Rabinovich, 2008). Sialic acid-binding 
lectins, siglecs, also recognize sialic acid expressing pathogens and regulate the 
immune response (Crocker & Redelinghuys, 2008; Sato et al., 2009). In this 
context, Galectin-3 recognizes a diverse range of surface glycans of many 
pathogens, such as Neisseria gonorrhoeae, Leishmania major, Schistosoma 
mansoni, Candida albicans and Trypanosoma cruzi (John et al., 2002; 
Kleshchenko et al., 2004; Kohatsu et al., 2006; Pelletier & Sato, 2002). 
Therefore, it has been suggested that galectins, including Galectin-3, act as PRRs 
(Cerliani et al., 2011; Sato & Nieminen, 2004; Sato et al., 2009). The recognition 
of these pathogens by Galectin-3 can initiate an immune response, which 
subsequently leads to the clearance of microorganisms or instead may promote 
infection (Sato et al., 2009) (Figure 1.10). In addition, Galectin-3 is known to be 
released from the epithelium, endothelium and professional immune cells, such as 
inflammatory activated macrophages, as a result of bacterial infection, which 
further supports the consideration of Galectin-3 as PRRs (Almkvist & Karlsson, 
2004; Sato et al., 2009). An example of the latter has been reported by a recent 
study where the binding of Galectin-3 to Toxoplasma gondii 
glycosylphosphatidylinositols in macrophages was found to be essential for 
parasite recognition and TNF production (Cerliani et al., 2011; Debierre-
Grockiego et al., 2010). 
In addition, instead of activating the immune system Galectin-3 may confer a 
GLUHFWLPPXQHIXQFWLRQ7KLVLVEHVWH[HPSOLILHGE\WKHELQGLQJRIWKHĮ-2-type 
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mannans of Candida albicans with Galectin-3, which results in a loss of fungal 
viability (Cerliani et al., 2011; Kohatsu et al., 2006). 
On the other hand, several studies have suggested that Galectin-3-pathogen 
interactions may promote infection. In this context, Galectin-3 may facilitate H. 
pylori infection through allowing bacterial adhesion to the gastric epithelium 
(Cerliani et al., 2011; Fowler et al., 2006) (Figure 1.12).  
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Figure 1.12: Role of galectins, including Gal-3, in host±pathogen interactions 
and innate immunity. The recognition of specific glycans by galectins can lead to 
pro-inflammatory responses and pathogen clearance or favour immune suppressive 
microenvironments that promote chronic infection. For example, the recognition of the 
Į-2-type mannans of Candida albicans by Galectin-3 lead to fungal killing. However, in 
parasitic infection such as Schistosoma mansoni and Trypanosoma cruzi, Galectin-3 
helps in the recognition of these pathogens by macrophages, which subsequently leads to 
pathogen eradication. On the other hand, Galectin-3 can promote the infections of H. 
pylori and Neisseria gonorrhoeae by enabling bacterial adhesion and bacterial host cell 
recognition, respectively. Reproduced from (Cerliani et al., 2011). 
 
A brief overview of Galectin-¶VUROHDV355s has been given first in this review 
in order to understand the subsequent illustration of Galectin-3 interactions with 
different pathogens and the consequences of these interactions (described below).  
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1.15.4.1. Bacteria 
Galectin-3 recognizes the N-DFHW\OODFWRVDPLQH/DF1DF*DOȕ-4GlcNAc residue 
of bacterial lipooligo(poly)saccharides. This interaction of Gal-3 has been 
suggested by several reports, including different bacteria, such as H. pylori, 
Neisseria gonorrhoeae, E. coli and Klebsiella pneumonia (John et al., 2002; Li et 
al., 2008; Mey et al., 1996). Galectin-3 seems to be involved in Pseudomonas 
aeruginosa binding with the corneal epithelium via LPS (Gupta et al., 1997). Up 
to now, two independent sites of Galectin-3 have been suggested to mediate the 
binding with bacterial LPS. First, the binding site represents the CRD of Gal-3 
OHFWLQ GRPDLQ ZKLFK ELQGV ȕ-galactosides containing LPS from Klebsiella 
pneumonia (Mey et al., 1996). The second site is the N-terminal part of Gal-3 
(Non-lectin domain), which binds the lipid A moiety of LPS. LPS from S. 
minnesotaZKLFKLVGHYRLGRIȕ-galactosides, only binds the N-terminal domain 
of Gal-3 (Mey et al., 1996), while LPS from E. coli binds both the CRD and N-
terminal domain of Gal-3 (Li et al., 2008). It has been suggested by Li et al 
(2008) study, that the Galectin-3 acts as a negative regulator of LPS. This was 
evident by elevated cytokine production from macrophages of Galectin-3 
deficient mice when challenged with LPS, which was suppressed by the addition 
of exogenous Gal-3 (Li et al., 2008).  
It has been demonstrated that Galectin-3 accumulates in alveolar space after the 
induction of pneumonia with S. pneumonia, which correlates with neutrophil 
extravasation (Sato et al., 2002). It is worth noting that the recruitment of 
neutrophil from blood vessels to the infection site (neutrophil extravasation) is 
considered to be one of the most important components of innate immunity (Sato 
et al., 2002). Such recruitment requires the neutrophil to be firmly attached to the 
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endothelial wall of blood vessels, which is mediated in part by two types of 
adhesion molecules, beta (2) integrins and selectins (Sato et al., 2002), taking into 
consideration that, in vitro, Galectin-3 has been shown to promote neutrophil 
adhesion to the endothelium owing to the direct crosslinking between the 
neutrophil and the N-terminal aggregating domain of Galectin-3 (Almkvist & 
Karlsson, 2004). Returning to the previous point, during streptococcal pneumonia 
it has been suggested that Galectin-3 plays a role in beta (2) integrin-independent 
neutrophil extravasation (Sato et al., 2002). In contrast, Galectin-3 does not 
accumulate during neutrophil emigration in the alveoli induced by E. coli 
infection since the majority of neutrophil emigration is known to be beta (2) 
integrin-dependent (Sato et al., 2002). This has been further supported by a recent 
study (Farnworth et al., 2008), which showed that the migration of neutrophils to 
the S. pneumoniae-infected alveoli is reduced dramatically in Galectin-3 deficient 
mice. The development of more severe pneumonia with increased bacteremia and 
lung damage following infection with S. pneumonia is observed in Galectin-3 null 
mice when compared with wild-type mice (Farnworth et al., 2008). A reduction in 
the severity of pneumococcal pneumonia has been attributed in part to Galectin-3 
via its augmentation of neutrophil function (Farnworth et al., 2008). In addition, 
exogenous Galectin-3 induces the neutrophil phagocytosis of bacteria and delayed 
neutrophil apoptosis (Farnworth et al., 2008). It has also been shown that 
Galectin-3 has a bacteriostatic effect on S. pneumonia in vitro (Farnworth et al., 
2008). The addition of recombinant Gal-3 in vivo helps to protect Galectin-3 
deficient mice from developing severe pneumococcal pneumonia (Farnworth et 
al., 2008).   
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Galectin-3 expression has been shown to be upregulated in several infections, 
including pneumococcal meningitis (PM) (Bellac et al., 2007; Coimbra et al., 
2006). 
1.15.4.2. Parasites 
Not only lactosamine containing glycans have been shown to interact with Gal-3 
but also other types of ß-galactoside on the parasite surface, including (Galß1-3)n 
and (GalNacß1-4GlcNac) (Sato et al., 2009). For example, Galectin-3 binds the 
polygalactosyl repeat residue (Galß1-3)n of Leishmania major 
lipophosphoglycans (LPGs) (Pelletier & Sato, 2002). This binding leads to the 
cleavage of Galectin-3, producing truncated Galectin-3 that has the CRD but lack 
the N-terminal domain (Pelletier & Sato, 2002). Truncated Gal-3 lacks the ability 
to oligmerize or to form a stable association on the cell surface, which is required 
for Gal-3 innate immune modulation. Thus it has been suggested that this 
truncation of Gal-3 in response to Leishmania major may play a role in species-
specific immune responses (Pelletier & Sato, 2002). In addition, Galectin-3 binds 
T. cruzi and enhances its adhesion to the smooth muscle cells of coronary arteries 
(Kleshchenko et al., 2004). The silencing of Galectin-3 in these cells leads to a 
reduction in T. cruzi adhesion, which is restored by adding exogenous Gal-3 
(Kleshchenko et al., 2004). This provides evidence for the involvement of 
endogenous Galectin-3 in host±parasite interaction (Sato et al., 2009). Another 
XQLTXHȕ-galactoside (GalNacß1-4GlcNac), known as LacdiNAc, is expressed by 
parasitic worms or helminths and is recognized by Galectin-3 (van den Berg et 
al., 2004). This recognition increases the phagocytosis of LacdiNAc coated beads 
by macrophages (van den Berg et al., 2004). 
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1.15.4.3. Fungi  
Galectin-3 can differentiate between pathogenic fungal species, such as Candida 
albicans and non-pathogenic S. cerevisiae (Kohatsu et al., 2006). Such 
recognition is mediated by Gal-3 binding to the ß-1,2-ROLJRPDQQRVLGHV0DQȕ±
2)n  of Candida albicans, which are present in the cell wall glycolipid (Kohatsu et 
al., 2006). This glycan is specifically expressed by Candida albicans and is 
involved in the binding with the macrophage membrane, resulting in TLR2-
dependent NF-ɄB activation and tumour necrosis factor-a (TNF-a) (Fradin et al., 
1996). Interestingly, Galectin-3-Candida albicans binding leads to fungi being 
killed, indicating the fungicidal effect of Gal-3 (Kohatsu et al., 2006). 
1.16. Aims of the study  
The aim of this study was to characterize the role of Gal-3 in meningococcal-host 
cell interaction and identify the non-LOS meningococcal molecules that bind Gal-
3. It was also our aim to investigate the dimerization of Galectin-3 with 67 LR/37 
LRP, and to study the effect of meningococcal 67 LR/37 LRP adhesins on 
receptor gene expression.  
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2. Chapter 2: Methods and materials 
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2.1. Bacterial strains, growth conditions and media  
N. meningitidis serogroup B, strain MC58 wild type (B:15:P1.7.16b) (Tettelin et 
al., 2000). Different meningococcal mutants (Table 2.1) were produced in the 
laboratory. Clinical isolates used are listed in Table 2.2. All Neisseria strains were 
cultured on chocolated horse blood agar (Oxoid) at 37°C in an atmosphere of 5% 
CO2. When grown in suspension, all meningococcal strains were grown in brain-
heart infusion (BHI) broth (Oxoid) at 37°C with agitation. H. pylori 26695 strain 
was used and grown on blood agar plate (Oxoid) at 37°C under microaerobic 
conditions. 
Strains  Description Source or references 
MC58 wild-type serogroup B strain (Tettelin et al., 2000) 
0&ǻPilQ PilQ deletion and replaced with omega 
cassette 
(Orihuela et al., 2009) 
0&ǻPorA PorA deletion and replaced with 
omega cassette 
(Orihuela et al., 2009) 
0&ǻPilE PilE deletion and replaced with 
kanamycin cassette 
In house 
0&ǻPglL PglL deletion and replaced with 
kanamycin cassette 
In house 
0&ǻPglC PglC deletion and replaced with 
omega cassette 
In house 
0&ǻPglLC PglC and PglL deletions and replaced 
with omega and kanamycin cassettes, 
respectively. 
In house 
0&ǻlgtf Lgtf deletion and replaced with kanamycin cassette In house 
Table 2.1: List of meningococcal strain used in this project. 
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Straina  Country of origin Date of 
isolation 
Disease Serogroup 
MC58 b UK  Invasive B 
z1503c China 1984 Invasive A 
z1035 c Pakistan 1967 Invasive A 
z4662 c Netherlands 1967 Invasive B 
z4665 c Netherlands 1977 Invasive B 
z6413 c South Africa 1990 Invasive C 
z6414 c New Zealand 1994 Invasive C 
z6415 c England 1996 Invasive C 
z3515 c Saudi 1987 Carrier A 
z1392 c Greece 1968 Carrier A 
z4686 c Norway 1988 Carrier B 
z4685 c Norway 1988 Carrier B 
z23279d UK 2009 Carrier B 
z23288 d UK 2009 Carrier B 
z23000 d UK 2009 Carrier B 
z23464 d UK 2009 Carrier B 
z22955 d UK 2009 Carrier B 
z22951 d UK 2009 Carrier Y 
z22972 d UK 2009 Carrier Y 
z23484 d UK 2009 Carrier Y 
z99615 d UK 2010 Carrier Y 
z22984 d UK 2009 Carrier Y 
z1506 c Brazil 1976 Unspecified A 
z4262 c USA 1964 Unspecified B 
z4765 c Brazil 1976 Unspecified C 
z5163 c Spain 1985 Unspecified C 
a.
 Further details of strains are available at http://pubmlst.org/;  
b.
 Strain obtained from ATCC. 
c.
 Strain obtained from Prof  D. Caugant 
d.
 Strains isolated in Nottingham, UK 
Table 2.2: List of meningococcal clinical isolates used in this project. 
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2.2. Transformation of N. meningitidis 
2.2.1. Chromosomal DNA extraction and purification from 
meningococcal cells 
Genomic DNA was isolated using a DNeasy® tissue kit (Qiagen) according to 
PDQXIDFWXUHUV¶ LQVWUXFWLRQV ,Q EULHI WKH VWUDLQV ZHUH JURZQ RYHUQLJKW RQ
chocolate agar then sub-cultured in 5 ml BHI. A maximum of 2 × 109 cells were 
harvested by centrifuging at 5,000 × g for 5 min and the supernatant discarded. 
The pellet was re-VXVSHQGHGLQȝORIEXIIHU$7/VXSSOLHGLQWKHNLWȝO
proteinase K (20 mg /ml ) were then aGGHGDQGLQFXEDWHGDW&IRUKUȝO
buffer AL (supplied with the kit) was added, mixed thoroughly by vortexing, and 
LQFXEDWHGDW&IRUPLQ7RSURGXFHDKRPRJHQHRXVVROXWLRQȝO
ethanol was added and mixed thoroughly by vortexing. The mixture was then 
applied to the DNeasy® Mini spin column including any precipitate formed from 
the ethanol addition and centrifuged at 6,000 × g. The flow-through was discarded 
DQG  ȝO EXIIHU $: VXSSOLHG ZLWK WKH NLW ZDV DGGHG WR WKH FROXPQ DQG
centrifuged for 1 min at 6,000 × g. The flow-through was again discarded and 500 
ȝO EXIIHU $: VXSSOLHG ZLWK WKH NLW ZDV DGGHG DQG FHQWULIXJHG IRU  PLQ DW
18,000 × g to remove any residual ethanol. Finally the DNA was eluted using 100 
ȝOQXFOHDVH IUHHGHLRnised water. Chromosomal DNA was stored at -20°C until 
required.  
2.2.2. Natural transformation of N. meningitidis 
N. meningitidis was grown in BHI broth to an optical density of 0.2 at 600nm and 
added to a 15 ml tube containing 1.5 ml of BHI agar. After incubation for 2 h at 
37°C in 5% CO2 250ng of the mutagenic plasmid DNA was added to the culture 
and incubation was continued overnight. The cells were then harvested and plated 
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on BHI agar plates supplemented with the appropriate antibiotic and incubated 
overnight at 37°C in 5% CO2. Colonies were observed after 24 and 48 h.  
$QWLELRWLFV XVHG ZHUH NDQDP\FLQ 2[RLG ȝJPO VWUHSWRP\FLQ 2[RLG
ȝJPODQGVSHFWLQRP\FLQ2[RLGȝJPO 
2.2.3. Chemical transformation of N. meningitidis 
Non piliated meningococci transformed by chemical transformation method 
(Bogdan et al., 2002). N. meningitidis was grown in BHI broth to an early 
exponential phase (OD600 0.5±0.6). The cells were harvested by centrifugation at 
1000xg for 10 min at 4°C and gently resuspended in 1.0 ml of ice cold 
Transformation Solution (TS) (Appendix B). An aliquot of 190 µl of the cells 
resuspended in TS was transferred to a sterile 1.5 ml eppendorf tube. 100 ng of 
mutagenic plasmid or N. meningitidis chromosomal DNA was added to cells and 
mixed gently by stirring with a pipette tip. The cells were incubated on ice for 15 
min. 1.3 ml of BHI broth was added to the cells and incubated at 37°C for 1 hr with 
shaking at 250 rpm. The culture was then centrifuged at 9000 rpm in a microfuge for 4 
min, re-suspended in 200µl of BHI broth and spread on a BHI agar plates containing 
antibiotics and incubated at 37°C in 5% CO2 for 1±3 days or until colonies appeared. 
2.2.4. Electroporation of N. meningitidis cells 
Electroporation method was used for meningococcal transformation as described 
before (Duenas S et al., 1998). The overnight growth from chocolated horse blood 
agar plate was harvested into 10 ml of BHI broth and centrifuged (4000 rpm, 10 
min). The bacteria were then resuspended in 20 ml of ice-cold S&G buffer (272 
mM sucrose, 15% glycerol) before being re-centrifuged. This washing procedure 
was repeated three times before the bacterial cells were finally resuspended in 1 
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ml S&G buffer and left on ice until required. Purified DNA (1 - 5 Pg) was added 
to an electroporation cuvette (0.2 cm inter-electrode distance; Bio-Rad, UK) 
along with 40 Pl of competent N. meningitidis cells and placed on ice for 10 min. 
This was then subjected to electroporation in a Bio-Rad Gene Pulser at a voltage 
of 2.5 kV, a resistance of 400 : and a capacitance of 25 PFD. The contents of the 
tube were then added to 2 ml of BHI and incubated at 37°C for 5 hr. Aliquots 
were plated out onto BHI plate containing any appropriate selective antibiotics 
and incubated for up to 2 days at 37qC in 5% CO2. 
2.3. Enzyme linked immunosorbant assay 
2.3.1.  Digoxigenin labeling of bacteria  
Bacteria were harvested from an overnight plate culture and suspended in PBS-T, 
washed 3 times and suspended in PBS (PH 7.2). Optical density at 600 nm was 
adjusted to 1, and then digoxigenin-3-0-succinyl-İ-aminocaproic acid-N-hydroxy-
succinimide ester (DIG-NHS; Roche) was added and incubated at room 
temperature for 2 hrs. Bacteria were then washed 3 times with PBS-T and 
suspended in PBS containing 1% bovine serum albumin. Optical density at 600 
nm was adjusted to 0.02. 
2.3.2.  ELISA  
Purified recombinant human rGalectin-3 full molecule or its C terminal (CRD) 
(Calbiochem) or recombinant laminin recptor (rLR) or BSA (5µg/ml) diluted in 
PBS was used to coat Covalink amino-reactive 96 well microtiter plates 
(Immoblizer Amino; Nunc) overnight at 4 qC. Wells were washed with PBS-T 3 
WLPHVDQGEORFNHGZLWKȝORI%6$IRUKUDWURRPWHPSHUDWXUH%ORFNLQJ
buffer was decanted and 10ȝORIHLWKHU',*-labelled bacteria or purified proteins 
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(rLR U3RUDU3LO4DQGORRSV\QWKHWLFSHSWLGHȝJPOLQ3%6ZHUHDGGHGDQG
incubated for 4 hours at room temperature, or at 4°C overnight. The plate was 
vigorously washed with PBS-T 5 times with 5 min soaking intervals  and 
incubated with anti- digoxigenin alkaline phosphatase antibody (Roche, 1:5000) 
or polyclonal anti-37 LRP (1:1000); anti-PilQ (1:10000); anti-PorA(1:10000); 
anti-Loop4 (1:10000)  in PBS/1% BSA at room temperature. Bacterial incubated 
plates were incubated at room temperature for an additional 1h and washed 
several times as described above. 100µl of alkaline phosphatase substrate 
(5mg/ml;Roche) were added to each well, and the absorbance was measured at 
405nm after 15min using an ELISA plate reader. Purified protein plates were 
incubated with protein antibody at room temperature for an additional 2h and 
washed several times as described above. Plates were incubated with anti-rabbit 
alkaline phosphatase (1:12,000, Sigma) for 1h at room temperature followed by 
washing 3 times with PBS-T and 100µl of alkaline phosphatase substrate 
(5mg/ml; Roche) was added and absorbance measured at 405nm. Inhibition 
assays were performed as described above, except that bacteria were pre-
incubated with lactose or sugars for 2h at room temperature before being added to 
the ELISA plates.  
2.4. Expression and purification of recombinant proteins 
2.4.1.  Protein expression 
E. coli BL21(DE3) and JM109, containing recombinant plasmids pET2837 LRP, 
PQE30PorA and PNJ072PilQ (courtesy of N. Abouseada and N. Oldfield) were 
cultured into 50ml LB broth (Fisher Scientific) containing (50Pg/ml) of 
kanamycin or (100Pg/ml) RI DPSLFLOOLQ RYHUQLJKW DW Û& &XOWXUHV ZHUH WKHQ
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transferred into 1L of LB (1:20 dilution) containing kanamycin or ampicillin, 
respectively and incubated for 2hr until the OD600 reached 0.6, at this point 1ml 
of culture was aliquoted and retained. Then 1mM RI ,37* ,VRSURS\O ȕ-D-1-
thiogalactopyranoside (Promega) was added to induce protein expression and 
cultures grown for an additional 3hr, and 1 ml of induced culture was aliquoted 
and retained.  The cultures were harvested and the pellets were collected and 
stored in -20qC freezer. E. coli JM109 containing blank plasmid PQE70 and E. 
coli BL21 (DE3) containing blank plasmid pET28a were used as a negative 
control. Aliquoted samples were centrifuged at 13,000 x g for 1min. The cell 
pellet was re-suspended in the appropriate volume of 5 x SDS sample buffer using 
the following formula (volume LQȝO 2'î7KHVDPSOHVZHUHERLOHG
for 5 min at 95°C and then centrifuged again at 13,000 x g for 1min to be 
analyzed by SDS-PAGE (Section 2.5). 
2.4.2. Purification of recombinant protein  
Cells from 50ml culture were re-suspended in 5ml of buffer B (8M urea (Sigma), 
0.1M NaHΑPOΓ (BDH) & 0.01M Tris.HCl (Sigma) pH 8.0) and then sonicated in 
an ice bath for 15 cycles of 10 sec with 5 sec of cooling between cycles. Lysate 
was centrifuged at 45000 rpm for 30-40min at 4qC to pellet cellular debris, 
followed by incubation of the supernatant with 20mM of imidazole (Qiagen) and 
FREDOWUHVLQ)LVKHU6FLHQWLILFRYHUQLJKWDW&Û6XSHUQDWDQWZDVSDVVHGWKURXJK
a gravity column and extensively washed with buffer C (8M urea, 0.1M NaHΑPOΓ 
& 0.01M Tris.HCl, pH 6.3) and incubated overnight at 4C° with buffer E (8M 
urea, 0.1M NaHΑPOΓ & 0.01M Tris.HCl, pH 4.5). Buffer exchange was performed 
using PD-10 desalting columns (Amersham Biosciences), replacing the acidic urea 
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buffer with PBS (pH 7.2). Protein concentration was measured using a Nanodrop 
ND-1000 spectrophotometer (NanoDrop Technologies) by measuring the absorbance 
at 280 nm and proteins were stored at ± 20°C. 
2.5. Cloning of laminin receptor and Galectin-3 
2.5.1. Bacterial strains, growth conditions and media  
E. coli strains and plasmids used in this chapter are described in Table 2.3. E. coli 
strains were routinely grown at 37°C on Luria-Bertani (LB) agar or in LB broth 
(Fisher Scientific) containing ampicillin (100 µg /ml) where necessary. Where 
appropriate, blue/white selection of transformants in cloning experiments was 
achieved using IPTG (Roche) and X-gal at 0.5 mM and 80 µg/ml, respectively. 
All liquid cultures were aerated by agitation at 200 revolutions per minute (r p m) 
in a shaking incubator. 
2.5.2. Extraction of plasmid DNA 
E. coli JM109, harboring the desired plasmid, were streaked out from -80°C 
glycerol stock on to LB agar plates containing appropriate antibiotic and 
incubated overnight at 37°C . The following day, a single colony was used to 
inoculate a 10 ml of LB broth supplemented with 100 µg /ml ampicillin. The 
broth culture was incubated at 37°C overnight with shaking at 200 rpm. 
Purification of plasmids was achieved using 5 ml overnight cultures using a 
QIAprep spin kit (Qiagen) according to the manufacturerÿs instructions. In case 
of large-scale (70-100 µg) plasmid purification, GeneElute the Midi Prep kit 
(Sigma) was used according to manufacturerÿs recommendation. 
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2.5.3. Quantification of DNA and protein 
The concentration of purified PCR products, plasmid, genomic DNA and purified 
proteins was quantified using a NanoDrop (ND-1000) spectrophotometer (Agilent 
Technologies). 
2.5.4. Polymerase chain reaction (PCR) 
All PCR reactions were performed in a 50 µl final volume using sterile 0.2 ml 
thin-walled PCR tubes and cycled using a C1000 model Thermal Cycler (BIO-
RAD). A master mix containing all of the PCR components except template DNA 
was prepared in a pre-chilled, sterile microcentrifuge tube and thoroughly mixed 
by vortex. Following a brief centrifugation, a 50 µl aliquot of master mix was 
dispensed into chilled PCR tubes and 1 µl appropriate template DNA. The 
solution was mixed by gently stirring with a pipette tip and kept on ice prior to 
placement in the thermal cycler. Unless otherwise stated, all PCR mixtures 
contained: 100 ng of chromosomal DNA or 1-10 ng of Plasmid DNA; each of the 
respective primers to a final concentration of 300 nM; 5 µl of 10x Expand buffer 
(Roche); dNTPs (Roche) to a final concentration of 200 µM, Expand Hi Fidelity 
DNA polymerase 0.42 µl (3.5 U/ µl) (Roche) and the reaction mixture was made 
up to a final volume of 50 µl with dH2O. The PCR conditions were: initial 
template denaturation step of 3 min at 95°C, followed by 30 cycles of incubation, 
annealing at 55°C for 1 min, primer extension at 72°C for 3 min, and 95°C for 
45s, with final extension at 68°C for 10 min. 
2.5.5. Agarose gel electrophoresis 
1% agarose gel electrophoresis was used to analyse the PCR and plasmid 
products. The prepared gel was stained with 10µg/ml ethidum bromide (Sigma) 
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and run in 1 x Tris Acetate EDTA buffer (TAE buffer, Sigma) at 5 V/cm for1 hr. 
The gel was visualized using an ultraviolet trans-illuminator to detect the 
ethidium bromide-labelled DNA. Quick load (100bp and 1kb) and 2-log (0.1-10.0 
kb) DNA ladder mixes (New England Biolab) were used to estimate the size of 
PCR product and linearized plasmid. 
2.5.6. Poly-A tailing  
PCR products were subjected to A tailing procedure according to manufacturer 
instruction (Promega).  In this procedure, 7µl of PCR product, Taq DNA 
polymerase, Polymerase 10X Reaction Buffer with MgCl2, dATP to a final 
concentration of 0.2mM and de-ionized water (to a total volume 10µl) were added 
and incXEDWHGDWÛ&IRU-30min. As a result, this poly-A tailed PCR product 
was used in further cloning steps. 
2.5.7. Purification of Gel-extracted DNA products 
For gel extraction of DNA fragments amplified by PCR or generated by 
restriction digestion, samples were separated by agarose gel electrophoresis and 
the band of interest was excised with Gene catcher Tips (Web Scientific) and 
purified using a Gel extraction Kit (Qiagen) according to manufacturer¶V
instructions.  
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Strains/plasmids Description Source or reference 
E. coli strain  
 
JM109 endA1 recA1 gyrA96 thi hsdR17 (rK-
rK-UHO$VXS(ǻODF-proAB) 
>)¶traD36 proAB laqIq=ǻ0@ 
Promega 
Plasmids   
pGEM-T easy Cloning vector encoding 
resistance to ampicillin 
Promega 
pET2837 LRP laminin receptor protein cloned in 
pET28 plasmid vector 
(Orihuela et al., 2009) 
pcDNA3.1zeo 
YFP 
Mammalian expression vector 
encoding full length venus YFP 
Kindly provided by Dr. N. 
Holliday (Kilpatrick et al.) 
pcDNA3.1zeo 
YNL 
Mammalian expression vector 
encoding N terminal of venus YFP 
Kindly provided by Dr. N. 
Holliday (Kilpatrick et al.) 
pcDNA3.1zeo 
YCL 
Mammalian expression vector 
encoding C terminal of venus YFP 
Kindly provided by Dr. N. 
Holliday (Kilpatrick et al.) 
Table 2.3: List of bacteria strain and plasmids used in this project. 
Primers Sequence ( 5 Ǡ- 3 Ǡ)a Restriction site 
LRP-F1 gcgcgaattcgccatgtccggagcccttgat 
 
EcoRI 
LRP-R2 gcgcctcgagagaccagtcagtggttgctcc XhoI 
Gal-3-F1 gcgcgaattcgccatggcagacaatttttcgct 
 
EcoRI 
Gal-3-R2 gcgcctcgagtatcatggtatatgaagcactggtg 
 
XhoI 
mCherry-F gcgcctcgaggtgagcaagggcgaggagga 
 
XhoI 
mCherry-R gcgctctagattacttgtacagctcgtccatgc XbaI 
aSequences in bold identify restriction enzyme sites and the kozak consensus 
sequence is underlined. 
Table 2.4: Primers used for cloning of laminin receptor and Galectin-3. 
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2.5.8. Cloning of laminin receptor and Galectin-3 in pGEM-T 
easy vector 
A 888bp DNA fragments corresponding to laminin receptor (37 LRP) coding 
sequences was amplified by PCR using pre existing vector (pET2837 LRP) 
(Orihuela et al., 2009) and the pair primers 37 LRPP-F1 and 37 LRPP-R2 (Table 
2.4). A 725bp DNA fragments corresponding to Galectin-3 coding sequences was 
amplified by PCR using cDNA sequences of human galectin-3 and the pair 
primer Gal-3-F1and Gal-3-R2 (Table 2.4). The forward and reverse primers have 
EcoRI containing Kozak sequence and XhoI restriction sites, respectively, as 
shown in Table 2.4. The PCR reaction was performed as described in Section 
2.3.4. The amplified PCR products of both receptors were extracted from the gel 
and underwent poly A tailing as described in Section 2.2.5 and 2.5.6, respectively. 
Then, digested with EcoRI and XhoI as described in Section 2.5.4 and and ligated 
to pGEM-T easy vector (Promega) DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV The 
ligated product was transformed into E. coli JM109 according to the 
PDQXIDFWXUHU¶V LQVWUXFWLRQV Screening for a successful clone was performed by 
colony PCR amplification of the desired DNA fragment and subsequent DNA 
sequencing.  
2.5.9. Cloning of laminin receptor and Galectin-3 in 
pcDNA3.1zeo containing vYFP, vYNL and vYCL 
37 LRP and Gal-3 cloned into pGEM-T easy vector were digested with EcoRI and 
XhoI. The digested receptors were extracted from the gel and ligated into 
pcDNA3.1zeo containing either full length or the C or N terminal regions of 
venus YFP (kindly provided by Dr. N. Holliday, Cell signalling Institution) 
(Kilpatrick et al.). The vector pcDNA3.1zeo containing either full length or the C 
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or N terminal regions of venus YFP were pre digested with the same enzymes to 
be prepared for subsequent ligation with 37 LRP and galectin-3. Then, ligated 
product was transformed into E. coli JM109 DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V
instructions. Screening for a successful clone was performed by colony PCR 
amplification of the desired DNA fragment and subsequent DNA sequencing. The 
resulting plasmids were designated 37 LRP and Gal-3.vYFP, vYNL and vYCL 
(Table 2.7, Figure 2.1). 
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Figure 2.1:  A map of the 37 LRP and Gal-3.vYFP, vYNL and vYCL 
constructed by cloning 37 LRP and Gal-3.  into pcDNA3.1zeo containing full 
length (vYFP), N-terminal (vYNL) and C-terminal (vYCL) of venus yellow 
fluorescence protein. The plasmids contain ampicillin resistance gene.   
  
Gal3.vYFP
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XhoI
XbaI
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XhoI
XbaI
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6392 bps
EcoRI
XhoI
XbaI
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B
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6134 bps
EcoRI
XhoI
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F
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2.5.10. Cloning of laminin receptor and Galectin-3 in 
pcDNA3.1zeo containing mCherry 
A 711bp DNA fragments corresponding to mCherry coding sequences was 
amplified from a pre-existing  vector (Shaner et al., 2004) (kindly provided by Dr. 
Shaista Bano , Center for Biomolecular Science, University of Nottingham, UK) 
using PCR and the pair primers mCherry-F and mCherry-R (Table 2.4), removing 
the start methionine and including a stop codon. The forward and reverse primers 
have XhoI and XbaI restriction sites, respectively, as shown in Table 2.3. The 
PCR reaction was performed as described in Section 2.3.4. 37 LRP.vYFP and 
Gal-3.vYFP vectors were linearized by digestion (Section 2.3.12) with XhoI and 
XbaI removing vYFP. The plasmids 37 LRP.mCherry and Gal-3.mCherry were 
constructed by ligating XhoI and XbaI digested, gel-purified mCherry PCR 
product with 37 LRP.pcDNA3.1zeo and Gal-3.pcDNA3.1zeo, respectively. Then, 
ligated product was transformed into E. coli JM109 according to the 
PDQXIDFWXUHU¶V LQVWUXFWLRQV 6FUHHQLQJ IRU D VXFFHVVIXO FORQH ZDV SHUIRUPHG E\
colony PCR amplification of the desired DNA fragment and subsequent DNA 
sequencing. The resulting plasmids were designated 37 LRP.mCherry and Gal-3. 
mCherry (Table 2.7, Figure 2.2). 
 
6446 bps
Gal-3.mCherry
EcoRI
XhoI
XbaI
Gal-3
mCherry
37 LRP.mCherry
6581 bps
EcoRI
XhoI
XbaI
37 LRP
mCherry
A B
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Figure 2.2:  A map of the 37 LRP and Gal-3.mCherryv constructed by 
cloning of mCherry into pcDNA3.1zeo containing 37 LRP and Gal-3. The 
plasmids contain ampicillin resistance gene.   
 
2.5.11. PCR site-directed mutagenesis. 
The generated pcDNA3.1 zeo mammalian expression vector carrying the wild 
type 37 LRP and Gal-3 cDNA that is C-terminally fused to vYFP, vYNL and 
vYCL were used as templates and mutants were generated by site directed 
mutagenesis. The PCR mutaJHQHVLVUHDFWLRQFRQWDLQHGLQDWRWDOYROXPHRIȝO
ȝO RI [ UHDFWLRQ 3IX8OWUD 5-QJ RI GV'1$ WHPSODWH ȝJȝO ILQDO
concentration of each of the oligonucleotide primers (Table 2.5) both containing 
the desired mutation which are complementary to opposite strands of the dsDNA, 
20mM final concentration of dNTPs mix (Roche) and dH22 $IWHU WKDW ȝO RI 
PfuUltra high-fidelity DNA polymerase 8 ȝO ZDV DGGHG WR HDFK UHDFWLRQ
mix the primers are extended during temperature cycling (Table 2.6), and allow 
the generation of a mutated plasmid containing staggered nick. Then the PCR 
product was treated with Dpn I endonuclease to digest the remaining parental 
DNA template and to select for mutation-containing synthesized DNA. 
Subsequently, transformation was carried out into E. coli JM109 competent cells 
that were plated on an LB/ampicillin plate for the selection after recovering the 
cells for an hour at 37°C. Then samples were sent for sequencing. All generated 
constructs are described in Table 2.7 and primers used in all cloning procedures 
are described in Table 2.4 and 2.5.  
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Primers Sequence ( 5 Ǡ- 3 Ǡ)a 
LRP.FP.M.C148A cctacctaccattgcgctggctaacacagattctcctctg  
LRP.RP.M.C148A cagaggagaatctgtgttagccagcgcaatggtaggtagg 
LRP.FP.M.C163A tggacattgccatcccagccaacaacaagggagctc 
LRP.RP.M.C163A gagctcccttgttgttggctgggatggcaatgtcca 
Gal-3.FP.M.C173A gagaacaacaggagagtcattgttgccaatacaaagctggataataactg  
Gal-3.RP.M.C173A cagttattatccagctttgtattggcaacaatgactctcctgttgttctc  
Table 2.5: Primers used for site-directed mutagenesis of laminin receptor 
and Galectin-3. 
 
Segment Cycles Temperature Time 
 
1 1 95°C  30 seconds 
2 16 95°C                   30 seconds 
55°C                   1   minute 
  
  
68°C  4.5 minute 
Table 2.6: Cycling Parameters for the QuikChange II-E Site-Directed 
Mutagenesis Method. 
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Name of construct Description 
 
Vector Restriction 
sites 
37 LRP.vYFP 
Laminin receptor wild 
type fused to venus 
yellow fluorescent 
protein (vYFP) 
pcDNA3.1zeo EcoRI /XhoI 
37 LRP.vYNL Laminin receptor wild 
type fused to N-terminal 
of venus yellow 
fluorescent protein 
(vYNL) 
pcDNA3.1zeo EcoRI /XhoI 
37 LRP.vYCL Laminin receptor wild 
type fused to C-terminal 
of venus yellow 
fluorescent protein 
(vYCL) 
pcDNA3.1zeo EcoRI /XhoI 
Gal-3.vYFP Galectin-3 wild type 
fused to venus yellow 
fluorescent protein 
(vYFP) 
pcDNA3.1zeo EcoRI /XhoI 
Gal-3.vYNL Galectin-3 wild type 
fused to N-terminal of 
venus yellow 
fluorescent protein 
(vYNL) 
pcDNA3.1zeo EcoRI /XhoI 
Gal-3.vYCL Galectin-3 wild type 
fused to C-terminal of 
venus yellow 
fluorescent protein 
(vYCL) 
pcDNA3.1zeo EcoRI /XhoI 
37 LRP.C148AvYFP Laminin receptor  fused 
to venus yellow 
fluorescent protein 
(vYFP) containing 
cysteine mutated to 
alanine at position 148  
pcDNA3.1zeo EcoRI /XhoI 
37 LRP.C163AvYFP Laminin receptor  fused 
to venus yellow 
fluorescent protein 
(vYFP) containing 
cysteine mutated to 
alanine at position 163 
pcDNA3.1zeo EcoRI /XhoI 
37 
LRP.C148/163AvYFP 
Laminin receptor  fused 
to venus yellow 
fluorescent protein 
(vYFP) containing 
cysteines mutated to 
alanines at positions 
148/163 
pcDNA3.1zeo EcoRI /XhoI 
37 LRP.C148AvYCL Laminin receptor  fused 
to C-terminal of venus 
yellow fluorescent 
pcDNA3.1zeo EcoRI /XhoI 
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protein (vYCL) 
containing cysteine 
mutated to alanine at 
position 148 
37 LRP.C148AvYNL Laminin receptor  fused 
to N-terminal of venus 
yellow fluorescent 
protein (vYNL) 
containing cysteine 
mutated to alanine at 
position 148 
pcDNA3.1zeo EcoRI /XhoI 
37 LRP.C163AvYNL Laminin receptor  fused 
to N-terminal of venus 
yellow fluorescent 
protein (vYNL) 
containing cysteine 
mutated to alanine at 
position 163 
pcDNA3.1zeo EcoRI /XhoI 
37 LRP.C148AvYFP Laminin receptor  fused 
to venus yellow 
fluorescent protein 
(vYFP) containing 
cysteine mutated to 
alanine at position 148  
pcDNA3.1zeo EcoRI /XhoI 
37 LRP.C163AvYFP Laminin receptor  fused 
to venus yellow 
fluorescent protein 
(vYFP) containing 
cysteine mutated to 
alanine at position 163 
pcDNA3.1zeo EcoRI /XhoI 
Gal-3.C173AvYFP Galectin-3 fused to 
venus yellow 
fluorescent protein 
(vYFP) containing 
cysteine mutated to 
alanine at positions 173 
pcDNA3.1zeo EcoRI /XhoI 
Gal-3.C173AvYCL Galectin-3 fused to C-
terminal of venus 
yellow fluorescent 
protein (vYCL) 
containing cysteine 
mutated to alanine at 
position 173 
pcDNA3.1zeo EcoRI /XhoI 
Gal-3.C173AvYNL Galectin-3 fused to N-
terminal of venus 
yellow fluorescent 
protein (vYNL) 
containing cysteine 
mutated to alanine at 
position 173 
pcDNA3.1zeo EcoRI /XhoI 
37 LRP.C163AvYNL Laminin receptor  fused 
to N-terminal of venus 
yellow fluorescent 
protein (vYNL) 
pcDNA3.1zeo EcoRI /XhoI 
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containing cysteine 
mutated to alanine at 
position 163 
37 LRP.mCherry Laminin receptor  fused 
to N-terminal of 
mCherry 
pcDNA3.1zeo EcoRI /XhoI 
Gal-3.mCherry Galectin-3  fused to N-
terminal of mCherry 
pcDNA3.1zeo EcoRI /XhoI 
Table 2.7: Names and descriptions of constructs used in this project. 
2.5.12. Restriction endonuclease digestion 
Restriction digestion reactions were routinely carried out in a 2ȝOfinal volume. Unless 
RWKHUZLVHVWDWHGȝJRI'1$IRUXVLQJLQVXE-cloning), was digested as a double digest 
with appropriate enzymes and compatible buffers. Restriction endonuclease enzymes and 
buffers were purchased from New England Biolabs or Roche and used according to the 
directions of the manufacturer. 
2.5.13. Ligation Reaction 
Appropriate amounts of vector and insert DNA were combined in a 1:3 ratios in a 
sterile microcentrifuge tube and the reaction was assembled in 10µl final volume. 
A typical ligation reaction contained; 100 ng insert, 50-100 ng plasmid DNA, 1 µl 
T4 DNA ligase (New England Biolabs), 1 µl 10 × ligation buffer (New England 
Biolabs), and where required dH2O was added to make a final volume of 10 µl. 
The ligation reaction was incubated at 16°C for 1h and then overnight at 4°C. An 
aliquot of 1.5 µl was used to transform E. coli JM109 competent cells. 
2.5.14. Transformation 
Briefly, an aliquot of 50 µl of frozen competent E. coli cells JM109 (Promega), 
was thawed on ice 5 min prior to transformation. 100 ng of plasmid DNA was 
added to cells and mixed gently by stirring with a pipette tip. The cells were 
incubated on ice for 20 min followed by heat shock at 42°C in water bath for 50 s 
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without shaking. Immediately after heat treatment, the cells were transferred on to 
ice for 2 min. 400 ȝO of S.O.C medium (Invitrogen)was added to the cells and the 
cell suspension was incubated at 37°C for 1.5 hr with shaking at 250 rpm. The 
transformation reaction was plated out as 100µl, 150 ȝO, and 200 ȝO, on LB agar 
containing appropriate antibiotic and incubated overnight at 37°C. 
2.5.15. DNA sequencing 
DNA constructs were sequenced in both directions using T7 and BGH primers at 
the School of Biomedical Sciences (University of Nottingham) on an ABI 377 
automated DNA sequencer. 
2.6. Cell line and cell culture condition  
Primary human brain microvascular endothelial cells (HBMECs, ScienCell 
Research Laboratories) were cultured in human fibronectin coated flasks 
(Biocoat, BD-Falcon) at 37°C, 5% CO2 in endothelial cell medium (ECM, 
Science Cell Research Laboratories) supplemented with endothelial cell glial 
supplement (ECGS, Science Cell Research Laboratories), 1% (v/v) antibiotic-
antimycotic solution (Gibco) and 10% (v/v) fetal bovine serum (FBS, Science 
Cell Research Laboratories). Astrocytes were cultured at 37°C, 5% CO2 in 
Astrocyte Medium (AM, Science Cell Research Laboratories) supplemented with 
astrocyte glial supplement (AGS, Science Cell Research Laboratories), 1% (v/v) 
antibiotic-antimycotic solution (Gibco) and 10% (v/v) fetal bovine serum (FBS, 
Science Cell Research Laboratories). Neuro2a , mouse neuroblastoma cell line 
(N2a, ATCC via LGC Standards) were cultured at 37°C, 5% CO2 in Eagle's 
Minimum Essential Medium (EMEM, ATCC) supplemented with1% (v/v) 
antibiotic-antimycotic solution (Gibco) and 10% (v/v) fetal bovine serum (FBS, 
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6FLHQFH &HOO 5HVHDUFK /DERUDWRULHV &26 FHOOV ZHUH JURZQ LQ 'XOEHFFR¶V
PRGLILHG (DJOH¶V PHGLXP DMEM, Invitrogen) supplemented with 1% (v/v) 
antibiotic-antimycotic solution (Gibco) and 10% (v/v) fetal bovine serum, at 37°C 
and 5% CO2. Cell culture media was changed every two days and cells were split 
using trypsin-EDTA (Gibco) when they became 90% confluent. Cells were grown 
the day before transfection in 6-well or 12 well or 24-well plates in order to reach 
a confluency of 50-70 % on the day of transfection. For immunofluorescence 
assays, cells were grown on 12 mm diameter glass coverslips with appropriate 
coating and media.  
2.7. Transfection and harvesting cells  
Cells were grown the day before transfection in 6-well or 12 well or 24-well 
plates in order to reach a confluency of 50-70 % on the day of transfection. Cells 
were transiently transfected with Trans IT-2020 transfection reagent (Mirus) 
according to the PDQXIDFWXUHUV¶LQVWUXFWLRQV'1$ZDVFRPSOH[HGZLWK7UDQV,7-
2020 in serum-free, antibiotic free media at a ratio of 2Pg DNA: 1Pl TransIT-
2020 at room temperature for 25 min. 250Pl of DNA: TransIT-2020 complex was 
added to each well of the 6 well plate or 100Pl DNA: TransIT-2020 complex was 
added to each well of the 12 well plates. After 4 hr of incubation, the media was 
changed and the transfected cells were cultured at 37°C in a 5% CO
2
atmosphere 
for 24 hours. After 24 hours, cells grown on coverslips were fixed with 4% PFA 
and subjected to immunofluorescence staining and confocal microscopy as 
described in section 2.5 and 2.6, respectively. Transfected cells in 6 well plates 
were washed with ice-cold 1X phosphate buffered saline (PBS) and harvested by 
scraping in 2x SDS sample buffer or subjected to subcellular fractionation. For 
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subcellular fractionation, cells were harvested and washed twice with ice-cold 
PBS and separated into cytosolic, membrane, soluble and chromatin bound 
nuclear, and cytoskeleton fractions (Subcellular Protein Fractionation Kit, 
7KHUPR6FLHQWLILFDFFRUGLQJWRWKHPDQXIDFWXUHU¶VSURWRFRO 
2.8. Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
The recombinant proteins were electrophretically separated by 7.5% SDS-PAGE 
(Appendix B) using Mini- Protean III equipment (BIO-RAD) at a constant 30mA 
per gel with a 200V voltage limit for approximately 40-45 min. Protein samples 
were resuspended in 1 × or 5 × SDS sample buffer (Appendix B) and heated at 
100°C for 5 min. An aliquot of 10µl of sample was loaded into each well of the 
gel and 10µl of pre-stained broad range protein markers (New England Biolabs) 
were loaded into an adjacent lane. Proteins separated by SDS-PAGE were 
visualized by staining with SimplyBlue SafeStain (Invitrogen) or PageBlueTM 
Protein Stain Solution (Fermentas) according to the manufacturer¶s instructions.  
2.9. Immunoblot analysis 
For Immunoblot analysis, the proteins separated by 10% SDS-PAGE were 
transferred onto a nitrocellulose membrane (Biorad) in semi-dry blotting buffer 
(Appendix B) using a Trans-Blot SD semidry transfer cell (BIO-RAD) at a 
constant currant of 14 mA for approximately 30 min. The membranes were 
blocked with PBS containing 1% bovine serum albumin (BSA, sigma) for 1 hour 
at RT. The membranes were then probed with primary antibodies (in PBS-1% 
BSA) for 1 hr at room temperature or overnight with shaking at 4°C. The 
following day, the membranes were washed three times 15 min each with Tris 
Buffered Saline-Tween (TBS-T), and incubated into secondary antibody (anti-
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mouse IgG conjugated to alkaline-phosphtase or anti-rabbit conjugated to alkaline 
phosphtase or anti-rat IgG conjugated to alkaline-phosphtase) (Sigma) at the 
concentration of 1:30,000 for 1 h at RT. After 1 h the membranes were washed 
six times with TBS-T for 10 min each time. The  membrane was then developed 
using the BCIP (5-bromo-4- chloro-3-indolylphosphate)̢Nitro Blue Tetrazolium 
liquid substrate (PerkinElmerTM). Primary antibodies included anti-GFP rabbit 
polyclonal antibody (sc-8334, Santa Cruz) (1:200), anti-mCherry rabbit 
polyclonal antibody (632496, Clontech), anti-penta-His Tag antibody (Sigma); 
anti-InH37 LRPP (In house laminin receptor precursor) rabbit polyclonal 
antibody (1:1000); rat monoclonal anti-Galectin-3 Mac-2 (clone M3/38, 125402, 
BioLegend) (1:1000) and anti-galectin-3 mouse monoclonal antibody (MAB4033, 
Millipore) (1:1000).  
2.10. Immunofluorescence  
Cells transfected with required constructs were fixed on cover slips with 4% 
paraformaldehyde (PFA) in PBS for 10 minutes at room temperature before being 
washed twice with PBS and incubated in 4% BSA in PBS (blocking solution) for 
one hour at room temperature. Then cover slips were incubated with primary 
antibody(s): primary antibody(s): anti-GFP rabbit polyclonal antibody (sc-8334, 
Santa Cruz) (1:100); anti-6737 LRP Mlu5 and Ab711(Abcam) (1:100); anti-
InH37 LRPP rabbit polyclonal antibody (1:100); rat monoclonal anti-mouse 
galectin-3 Mac-2 (clone M3/38, 125402, BioLegend) (1:200); goat polyclonal 
anti-human galectin-3 (AF1154, R and D systems) (1:100) and mouse monoclonal 
anti-human galectin-3 antibody (MAB4033, Millipore) (1:100)  in PBS/4% BSA 
for 1hr. Coverslips were washed 20 times in PBS-T, 40 times in PBS and 
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incubated with secondary antibody(s): anti-mouse Alexa Fluor 647 antibody 
(1:2000); anti-mouse Alexa Fluor 680 antibody (1:100); anti-rabbit Alexa Fluor 
680 antibody (1:100); anti-rabbit Alexa Fluor 488 antibody (1:400); anti-mouse 
Alexa Fluor 488 (1:400); anti-goat Alexa Fluor 488 (1:400); anti-rat Alexa Fluor 
647 (1:400); (all from Molecular Probes), in PBS/4% BSA for 1hr and washed 20 
times in PBS-T, 40 times in PBS and 20 times  in dH2O. Coverslips were 
mounted using Fluoromount (Sigma) mounting media and images obtained by 
confocal microscope (Zeisis LSM700).   
2.11. Confocal microscopy 
Images were captured using a Zeiss LSM700 confocal microscope (Carl Zeiss, 
Ltd., Welwyn, UK) using Plan-Apochromat 63x/1.4 Oil DIC M27. Alexa 488 and 
vYFP, mCherry, Alexa 680 and 647 and Hoechst were detected using the 
following lasers respectively 488 nm or 561 nm or 639 nm or 405 nm nmlasers 
were used. The image size was 1024 × 1024 with 8 averages taken per frame and 
a pinhole size of 1 Airy Unit. All control images were captured with the same 
laser power, gains and zoom settings. Identical linear adjustments to contrast and 
brightness were made to representative images in the figures for presentation 
purposes. Images were captured using the Zen 2009 software package and 
processed by Image J and CS4 photoshop. 
2.12. Flow cytometry 
Flow cytometric analysis of cell surface receptors was performed by incubation of 
HBMECs with mouse monoclonal anti-67 LR antibody MLuC5 (8 or 4µg/µl; 
Abcam) or mouse monoclonal anti-Galectin-3 (20µg/ml; Millipore, Chemicon) 
/106 FHOOV IRU KU DW Û& 7KHQ FHOOV ZHUH ZDVKHG WKUHH WLPHV ZLWK 3%$ EXIIHU
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(0.5% BSA and 0.5% sodium azide) and exposed to (1:50 dilution) of Alexafluor  
467goat anti-mouse IgM or 488 goat anti-mouse IgG (all from Molecular Probes) 
IRUKUDWÛ&$IWHUZashing with PBA buffer, cells were resuspended in 250µl 
of 0.5% paraformaldehyde and subjected to flow cytometry (Coulter Altra Flow 
Cytometer). In some experiments the cells were incubated with different bacterial 
proteins (rPorA, rPilQ and Loop4 all at 20µg/ml) for 2hr at room temperature 
before incubation with primary antibody. For BiFC analysis, COS7 cells were 
grown in 6-well plates and 24 hours after transfection, cells were gently detached 
using cell dissociation solution (Sigma), washed with PBA buffer (0.5% BSA and 
0.5% sodium azide) and resuspended in 0.5% paraformaldehyde in PBS and 
subjected to flow cytometry (Coulter Altra Flow Cytometer). Data acquisition and 
analysis were performed with weasel 2.5 software. In each case, 50,000 cells were 
counted in triplicate and used to calculate the average BiFC signal intensity ± SE. 
Full-length YFP fluorescence signal was used as the interassay reference for 
maximal fluorescence in each experiment, against which the BiFC signal 
intensities were compared. 
2.13. Adhesion and invasion assay 
2.13.1. Preparation of meningococci 
N. meningitidis strains, MC58-WT were streaked onto chocolate agar plates and 
incubated as described in section 2.11. The following day, meningococci were 
cultured into 10ml BHI Brain Heart Infusion (Appendix B) and incubated at 37°C 
with shaking (200 rpm) until the OD600 reach 0.5.  
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2.13.2. Preparation of cells 
N2a cells were cultured in EMEM supplemented with1% antibiotic-antimycotic 
solution (Gibco) and 10% fetal bovine serum were transiently transfected with 
galectin-3 and grown to confluence in 24-well tissue culture plates (Costar) at 
37°C, 5% CO2. Prior to all experiments, mono-layers were transferred to EMEM 
supplemented with 2% FCS to remove the antibiotics. 
2.13.3. Association assay 
Association assays were performed essentially as previously described (Oldfield 
et al., 2007). Briefly, N2a monolayers were infected with 1 x107 cfu of 
meningococci (multiplicity of infection of 300) (confirmed retrospectively by 
plating out aliquots of serially diluted inoculums) and left to associate for 2 h in 
5% CO2 at 37eC. To assess total cell association, monolayers were washed four 
times with 1 ml 1 × PBS per well. The monolayers were then disrupted and 
homogenized in 1 ml 0.1% saponin in PBS. Meningococci were enumerated by 
serial dilution of the homogenized suspensions and subsequent determination of 
colony-forming units by plating 10 µl spots from appropriate dilutions of the 
lysates on agar. 
2.13.4. Invasion assay 
N2a monolayers were infected as described in section 2.13.3, but were left to 
associate for 4 h in 5% CO2 at 37°C. The media was then removed and 1 ml 
EMEM containing gentamicin  (100µg/ml) were added per well to kill the extra-
cellular bacteria for 30 mins. Prior to further steps, aliquots of the gentamicin-
containing supernatants were plated out to confirm killing of extra-cellular 
bacteria. Furthermore, the susceptibility of all meningococcal strains to 
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gentamicin at 100 µg/ ml  was confirmed prior to testing. To assess cell invasion, 
monolayers were washed three times with 1 ml 1 × PBS per well. The monolayers 
were then disrupted and homogenized in 1 ml 0.1% saponin in PBS. 
Meningococci were enumerated by serial dilution of the homogenized 
suspensions and subsequent determination of colony-forming units by plating 50 
µl aliquots from appropriate dilutions of the lysates on agar. 
2.14. Animal study 
2.14.1. Ethics statement 
Mice experiments described in the present study were conducted at the animal 
facility of Wenner-Grens Institute, Stockholm University. Animal care and 
experiments were conducted adhering to the LQVWLWXWLRQ¶V JXLGHOLQHV IRU DQLPDO
husbandry. All protocols were approved by the Swedish Ethical Committee on 
Animal Experiments (Approval ID: N316/10).  
2.14.2. Mouse strains 
The hCD46Ge transgenic mouse line (CD46+/+) was created using B6C3F1 
hybrids. It harbors the complete human CD46 gene and expresses CD46 in a 
human-like pattern (Mrkic et al., 1998). Previous studies have shown that this 
mouse model can develop meningococcal disease (Johansson et al., 2003; 
Johansson et al., 2005). 
2.14.3. Mouse infection studies 
Serogroup B N. meningitidis MC58 and the mutant strains were grown for 18 
hours at 37 °C in a 5% CO2 atmosphere on GC agar (Difco) supplemented with 
Kelloggs (Kellogg et al., 1968). Bacteria were suspended in GC liquid and each 
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mouse was challenged intraperitoneally (i.p.) with 1.2x109 &)8 LQ ȝ/ *&
liquid. Experiments were performed with 6±8 week old mice (n=10 mice per 
group). ,QFRQWUROJURXSPLFHZHUHFKDOOHQJHG LSZLWKȝ/*& OLTXLG The 
health status of all mice was closely monitored for 7 days. At indicated time 
points, whole blood samples were collected from the tail vein for measurement of 
cytokines, chemokines and bacteremial levels. (Brain were collected at the end of 
the experiment and stored in 4% formaldehyde). 
2.14.4. Immunofluorescence 
Paraffin embedded tissue sections of mice brains were subjected to 
immunofluorescence staining by an antigen retrieval method. The sections were 
deparaffinized in xylene and rehydrated through graded ethanols. For antigen 
retrieval, the slides were autoclaved for 5 mins in 10 mmol/L sodium citrate 
buffer (pH 6.0) and cooled for 10 minutes at room temperature. Sections washed 
one time with PBS-T and three times with PBS for 5 minutes each time and 
blocked for 1 hour in 4% BSA in PBS/0.3% Triton X-100 at room temperature. 
Sections were incubated overnight with the two antibody combinations of anti-
InHLRPP rabbit polyclonal antibody (1:100) and rat monoclonal anti-mouse 
Galectin-3 Mac-2 (clone M3/38, 125402, BioLegend) (1:10) in 4% BSA in 
PBS/0.3% Triton X-100 at 4 °C. After washing, the slides were incubated with 
secondary antibody(s): anti-rat Alexa Fluor 647 antibody (1:100) and anti-rabbit 
Alexa Fluor 488 antibody (1:200); in 4% BSA in PBS/0.3% Triton X-100 for 1hr 
at room temperature. Following extensive washing, sections were covered with 
Fluoromount (Sigma) mounting media and images obtained by confocal 
microscope (Zeisis LSM700). Controls for unspecific binding by secondary 
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antibodies were included in each staining.  Brain tissue sections obtained from 
eight mice were analyzed and images from two mice are presented. Fluorescence 
intensity quantified by ImageJ software. 
2.15. Real time quantitative PCR (qPCR) 
2.15.1. Induction of HBMECs 
The propagation of HBMECs was described in section 2.1.7. The HBMEC 
monolayer was grown to confluence in T25 tissue culture flasks and induced with 
the recombinant meningococcal proteins (rPorA, rPilQ and Loop4 of PorA) at a 
FRQFHQWUDWLRQRIȝJPORU3%6DVDQHJDWLYHFRQWURO7KHQFXOWXUHVZHUHUH-
incubated for 24 hr at 37°C with 5% CO2 after which monolayer were washed 
with cold PBS and total RNA was extracted as described in section 2.2.2. The 
cells were examined by microscopy before and after induction to exclude any 
infection.  
2.15.2. Extraction of total RNA and cDNA synthesis 
Total RNA was extracted using an RNeasy Plus Micro kit (QIAGEN) in 
conjunction with the QIA shredder system (QIAGEN) according to the 
PDQXIDFWXUHU¶V LQVWUXFWLRQV 7KH TXDOLW\ RI 51$ VDPSOHV ZDV YHULILHG E\
measuring the optical density (OD, 260/280) absorption ratio of 1.8 (range 1.8-2). 
To ensure the removal of any residual DNA contamination, the RNA samples 
were incubated with RNAase-free Turbo-DNAse I (Ambion) at 37qC for 20min, 
and then DNAase I was heat-inactivated at 65qC for 10min. The total RNA was 
cleaned up and concentrated using RNeasy MinElute Cleanup kit (QIAGEN) 
DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQVDQGWKH2'PHDVXUHGDJDLQ)XUWKHU
confirmation of DNA removal from RNA samples was examined by PCR 
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amplification of the 37 LRP gene using 37 LRPP-F1 and 37 LRPP-R2 primers 
(Table 2.7ZLWKȝJRI51$DV WHPSODWHDQG37 LRP PCR product as positive 
controls. cDNA was obtained using QuantiTect Reverse Transcription Kit 
4,$*(1DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV 
2.15.3. Primer optimization, standard curves and qPCR 
Quantitative PCR was performed using AB7500 Real time PCR system (Applied 
Biosystem) and Power SYBR green master mix (Roche) according to the 
PDQXIDFWXUHU¶V LQVWUXFWLRQV3ULPHUV VSHFLILF WR37 LRP and B-actin (Table 2.8) 
were designed and used for amplification of 98bp and 55bp fragments, 
respectively. Primers were optimized using different concentrations (0.5-9µM) of 
forward and reverse primers with 10 ng/µl of HBMEC cDNA utilized as template 
and 2x buffer of Power SYBR Green Master Mix for both 37 LRP DQG ȕ-actin 
PCR reaction. To test PCR efficiency, a standard curve was generated with serial 
fivefold dilution of a known amount (100 ng/µl) of HBMEC cDNA using 3µM of 
forward and 9µM of reverse primers. A standard curve was plotted for 37 LRP 
and B-actin using template dilution YHUVXV &7 DQG ¨&7 YDOXHV 7KH TPCR 
UHDFWLRQPL[WXUHȝOWRWDOYROXPHFRQVLVWHGRIȝORIF'1$QJȝOȝO
of Power SYBR green master mix; 3µM of forward and 9µM of reverse primers 
and H2O. Reactions started with a 2min hold at 50°C, then 10min at 95°C 
followed by 40 cycles of denaturation at 95°C for 150sec followed by 
annealing/extending at 60°C for 1min. Quantification was relative to untreated 
+%0(&V DQG ZDV GHWHUPLQHG E\ WKH ǻ¨&7 PHWKRG DV GHVFULEHG SUHYLRXVO\
(Livak & Schmittgen, 2001). 
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Gene Forward oligonucleotide sequence 
( 5¶- 3¶) 
Reverse oligonucleotide 
sequence ( 5¶- 3¶) 
Laminin receptor GGAAAAGTGATGGCATCTATATCA ATCAGCAGGGTTTTCAATGG 
B-actin GCGCGGCTACAGCTTCA CTTAATGTCACGCACGATTTCC 
Table 2.8: Forward and reverse primers sequences used in qPCR 
experiments 
2.15.4. Data analysis 
7KH ǻǻ&W PHWKRG IRU UHDO-time relative quantitative PCR with power SYBR 
Green detection was used to estimate the 67 kDa 37 LRP gene expression in 
HBMECs. Analysis of real-time PCR amplification data was performed using 
SDS software (Applied Biosystems). Standard curves for target and endogenous 
gene were plotted showing CT value versus log of initial concentration of cDNA. 
The slope of the standard curve was calculated to describe the efficiency of PCR 
(if the PCR amplification is exponential, resulting in a doubling of product in 
HYHU\F\FOHWKHVORSHZLOOEHíDVF\FOHVDUHUHTXLUHGWRJHQHUDWHD-fold 
increase in product). The expression of the target gene (6737 LRP) in the 
experimental samples (induced HBMECs with rPorA, Loop4 of PorA and rPilQ) 
relative to a control calibrator (HBMECs treated with PBS) and B-actin as 
endogenous gene, was analyzed based on the relative quantification approach as 
recommended in AB 7500 User Bulletin (Applied Biosystems). 
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3. Chapter 3: Investigation of N. meningitidis binding to 
Galectin-3 
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3.1. Introduction: 
Adhesion of N. meningitidis to host cell surfaces is mediated by its Type IV pili 
(T4p) (Scheuerpflug et al., 1999) and the cellular receptor for T4p was proposed 
to be CD46 (Kallstrom et al., 1997). A further study reported CD46-independent 
adhesion (Kirchner et al., 2005), which necessitates further characterization of the 
initial attachment. After initial adhesion of host cell, the poly-saccharide capsule 
and T4p expression is downregulated (Deghmane et al., 2002) allowing more 
intimate adhesion, which is further maintained by outer membrane opacity 
proteins, including Opa and Opc (Moore et al., 2005; Virji et al., 1993a; Virji et 
al., 1994). Opa and Opc can interact directly with heparan sulphate proteoglycans 
HSPGs (Prince et al., 2001; Virji et al., 1999). In addition, interaction of Opc 
with serum proteins vitronectin mediates bacterial binding to endothelial integrins 
Į9ȕDQGĮȕ (Unkmeir et al., 2002; Virji et al., 1994). Opc may also directly 
bind to extracellular matrix (ECM) proteins, such as vitronectin and fibronectin 
(Prince et al., 2001). Moreover, Opa protein binds carcinoebryonic antigen-related 
cell adhesion molecules (CEACAMs) (Virji et al., 1999).  
Recently, it has been found that bacteria causing meningititis including  Neisseria 
meningitidis target the 67 kDa laminin receptor (67 LR) on the surface of human 
and rodent brain microvascular endothelial cells (Orihuela et al., 2009). The 37-
kDa/67-kDa laminin receptor acts as cell surface receptor for many other 
neurotropic pathogens including bacterial cytotoxin necrotizing factor-1 (CNF-1) 
of E. coli K1(Kim et al., 2005), prions (Ludewigs et al., 2007) and various viruses 
(Akache et al., 2006; Bondarenko et al., 2003; Sakoonwatanyoo et al., 2006; 
Wang et al., 1992).  Dimerization status of the 67 LR has not yet been elucidated. 
Previous reports suggest homo or heterodimerization of the 67 LR precursor form 
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37 kDa LRP (37 LRP) with galectin-3 (Gal-3) (Buto et al., 1998; Castronovo, 
1993; Landowski et al., 1995). Interestingly, Gal-3 is a ß-galactosidase binding 
proteins, which belongs to S-type lectin (termed galectin) family (Barondes et al., 
1994a), and plays an important role in host±pathogen interactions and 
inflammation (Vasta, 2009). Galectins were initially called S-type lectins (i.e., 
thiol-dependent), because some members appear to require reducing conditions to 
exhibit their biological function (Leffler et al., 2004). However, this name is no 
longer considered appropriate as many other galectins maintain their biological 
function in the absence of reducing agent (Leffler et al., 2004). Galectin-3 is also 
known to interact with ß-galactoside containing glycans on the surface of many 
invading pathogens and host cell (reviewed in Vasta 2009).  
The glycans covering the surface of many pathogens are added to proteins by a 
process called glycosylation; the most common post translational modification of  
proteins. There are two types of glycosylation in bacterial pathogens: N-
glycosylation and O-glycosylation. In N- linked glycosylation which is best 
exemplified by a system in Campylobacter jejuni, the glycan is covalently 
attached to the amino groups of asparagines residues in the sequence of type Asn-
Xaa-Ser/Thr, where Xaa is any amino acid except for proline (Kowarik et al., 
2006). The O-linked glycans are associated covalently with the hydroxyl groups 
of serines or threonines. The Type IV pilin (PilE) of pathogenic Neisseria was 
one of the first examples of an O-glycosylated glycoprotein (Power et al., 2000). 
Depending on the host strain, two types of O-linked trisaccarides have been 
identified in N. meningitidis pili, these include: Gal-ȕ -Gal-Į-DATDH 
(DATDH represents 2, 4-diacetamido-2, 4, 6-trideoxyhexose) (Stimson et al., 
1995), or Gal-ȕ -Gal-Į -GATDH (GATDH represents 2-glyceramido-4-
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acetamido-2, 4, 6-trideoxyhexose) (Chamot-Rooke et al., 2007) (Table 3.1). 
Another truncated O-linked disaccharide, Gal-Į, 3GlcNAc, is also present in N. 
meningitidis strain 8013 (Marceau et al., 1998) (Table 3.1).  
Protein 
target 
OTa
se 
OTase 
transfer 
abilities 
Amino 
acids 
modified 
Sugars transferred Ref. 
Pilin 
(PilE) 
PglL Promisc
uous; 
multiple 
O-linked 
repeats 
Serine 63 
 
(Stimson et 
al., 1995) 
 
(Chamot-
Rooke et 
al., 2007) 
 
(Marceau et 
al., 1998) 
Table 3.1: Structure of meningococcal O-linked glycosylated pilin. Adapted 
from (Nothaft & Szymanski, 2010) *Key to Symbols: 
 
Pilin glycosylation genes (pgl) encode the enzymes required for synthesis and 
transfers of glycans to meninigococcal PilE have recently been identified 
(Chamot-Rooke et al., 2007; Power et al., 2000; Power et al., 2003). These 
glycans synthesized by the sequential action of pglD, pglC and PglB (for 
DATDH) or PglB2 (for GATDH) are summarized in Figure 3.1. The O-linked 
glycan  is transferred onto Ser63 of PilE by pilin glycosylation ligase, PglL (O-
OTases) (Power et al., 2006) (Figure 3.1). Mutations of pglL produce non 
glycosylated pilin, which is not recognized by antibodies specific for N. 
meningitidis C311 trisaccharide (Power et al., 2006). Interestingly, a recent report 
ß     4 Į3
Gal-ȕ-Gal-Į-DATDH
ß     4 Į3
Gal-ȕ-Gal-Į3-GATDH
Gal-Į*OF1$F
Į3
DATDH GATDHGal GlcNAc
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has found that the meningococcal outer membrane protein AniA is O-
glycosylated (Ku et al., 2009).  
  
Figure 3.1: overview of Neisseria O-linked pathways for protein 
glycosylation. Block transfer of oligosaccharides from the lipid anchor to the protein 
target, as occurs in Neisseria meningitidis. First, an initiating enzyme (PglB or PglB2) 
links a sugar residue (DATDH or GATDH) onto the lipid carrier at the plasma 
membrane. Further glycan (galactose) residues are then added by a set of 
glycosyltransferases (Gtase). After assembly, the lipid-linked saccharide is moved across 
the membrane by translocase (PglF). Finally, a conjugating enzyme (PglL), transfers the 
or
PglB2
PglC
UDP
PglD
PglB PglB2or
UDP UDP
C
yt
o
pl
a
sm
PglB
Phosphate
Lipid carrier
PglF PglL
Protein
S/T
or
or
or
or
U
D
P
PglA PglE
Gtase
Pe
rip
la
sm
Intiating enzymes
Translocase
Conjugating enzymes
DATDH
GATDH
Gal
GlcNAc
  
102 
 
glycan to Ser63 of the pilin subunit PilE or to Ser/Thr residues in other periplasmic and 
membrane proteins. (Hug & Feldman, 2011; Nothaft & Szymanski, 2010). 
 
A variety of bacteria, including S. pneumonia (Sato et al., 2002), H. Pylori 
(Fowler et al., 2006), N. gonorrhea (John et al., 2002) , P. aeruginosa (Gupta et 
al., 1997), Escherichia coli O86 (Stowell et al., 2010) and Klebsiella pneumonia 
(Mey et al., 1996) have been found to bind Gal-3. This binding is suggested to be 
mediated by bacterial lipopolysaccharide (LPS) either engaging the Gal-3 C-
terminal CRD (carbohydrate recognition domain, lectin-domain) or the N-
terminal (non-lectin domain) or both. Other microbial ligands have also been 
shown to bind Gal-3, these include: Candida albicans oligomannosides (Kohatsu 
et al., 2006), T. gondii glycosylphosphatidylinositols (Debierre-Grockiego et al., 
2010), Leishmania major lipophosphoglycan (Pelletier & Sato, 2002), 
Trypanosoma cruzi 45- (mucin), 32-, and 30-kDa surface proteins (Moody et al., 
2000), Mycobacteria phosphatidylinositol mannosides and mycolic acid (Barboni 
et al., 2005; Beatty et al., 2002) and P. mirabilis fimbriae (Altman et al., 2001). 
Importantly, Gal-3 contributes to the innate immune response against many 
pathogens. In this context, it exerts a fungicidal effect on  Candida albicans 
(Kohatsu et al., 2006) and  a bacteriostatic effect on  S. pneumonia  (Farnworth et 
al., 2008). Other studies suggest that pathogen-Gal-3 interaction mediates the 
adhesion of the pathogen and thus enhances the infection process (described in 
detail in Chapter 1) (Cerliani et al., 2011). For example, transient expression of 
Gal-3 increased H. pylori adhesion to host cell (Fowler et al., 2006). Moreover, 
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Gal-3 also mediates P. mirabilis adhesion to Madin-Darby canine kidney 
(MDCK) cells (Altman et al., 2001). 
Much attention has been paid recently to the role of Gal-3 in the CNS (Bellac et 
al., 2007; Coimbra et al., 2006; Mok et al., 2007; Reichert & Rotshenker, 1999). 
During pneumococcal meningitis (PM), Galectin-3 is up regulated in the cortex 
and hippocampus (Bellac et al., 2007; Coimbra et al., 2006). Distribution of 
Galectin-3 in different regions of infant rat brain and predominant expression in 
inflammatory cells highlight the role of neuroinflammation in the 
pathophysiology of PM (Coimbra et al., 2006). In addition, in an experimental 
prion disease model, induced Gal-3 expression has been shown in activated 
microglia (Mok et al., 2007). Importantly, based on the known structure of 
meningococcal LOS, the terminal oligosaccharide glycans are predicted to be 
recognized by Gal-3 (Vasta, 2009) which has been confirmed recently by (Paola 
Quattroni, 2010). Although binding of Galectin-3 with meningococcal LOS is 
shown to be interrupted by lactose, some residual binding  to meniningococci has 
been found in the presence of lactose (Paola Quattroni, 2010). Such remaining 
binding suggests involvement of additional meningococcal ligands other than 
LOS that mediate the rest of Galectin-3 binding with N. meningitidis.   
The aims of this chapter were to examine the binding of lactose bound Gal-3 to N. 
meningitidis, and identify non-LOS meningococcal ligands that bind Gal-3. 
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3.2. Results: 
3.2.1. N. meningitidis binds rGal-3 
It has been predicted and recently shown that the Galectin-3 binds the lactosamine 
residue of meningococcal LOS (Quattroni et al., 2012; Vasta, 2009). In order to 
identify non-LOS meningococcal ligands that binds Gal-3, lactose bound Gal-3 
was used and its binding with N. menigitidis was examined using ELISA. Purified 
recombinant galectin-3 full molecule (rGal- RU LW¶V FDUERK\GUDWH UHFRJQLWLRQ
domain (rCRD) was immobilized on an ELISA plate, and then probed with DIG-
labelled wild type meningococci. It is notable that the rGal-3 and rCRD used in 
this study were both lactose bound. Helicobacter pylori (strain 26695), which is 
known to bind Gal3 was used as positive control (Fowler et al., 2006). As shown 
in Figure 3.2A, N. meningitidis (MC58) bound Gal-3 to a greater extent than H. 
pylori. In addition, the CRD part of Gal-3 was able to bind N. meningitidis strain 
MC58 but significantly less than the whole Gal3 molecule (Figure 3.2B, P = 
0.0001). This result showed meningococcal binding with lactose bound Gal-3 full 
molecule and its CRD. 
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Figure 3.2: Binding of N. meningitidis to rGal-3 and its C-terminal. ELISA 
plates were coated with rGal-3 full molecule and rCRD. Dig-labelled N. meningitidis 
(MC58) and H. pylori (as negative control) were used to probe the plates and binding was 
measured by detecting the digoxigenin using anti-digoxigenin. BSA-coated wells were 
included as a negative control, and the mean value obtained from the bacteria-BSA 
coated wells was subtracted from rGal-3 and rCRD coated wells. The data represent the 
mean at wavelength of 405 nm ± SEM (error bars) of a sample tested in triplicate. 
Experiments were repeated three times, with consistent results. 6WXGHQW¶Vt-test; ***P < 
0.001).  
  
106 
 
3.2.2. Meningococcal Galectin-3 binding is not inhibited by 
carbohydrates 
Competition assay using different competing glycans (Table 3.2) was done to 
examine if the binding of rGal-3 to MC58 will be affected by these glycans or 
not. As shown in Figure 3.3A, the binding of MC58 to rGal-3 was not inhibited 
by preincubation of MC58 with different concentrations of lactose, confirming 
that the lactose-binding sites of Gal-3 were occupied by lactose-liganding. Other 
glycans were also tested for their ability to interrupt meningococcal Galectin-3 
interaction. Similarly, the binding of rGal-3 to MC58 was not reduced in the 
presence of H type II, lewis x and y and galactose (Figure 3.3B). 
Name of sugar Structure* Sequence 
Galactose 
 
 
Fucose 
 
 
Lactose 
 
 
Lewis x 
 
 
Lewis y 
 
 
H II 
 
 
Table 3.2: Carbohydrates used in rGal-3 competition assay. *Key to Symbols: 
 
Gal
Fuc
ß         4 Galß-4Glc
ß     4
3
Galß-4GlcNAc
3
FucĮ1
3
ß     42 FucĮ1-2Galß-4GlcNAc3
FucĮ1
ß     4 ß        4ß     3 Galß-4GlcNAcß-3Galß-4Glc
Gal Glc GlcNAcFuc
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Figure 3.3: Meningococcal binding to rGal-3 in the presence ofcarbohydrate. 
Binding of digoxigenin-labelled N. meningitidis strain MC58 to immobilized rGal-3 was 
not inhibited by pre incubation with different concentrations of lactose (A) or different 
sugars at concentration 30 µg/ml (B). BSA-coated wells were included as a negative 
control, and the mean value obtained from the bacteria-BSA coated wells was subtracted 
from rGal-3 coated wells. Binding of the MC58 in the absence of sugars served as 
positive control. The data represent the mean of optical density at a wavelength of 405 
nm ± SEM (error bars) of a sample tested in triplicate. Experiments were repeated three 
times, with consistent results. 
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3.2.3. Binding of meningococcal clinical isolates to rGal-3 
To investigate whether other N. meningitidis strains (different serogroups and 
MLST types) could bind rGal-3, 25 N. meningitidis clinical isolates were 
analyzed for rGal-3 binding in comparison with the serogroup B MC58 strain. 
The results clearly indicate that all meningococcal strains bind Gal3, albeit to 
variable degrees, irrespective of their invasiveness, phenotypic characteristics or 
geographical distribution (Figure 3.4). 
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3.2.4. Meningococcal Galectin-3 binding is mediated by pilus 
component 
3.2.4.1. Retagging 
To identify the non-LOS meningococcal surface ligands that mediate interaction 
with lactose-liganded Gal3, we employed the re-tagging (a contact-dependent 
cross-linking) approach in conjunction with SDS-PAGE, immunoblotting and 
MALDI-TOF, as previously described (Marceau et al., 1998). The principle of 
this technique is based on the use of a receptor-bound multifunctional crosslinker 
consisting of a biotin-group and a photo-reactive group, the ultraviolet irradiation 
covalently binds to the target adhesin, and afterwards, in a reducing condition the 
biotin tag will be transferred to the target protein and transfer of the biotin tag to 
the bound adhesin (Mahdavi et al., 2002). The re-tagging identified 
meningococcal PilQ and PilE as adhesins for rGal-3 as demonstrated in Table 3.3. 
Gene number 
and name 
Mass in kilodalton 
(kDa) 
Score Descrption of protein 
matched 
PilQ 
NMB1812 
82.4 2463.12 Type IV pilus biogenesis 
and competence protein N. 
menigitidis sergroup B 
PilE 
NMB0018 
18.1 2029.04 Type IV pilus pilin protein 
N. menigitidis sergroup B 
Table 3.3: Mass spectrometry analysis of reactive bands identified from 
meningococcal MC58 exposed to cross linked rGal-3 (using MASCOT 
dataset). 
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3.2.4.2. ELISA 
In order to further confirm the retagging results, meningococcal mutants lacking 
PilE and PilQ were examined in ELISA experiments for their abilities to bind 
Gal-3. As shown in Figure 3.5, both ǻpilQ DQG ǻpilE mutants showed 
significantly reduced Gal3 binding when compared with the wild type parent 
strain (P = 0.0114 and P = 0. 0.0165, respectively). Mutation of PorA (another 
integral outer membrane protein which binds LR) had no effect on Gal3 binding 
(negative control). Attempts were made to generate double knock outs of PilE and 
PilQ in order to examine its binding with rGal-3. Different approaches including; 
natural transformation, electroportaion (Duenas S et al., 1998) and chemical 
transformation (Bogdan et al., 2002) were carried out to obtain the clone. 
However, all these attempts were unsuccessful because transformation of 
meningococci depends on bacterial piliation, and both pilQ and PilE single 
mutants are non-piliated.  
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Figure 3.5: Meningococcal ligands mediate Galectin-3 binding. Binding of 
digoxigenin-ODEHOOHG0&DQGFRUUHVSRQGLQJPXWDQWVǻpilQ, ǻpilEDQGǻporA 
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(used as negative control) to rGal-3 coated ELISA plate. BSA-coated wells were 
included as a negative control, and the mean value obtained from the bacteria-
BSA coated wells was subtracted from rGal-3 coated wells. The data represent the 
mean (OD) at wavelength of 405 nm ± SEM (error bars) of a sample tested in 
triplicate. Asterisks indicate the significant dHFUHDVHRIǻpilQ DQGǻpilE mutants 
binding to rGal-3 compared with MC58 wild type strain. Experiments were 
repeated three times, with consistent results. 6WXGHQW¶Vt-test; *P < 0.05). 
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3.2.5.  rGal-3 interacts with meningococcal LR ligands 
Previous reports suggest hetero-dimerization of 67 LR with Gal-3 (Nelson et al., 
2008). Moreover, 67 LR initiates contact of meningococci with the BBB 
(Orihuela et al., 2009). So, the possible interaction between rGal-3 and purified 
rLR and also the corresponding meningococcal LR- ligands, PorA and PilQ, was 
examined. SDS-PAGE and Western blot analysis was performed to confirm the 
expression. As shown in (Lane 5, Figure 3.6; 7 and 8 A and B) rPilQ (82 kDa), 
rPorA (42 kDa) and rLR (37 kDa) were expressed after IPTG induction and gave 
the expected size around 82, 42 and 37 kDa, respectively. Furthermore, the 
expressed proteins were purified under denaturing conditions, using immobilized 
metal affinity chromatographyand the purity was verified by SDS-PAGE and 
Western blot analysis (Lane 7, Figure 3.6; 7 and 8 A and B).  In contrast, the 
expected bands were not observed in the negative control samples,  E. coli JM109 
and E. coli BL21(DE3) containing the blank plasmids PQE70 and pET28a (Lanes 
3 and 6, Figure 3.8; 5 and 6 A and B). These results confirm the specificity and 
purity of the expressed proteins. 
 
82 kDa
82 kDa
1        2         3           4       5                      6         7 A
B
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Figure 3.6: Analysis of expressed and purified 6× His-tagged rPilQ protein 
using metal affinity chromatography. (A) Western blot analysis; (B) SDS-PAGE 
analysis (Lane 1, prestained protein marker; Lane 2, Non induced E. coli PQE70 as 
negative control; lane3, IPTG induced E. coli JM109  PQE70 as negative control; Lane4, 
Non induced E. coli JM109 pPilQPNJ072 ; Lane5, IPTG induced E. coli JM109  
pPilQPNJ072; Lane 6, Purified extract from E. coli JM109  PQE70 as negative control; 
Lane 7, Purified recombinant PilQ (rPilQ). 
 
Figure 3.7: Analysis of expressed and purified 6× His-tagged rPorA protein 
using metal affinity chromatography. (A) Western blot analysis; (B) SDS-PAGE 
analysis (Lane 1, prestained protein marker; Lane 2, Non induced E. coli JM109 PQE70 
as negative control; lane3, IPTG induced E. coli JM109 PQE70 as negative control; 
Lane4, Non induced E. coli JM109  pPorAQE30; Lane5, IPTG induced E. coli JM109  
pPorAQE30; Lane 6, Purified E. coli JM109  PQE70 as negative control; Lane 7, 
Purified recombinant PorA (rPorA). 
47 kDa
47 kDa
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Figure 3.8: Analysis of expressed and purified 6× His-tagged rLR protein 
using metal affinity chromatography. (A) Western blot analysis; (B) SDS-PAGE 
analysis (Lane 1, prestained protein marker; Lane 2, E. coli BL21(DE3) pET28a as 
negative control; lane3, IPTG induced E. coli BL21(DE3) pet28a as negative control; 
Lane4, Non induced E. coli BL21(DE3) pET28LR; Lane5, IPTG induced E. coli 
BL21(DE3) pET28LR; Lane 6, Purified extract from E. coli BL21(DE3) pET28a as 
negative control; Lane 7, Purified recombinant LR (rLR). 
 
The ELISA plate were coated with rGal-3, blocked and later challenged with each 
purified protein (rPorA and rPilQ) or loop 4 synthetic peptide.  This loop has been 
shown to be essential for rPorA-rLR binding (Abouseada, 2009). After rigorous 
washing, antibodies against each protein were added to detect the interaction 
between the bacterial proteins and rGal-3. Immobilized galectin-3 was able to 
interact with each of the three proteins and loop 4 synthetic peptide, and the 
binding was significant (***P < 0.001 and **P < 0.01) in comparison to the 
negative control (BSA) used for each protein (Figure 3.9A). Stronger binding was 
noted for rPilQ (Figure 3.8A) with immobilized galectin-3, confirming previous 
A
47 kDa
47 kDa
1         2        3          4              5                       6         7 
B
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results where the binding decreased in the PilQ deletion mutant but not with the 
PorA deletion mutant (Figure 3.8A). 
When the adsorbed rGal-3 and soluble phase proteins were reversed, such that 
rGal-3 was allowed to interact with rPilQ, rPorA, rLR and loop 4 synthetic 
peptide immobilized onto ELISA plates. The binding of adsorbed proteins with 
soluble Gal-3 was detected by antibodies against Gal-3. Similarly to solid phase 
rGal3, also Gal-3 in soluble phase soluble one bound rPilQ, rPorA, rLR and 
synthetic loop 4 peptide significantly (***P < 0.001 and **P < 0.01; Figure 
3.9B).   
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Figure 3.9: Binding of meningococcal proteins to immobilied and soluble 
rGal-3. Specific binding of recombinant purified proteins (LR, PorA and PilQ) and 
synthetic peptide (Loop 4 of PorA) to immobilized rGal-3 (A) or soluble rGal-3 to 
immobilized purified proteins (rLR, rPorA and rPilQ) and synthetic peptide loop 4 (B) 
coated ELISA plates. BSA-coated wells were considered  as a negative control, and the 
mean value obtained from each purified protein - BSA (A) or rGal-3-BSA (B) coated 
wells was subtracted from rGal-3 coated wells (A) or purified proteins coated wells (B). 
The data represent the mean (OD) at a wavelength of 405 nm ± SEM (error bars) of a 
sample tested in triplicate. Asterisks indicate the significant binding of purified proteins 
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to rGalectin compared with BSA. Experiments were repeated three times, with consistent 
results. 6WXGHQW¶VW- test; ***P < 0.001, **P < 0.01). 
 
3.2.6. O-glycans play roles in Gal3 binding  
To investigate the impact of PilE glycosylation on the meningococcal binding to 
rGal-3, different pilin glycosylation mutants ǻpglC ǻpglL DQG ǻpglC/L were 
generated and their binding with rGal-3 was compared with the MC58 wild type 
strain using ELISA. Mutation of pglC, pglL and pglC/L dramatically decreased 
rGal-3 binding by the organisms (p < 0.0001; Figure 3.10). Furthermore, using a 
deletion mutant lacking the gene encoding the glycosyl transferase (lgtF), which 
is required for chain elongation from the core lipid A-(KDO)2-Hep2, a very low 
but nevertheless significant Gal3-binding in comparable level with pilin 
glycosylation mutants was observed (Figure 3.10).   
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Figure 3.10: Meningococcal PilE O-glycans participate in rGal-3 binding. 
Binding of digoxigenin-labelled N. meningitidis (MC58),  ǻpglC, ǻpglL, ǻpglC/L and 
ǻlgtf to rGal-3 coated ELISA plate. BSA-coated wells were included as a negative 
control, and the mean value obtained from the bacteria-BSA coated wells was subtracted 
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from rGal-3 coated wells. The data represent the mean (OD) at a wavelength of 405 nm ± 
SEM (error bars) of a sample tested in triplicate. Asterisks indicate the significant 
decrease of ǻpglC, ǻpglLǻpglC/L and ǻlgtf binding to rGal-3 compared with MC58 
wild type strain. Experiments were repeated three times, with consistent results. 
6WXGHQW¶VWWHVW3 **P < 0.01). 
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3.3. Discussions: 
The gram-negative bacterium N. meningitidis continues to cause septicemia and 
meningitis across the world. It has the ability to cross the tight junction of the 
BBB and gain access to the CSF, where it can cause meningitis. Recently, much 
attention has focused on understanding the mechanism of interaction between the 
pathogen and BBB, which has led to the identification of several host receptors 
and pathogen adhesins (Orihuela et al., 2009; Unkmeir et al., 2002; Virji et al., 
1994).  The 37 LRP/67 LR is one of these receptors identified recently, which is 
targeted by meningococcal PorA and PilQ, pneumococcal CbpA and OmpP2 of 
H. influenza (Orihuela et al., 2009).  
Prevention of the 37 LRP/67 LR interaction with meningitis causing pathogens, 
by administration of polypeptides mimicking the binding proteins expressed on 
the surface of these pathogens, has been used as an approach for the development 
of a vaccine (St. Jude Children's Research Hospital, 2008; University of 
Nottingham, 2009). Importantly, it has been suggested that the 37 LRP/67 LR 
underlies the CNS tropism of the three most common bacteria causing meningitis: 
N. meningitidis, S. pneumonia and H. influenza (Orihuela et al., 2009).  Such 
significance of the 37 LRP/67 LR in term of meningococcal CNS tropism and as 
therapeutic target for treatment or prevention of meningococcal disease, require 
further characterization of the 67 LR dimer form in the BBB. Several studies 
suggest heterodimerization of 37 LRP with Gal-3 to form mature 67 LR (Buto et 
al., 1998; Castronovo et al., 1992). Galectin-3 is a ß-galactoside binding lectin 
that acts as receptor for many pathogens (Vasta, 2009). Although, both 37 LRP/67 
LR and Gal-3 exist in different cells and organs and participate in different 
disease, their role in the CNS has only emerged recently (Bellac et al., 2007; De 
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Giusti et al., 2011; Gauczynski et al., 2001; Mok et al., 2007; Orihuela et al., 
2009). 
In the literature, the interaction of Gal-3 with meningococcal LOS is predicted 
based on the presence of a carbohydrate moiety, N-acetyl lactoseamine (Gal-
GlcNAc), a known ligand for Gal-3 within the N. meningitidis LOS (Vasta, 
2009). Such prediction has been verified recently by Quattroni and co-workers 
(2012), who showed that the presence of lactose, a known ligand for Gal-3, 
partially inhibited meningococcal binding with Gal-3. This reveals involvement 
of other bacterial ligands in addition to the LOS in Gal-3 binding. Therefore, 
lactose bound Galectin-3 has been used in the current study in an attempt to 
identify non-LOS meningococcal ligands. The series of results provided in this 
chapter show that lactose liganded Gal-3 binds N. meningitidis and that the N-
terminal domain of Gal-3 appears to mediate the majority of this interaction 
(Figure 3.2). Nevertheless, the CRD domain of Gal-3 also binds meningococci, 
but to a less extent when compared to the N-terminal domain (Figure 3.2). 
Importantly, Gal-3 binding was not limited to the reference strain used, but 
extended to 25 other meningococcal clinical isolates (Figure 3.3). This indicated 
that the binding of Gal-3 is conserved among meningococcal clinical isolates.  
The retagging approach was used in the current study to identify non-LOS 
meningococcal ligands that bind lactose bound Gal-3. This approach identified 
the outer membrane protein (PilQ) and the major pilin subunit (PilE) as the two 
potential N. meningitidis adhesins for lactose liganded Gal-3 (Table 3.3). 
Mutations of meningococcal PilE and PilQ genes significantly reduced Gal3 
binding when compared with wild type parent strain (Figure 3.5), confirming the 
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retagging approach results. Interestingly, PilQ is a known adhesin for 37 LRP/67 
LR (Orihuela et al., 2009), which is an antigenically conserved outer membrane 
secretin (Hansen & Wilde, 1984) that is fundamental for type IV pilus expression 
at the cell surface (Tonjum et al., 1998).  It has a doughnut-like appearance with 
an apparent cavity (Frye et al., 2006) and forms a large (960 kDa) 
homododecamer complex, which is capable of generating bactericidal antibodies 
(Corbett MJ, 1988). Immunization with the PilQ complex has been shown to elicit 
bactericidal  and opsonic antibodies in mice as well as protect mice against 
bacteremic meningococcal disease (D. Halliwell, 2004). Although it is an 
abundant outer membrane protein, mice immunized with OMVs containing 
upregulated PilQ produced higher levels of anti-PilQ antibodies (Jan T. Poolman, 
2006). Recombinant PilQ significantly bound soluble and immobilized human 
rGal-3, supporting the demonstrated decrease in PilQ null mutant binding to rGal-
3 (Figure 3.9). Previous work showed that the rPilQ used were able to bind rLR in 
ELISA and  inhibited the meningococcal interaction with the rLR (Abouseada, 
2009). Additionally, fluorescent beads bearing rPilQ bound LR in mice, as seen 
through cranial window (Orihuela et al., 2009). There is no evidence yet for PilQ 
glycosylation, suggesting possible protein-protein interaction with Gal-3. This 
suggestion is in agreement with a previous study showing that Mannose binding 
lectin (MBL), another type of lectin,  binds nonglycosylated outer membrane 
proteins, Opa and PorB, of N. meningitidis in a carbohydrate independent manner 
(Estabrook et al., 2004).  
Surprisingly, recombinant purified PorA and its loop 4 peptide, which appears to 
be important for the 37 LRP/67 LR-PorA interaction (Abouseada, 2009), also 
bound rGal-3 (Figure 3.9). However, in the context of intact MC58 bacteria, 
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neither retagging nor ELISA  identify PorA as an adhesin for Gal-3, revealing that 
PorA might be sterically hindered by other surface structures, which may be 
affecting its recognition by rGal-3. One of the limitations of the above ELISA 
data is that the bacterial proteins (rPilQ, rPorA and rLR) and peptide (loop 4 of 
PorA) were used in ELISA at equal-weight (5µg/ ml) but not at equi-molar 
concentrations. This might contribute to the observed increase in binding of loop 
4 peptide with Gal-3 compared with other bacterial proteins (Figure 3.9A). In 
future investigations it will be necessary to use equimolar concentrations of these 
bacterial proteins and peptide to test their binding with Gal-3. 
Taking into consideration that the PorA mutant is still expressing meningococcal 
Gal-3 ligands (PilQ and PilE), this may compensate PorA deletion and explain the 
non-GLPLQLVKLQJ ELQGLQJ RI ǻPorA with rGal-3. However, N. meningitidis PilQ 
null mutants are non piliated and form  pilus fibers  trapped in the periplasm and 
not exported to the bacteria surface (Carbonnelle et al., 2006; Tonjum et al., 
1998). Additionally, another study has showed that deletion of PilQ in N. 
gonorrhea led to expression of extra cellular rare pilus filament (Drake & 
Koomey, 1995). In general, all Neisseria sp. PilQ mutants lack the property of 
autoagglutination and are non competent for DNA transformation which 
dependent on functional pilus expression (Drake & Koomey, 1995; Tonjum et al., 
1998). These indicate that the T4p produced by PilQ mutant is not properly 
functional.  7KHUHIRUHWKHREVHUYHGUHGXFWLRQRIǻpilQ binding to rGal-3 appears 
to have resulted from deletion of PilQ and non functional PilE collectively 
(Figure 3.5). It is possible therefore that N. meningitidis PilE facilitates initial 
adhesion with Gal-3, then when the T4p expression is downregulated to enable 
intimate contact, the Pilus retracts and thus the PilQ firmly binds Gal-3. A 
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secondary intimate contact could be mediated through PorA, more specifically its 
surface exposed loop 4.  
Another meningococcal Gal-3 ligand is PilE, the major pilin subunit protein of the 
type IV pilus (T4p). T4p play important roles in the initial adhesion to human 
cells and survival of meningococci in the human host during both colonization 
and disease (Pelicic, 2008; Pujol et al., 1997; Virji et al., 1991). PilE is expressed 
as prepilin and cleaved by a prepililn peptidase, PilD, to form the pilus fibre, 
which extrudes through PilQ. PilE is known to undergo several post-translational 
modifications including O-glycosylation (Banerjee & Ghosh, 2003). The 
meningococcal O-glycan is synthesized by the sequential action of the pilin 
glycosylation (pgl) enzymes, including pglC, and final sugar molecule is 
transferred onto  PilE by the action of the ligase pglL (Power et al., 2006). 
Interestingly, the current study showed that the mutation of pglL or pglC or both 
of them, dramatically decreased Gal3 binding by the organisms (Figure 3.10). It is 
interesting that pglL or pglC enzymes are not involved in meningococcal LOS 
biosynthesis and their mutation has no effect on the LOS structure or function 
(Kahler et al., 2001; Power et al., 2000; Power et al., 2006).   These strongly 
suggest that at least part of the Gal3-meningococcus binding is mediated by 
3LO(¶V O-glycan modification, which does not appear to compete with the LOS 
glycans.   
Such interaction of N. meningitidis pilin O-glycan with Gal-3 may have important 
role in meningococcal pathogenesis. Since in  P. aureginosa, pilin glycosylation 
is suggested to be a strong virulence factor. In this study, mutation of the pilO 
gene analogue of the N. meningitidis pglL gene, decreased bacterial twitching 
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motility, increased specificity to pilus specific bacteriophage and significantly 
decrease survival in the lung environment (Smedley et al., 2005). In a previous 
study,  N. meningitidis strain 8013 pilin glycan showed no deffect on bacterial 
piliation and/or  adhesion (Marceau et al., 1998). However, a recent study 
demonstrated that pilin glycosylation is engaged in invasion of N. gonorrhoeae 
into host cells (Jennings et al., 2011).  
It would be useful to use complementation approaches to genetically confirm that 
meningococcal-Gal-3 binding is mediated by PilQ and PilE. However, it should 
be noted that PilQ protein is required for the natural transformation of N. 
meningitidis as mentioned earlier (Drake & Koomey, 1995; Tonjum et al., 1998). 
Thus, it is not possible using this technique to complement the pilQ mutant. In the 
other hand, several attempts were made to generate PilE complemented mutants 
using natural transformation, electroportaion (Duenas S et al., 1998) and chemical 
transformation (Bogdan et al., 2002), however, all these attempts were 
unsuccessful. 
To the best of our knowledge, this is the first in vitro study demonstrating the 
contribution of N. meningitidis pilus components (PilE and PilQ) in Gal-3 
binding. This finding is unique because most studies in the field of Gal-3-baterial 
binding have mainly focused on LPS as potential ligands. Interestingly, one study 
has shown that non agglutination fimbriae (NAF) of P. mirabilis binds  Gal-3 in 
the outer membrane fraction of Madin-Darby canine kidney (MDCK) by overlay 
analysis (Altman et al., 2001). In this study, a monoclonal antibody against Gal-3 
N-terminal (Mac-2) inhibited the interaction between P. mirabilis and MDCK 
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cells. Furthermore, there was no detectable binding between P. mirabilis LPS and 
Gal-3 (Altman et al., 2001).  
In summary, the data represented in this chapter shows that Gal-3 targets N. 
meningitidis via its N-terminal (non-lectin domain). This binding was preserved 
among different meningococcal clinical isolates. Additionally, Gal-3 targets the 
major pilin subunit, PilE and pilus secretin PilQ of meningococci. Interestingly, 
knocking out pglL and pglC genes decline Gal-3 binding, which reveal the 
participation of PilE O-glycan in the Gal-3 interaction with meningococci. 
Moreover, soluble recombinant proteins (LR, PilQ and PorA) and loop 4 synthetic 
peptide of PorA bind immobilized Gal-3 and vice versa. 
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4. Chapter 4: Surface distribution of Laminin Receptor and 
Galectin-3. 
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4.1. Introduction: 
N. meningitidis must cross the BBB to cause meningitis. The BBB itself provides 
a stable environment for neural function by controlling the passage of molecules 
across the brain, and protects the brain from any microorganisms and toxins that 
are circulating in the blood (Kim, 2008). It is composed of brain microvascular 
endothelial cells, astrocytes and pericytes (Kim, 2008). Brain microvascular 
endothelial cells (BMEC) form the front line defense against invading pathogens. 
Subsequently, most of the research into meningococcal meningitis has focused on 
the interaction between meninigococci and brain endothelial cell lines. They 
differ from peripheral endothelial cells as they are continuous and characterized 
by tight intracellular junctions, high transendothelial electrical resistance and 
reduced level of endocytotic vesicles (Rubin & Staddon, 1999). Astrocytes are the 
most abundant cells in the CNS, which provide physical and nutritional support 
for neuron. In addition, an in vitro study has shown that the biogenesis of brain 
endothelium tight junctions is controlled by a factor produced from astrocytic 
end-feet ensheathing brain capillaries (Arthur et al., 1987). Importantly, 
astrocytes are activated by CNS microbial pathogens, including Neisseria 
meningitidis and inflammatory cytokines, hence, playing significant role in CNS 
inflammation (Chauhan et al., 2008).  
The availability of in vitro models (HBMECS, astrocytes and microglia) enables a 
better understanding of meningococcal pathogenesis. Therefore, to understand the 
role of Gal-3 as a potential meningococcal host receptor, and to investigate its 
possible dimerization with 37 LRP to form the 67 LR heterodimer, the surface 
distribution and expression pattern of 67 LR, 37 LRP and Gal-3 in HBMECs and 
astrocytes will be investigated in this chapter.  
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Galectin- LV D XQLTXH ȕ-galactoside binding lectin, which consists of three 
different domains: an N-terminal domain (ND), a repeated collagen-like sequence 
rich in proline, glycine, tyrosine and glutamine residues, and a CRD domain 
(Figure 4.1) (Barondes et al., 1994b). Galectin-3 exists in the cytoplasm and can 
be translocated to the nucleus, exported to the cell surface and excreted by a non-
classical, ER/Golgi-independent secretory pathway outside of cells (Dagher et al., 
1995; Hughes, 1999; Sato & Hughes, 1994).  
 
Figure 4.1. Schematic representation of the Galectin-3 structure.  The Gal-3  is 
composed of: the carbohydrate recognition domain (CRD) of about 130 amino acid 
residues, the proline-, glycine-, and tyrosine-rich repeating domain of about 100 amino 
acid residues and the N-terminal domain of about 30 amino acid residues. The figure was 
adopted from (Barondes et al., 1994b). 
 
Many of the Gal-3 biological activities depend on its cellular localization. For 
instance, cytoplasmic Gal-3 inhibits cell apoptosis through binding with apoptosis 
repressor Bcl-2 (Yang et al., 1996). In addition, and in the cytoplasm, Galectin-3 
interacts with activated GTP-bound K-Ras, and this interaction has shown to be 
involved in Gal-3-mediated transformation (Elad-Sfadia et al., 2004). In the 
C-terminal  CRD domain
N-terminal domain
PGAYPG(x)1-4
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nucleus, Galectin-3 acts as pre-mRNA splicing factor, and is involved in the 
regulation of gene transcription (Dagher et al., 1995; Lin et al., 2002). Although 
the nuclear and cytoplasmic localization of Gal-3 is well established, several 
factors have been reported to affect its localization. These factors include: the 
source of the cell under study, cell type, culture conditions, and proliferation 
status of the cell (Dumic et al., 2006). On the other hand, extracellular Gal-3 is 
involved in cell-cell and cell-matrix interactions, immune reaction and 
angiogenesis, by binding to the glycan moiety of cell surface glycoconjugates, via 
the CRD (Dumic et al., 2006). In addition, cell surface Gal-3 mediates homotypic 
cell adhesion by bridging through branched, soluble complementary 
glycoconjugates (Inohara et al., 1996). Moreover, it has been shown recently that 
surface Gal-3 confers resistance to death-receptor mediated apoptosis by 
immobilizing them in glycan nano-clusters (Mazurek et al., 2012).  
In addition to cellular localization, post-translational modification of Gal-3 is 
involved in the regulation of its biological function. Galectin-3 undergoes two 
distinct post-translational modifications: its cleavage and phosphorylation. There 
are two serines at positions 6 and 12 of the Gal-3 N-terminal domain that have 
been reported to be phosphorylated by casein kinase 1 (Huflejt et al., 1993).  The 
serine phosphorylation reduces Gal-3 binding to its glycoprotein ligands, such as 
laminin, which is proposed to be involved in the regulation of the multivalent 
binding activity of Gal-3 (Mazurek et al., 2000). It also plays a role in the 
translocation of Gal-3 between the nucleus and the cytoplasm (Cowles et al., 
1990). In addition, it appears to be required for the anti-apoptotic activity of Gal-3 
(Yoshii et al., 2002). This was evident by the ability of wild type Gal-3, but not 
serine substituted Gal-3, to protect human breast carcinoma cells from cisplatin-
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induced apoptosis (Yoshii et al., 2002). Additionally, phosphorylation of Gal-3 at 
tyrosine residue was reported to be important for the repair of hepatocytes injured 
by administration of CCl4 (Yamazaki et al., 2001). The other post-translational 
modification of Gal-3 is its susceptibility to cleavage by certain matrix 
metalloproteinases, MMP-2 and MMP-9  at the Ala62±Tyr63 peptide bond 
(Ochieng et al., 1998). The cleavage of Gal-3 is involved in progression of 
cancer, angiogenesis and apoptosis resistance in mouse models (Nangia-Makker 
et al., 2007). 
The 67 LR is a non-integrin cell surface receptor, which plays an important role in 
normal physiological and pathological state. Isolation of 67 LR from cells shows 
a size at 67 kDa on the denaturing polyacrylamide gel, however, its gene encodes 
a protein of only 33 kDa, which migrates with an apparent molecular mass of 37 
kDa on SDS-PAGE (Nelson et al., 2008). This 37 kDa gene product of 67 LR is 
well established to be a precursor form, named 37 LRP (37 kDa laminin receptor 
precursor) (Menard et al., 1997; Nelson et al., 2008). Interestingly, the 37 LRP 
has been found to be associated with the 40S ribosome, and also interacts with 
histones in the nucleus, in addition to its function as a precursor for the cell 
surface laminin binding receptor 67 LR (Ardini et al., 1998; Kinoshita et al., 
1998). 
 
Several hypotheses have been suggested, including posttranslational modification 
or formations of homo- or hetero-dimers, to explain mature 67 LR and 37 LRP 
molecular mass discrepancies (Landowski et al., 1995; Simona Butò, 1998). 
Landowski and Butò have shown that 37 LRP is post translationally modified by 
acylation (Fatty acylation is the covalent attachment of long chain fatty acids to 
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proteins) to form the surface mature form of 67 LR (Landowski et al., 1995; 
Simona Butò, 1998). Protein acylation is one of the major post-translational 
modifications, which is involved in protein trafficking, protein-protein interaction, 
lipid raft association, membrane targeting and protein signalling (Towler, Gordon 
et al. 1988; Resh 1999). The most common types of eukaryotic protein acylation 
are N-myristoylation, and S-palmitoylation. The N-myristoylation is the stable 
addition of 14-carbon saturated fatty acids to a glycine in the N-terminal end of 
the amino acid chain, via an amide bond (Resh, 1999; Towler et al., 1988). The 
N-myriosylated protein has a consensus recognition sequence (Met-Gly-X-X-X-
Ser/Thr) in which methionine is removed co-translationally by methionine 
aminopeptidase, and then myristic acid is linked to the glycine via an amide bond  
(Resh, 1999; Towler et al., 1988).  
S-palmitoylation or more specifically S-acylation refers to the covalent 
attachment of palmitate or other long chain fatty acids to the thiol of cysteine 
residues via an ester link. Due to the labile nature of the thioester linkage, the S-
acylation is reversible (Resh, 1999; Towler et al., 1988). Another type of  fatty 
acylation is called N-palmitoylation, and was first described in the secreted Sonic 
Hedgehog protein (Pepinsky et al., 1998). In N-palmitoylation, the palmitate is 
added irreversibly to a cysteine residue at the N terminus of a protein via an 
amide link. Another report has shown that N-palmitoylation occurs also at the N-
terminal glycine of G6Į (Mumby et al., 1994).  
It has been reported that the 67 LR is acylated by three fatty acids: palmitate, 
oleate and stearate (Landowski et al., 1995). In another study, formation of 67 LR 
was found to be inhibited by a fatty acid synthase inhibitor, such as cerulenin 
(Simona Butò, 1998). Furthermore, treatment with hydroxylamine led to cleavage 
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of 67 LR, suggesting ester-bound fatty acids, mainly palmitate, bound to cysteine 
(Buto et al., 1998). On the other hand, there was no effect on the size of protein 
after O-glycanase, neuraminidase or Endo-F glycosidase treatments (Landowski 
et al., 1995). Taken together, this indicated the involvement of S-acylation 
specifically palmitoylation in the 67 LR maturation process, however, 
glycosylation did not play a role in this process. The palmitoylation occurs most 
commonly on cysteine residues, and interestingly, the 67 LR has two-cysteine 
residues at position 148 and 163 in the C-terminal, which may be the amino acids 
subjected to palmitoylation. 
 
Both Gal-3 and 67 LR are multifunctional proteins that are ubiquitously expressed 
in a variety of tissues and cell types including endothelial cells (Orihuela et al., 
2009; Thijssen et al., 2008). To understand the dimerization status of 67 LR as a 
homo or heterodimer with Gla-3, the distribution and expression pattern of these 
receptors will be investigated in this Chapter.  
Fluorescent tagging of cellular protein is a useful method to visualize cellular 
distribution of many proteins including Gal-3 and 67 LR/37 LRP. The  green 
fluorescent protein (GFP) was first isolated from the jellyfish, Aequorea victoria 
and found to be an ideal fluorescent tag for direct visualization of protein in living 
cells (Prasher et al., 1992). This protein consists of 240 amino acids, and folds 
into an 11 ß-sheet barrel that accommodates an internal distorted helix. The 
chromophore is generated by auto-catalytic cyclisation and subsequent oxidation 
of three amino acids (Ser65, Tyr66, and Gly67) that are located in the central 
portion of the internal helix (Figure 4.2) (Rose et al., 2010). Residues at position 
  
134 
 
66 and 67 are strictly conserved in all known GFP like proteins, while serine 65 
may vary. Different GFP variants that cover a broad spectrum of fluorescence 
excitation and emission wavelengths have been identified recently (Nagai et al., 
2002). These variants result from alteration of the three amino acids constituting 
the chromophore, as well as the surrounding residues. Because the maturation of 
the GFP chromophore takes a long time, and it is highly sensitive to experimental 
conditions such as PH and salt contents, the Venus YFP has been developed 
(Nagai et al., 2002) (Figure 4.2). This variant of YFP is characterized by fast 
maturation, bright fluorescence and insensitivity to environmental changes and 
will be used in the current study (Nagai et al., 2002).   
 
 
 
 
Figure 4.2: Structure of Green Fluorescent Protein (GFP). (A) A schematic 
view of the green fluorescent protein (GFP) and two of its variants (EYFP and Venus 
YFP). The indicated residues are substitutions from GFP. Adapted and modified from 
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(Shyu et al., 2006). (B) A schematic diagram showing the structure of Aequorea 
fluorescent protein, which is FRPSRVHGRIȕVWUDQGV7KHDPLQRDFLGV, which develop 
into the chromophore, are located in a helix, connecting strand 3 with 4 (Rose et al., 
2010)&$VFKHPDWLFGLDJUDPVKRZLQJIRUPDWLRQRIȕEDUUHOVWUXFWXUHXSRQUHIROGLQJ
of the non fluorescent fragments generating the chromophore, as indicated by yellow star 
in the centre. Adapted and modified from (Rose et al., 2010). 
 
Previously, 37 LRP tagged to different fluorescent proteins have been used to 
study its subcellular distribution with prion protein (PrP) in baby hamster kidney 
(BHK) cells (Nikles et al., 2008). In addition, Galectin-3 labelled with GFP and 
other GFP variants was utilized in previous studies to understand the subcellular 
distribution of Gal-3 with different cellular proteins  (Nakahara et al., 2006). 
The key aim of this chapter was to study surface distribution of Gal-3, 67 LR and 
37 LRP. The expression and surface distributions of endogenous receptors were 
studied by; western blot, flow cytometry and immunofluorescence staining. The 
Receptors were then cloned into different fluorescent proteins to facilitate 
characterization of receptor distribution and subsequent understanding of receptor 
dimerization in Chapter 5. Moreover, investigation of the effect of cysteine 
substitutions into alanine at position 148 and 163 of 37 LRP, on the cellular 
distribution of fluorescently labelled receptors, was carried out. 
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4.2. Results: 
4.2.1. Surface distribution of endogenous 67 LR, 37 LRP and 
Gal-3  
To understand the expression and surface distribution of Gal-3 as a potential host 
receptor for meningococci, and of 67 LR/37 LRP, for its possible 
heterodimerization with Gal-3, several approaches including Western blotting, 
flow cytometry and immunofluorescence were carried out.  
4.2.1.1. Immunoblotting 
Total cell extracts of primary HBMECs, the major component cells of the BBB, 
were analyzed by immunoblotting to assess receptor expression using anti-67 LR, 
anti-37 LRP, and anti-Gal-3 antibodies. As shown in Figure 4.2A, a polyclonal 
antibody Ab711, directed against amino acids residue 263-283 of the laminin 
receptor (Castronovo et al., 1991b), detected both 37 LRP and 67 LR, at a 
predicted molecular mass of 37 kDa and 67 kDa, respectively. Whereas InHLRP 
antibody, which was directed against recombinant LR, recognised only a 37 kDa 
band (Figure 4.3B, lane 1). Both Ab711 and InHLRP antibodies detect 
recombinant LR in western blot (Figure 4.3A and B, lane 3), revealing antibody 
specificity. Furthermore, Gal-3 was detected with an apparent molecular mass of 
approximately 30 kDa, using a monoclonal antibody against human Gal-3 
(mab4033) (Figure 4.3C, lane 1). This antibody is directed against the N-terminal 
of Gal-3, and reacted with recombinant Gal-3 (Figure 4.3C, lane 3). Another 
polyclonal antibody against Gal-3 recognized the same band (data not shown). 
The results have shown that primary HBMECs express 67 LR, 37 LRP and Gal-3.  
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Figure 4.3: Immunoblotting analysis of 67 LR, 37 LRP and Gal-3 expression 
in HBMECs. Samples were separated on a 10% SDS-PAGE and blots were incubated 
with anti-67 LR (Ab711; 1:1000) (A), anti-37 LRP (InHLRP; 1:1000) (B), and anti-Gal-3 
(mab4033; 1:10000) (C), then detected with anti-rabbit and anti-mouse alkaline 
phosphatase (1:10,000 dilution) for 67 LR and its precursor form and Gal-3, respectively. 
Lane 1, Total HBMECs cell extracts; Lane 2, Bovine serum albumin as negative control; 
and Lane 3, Purified rLR (A and B) and rGal-3 (C) as positive control. 
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4.2.1.2. Surface expression by flow cytometry 
Next, surface expression of Gal-3 in HBMECs was examined and compared with 
67 LR and its precursor using flow cytometry analysis. As shown in Figure 4.4, 
histograms analysis of FACS data showed the right shift of HBMECs and 
approximately 70%, 80% and 64% of the cells expressing 67 LR, 37 LRP and 
Gal-3 on their surface, respectively. The results indicated that Gal-3 was localized 
on the surface of HBMECs in comparable levels with 37 LRP and 67 LR.  
 
 
Figure 4.4: Flow cytometric analysis of cell surface localization of 67 LR, 37 
LRP and Gal-3 in HBMECs.  HBMECs were analyzed for (A) 67 LR, (B) 37 LRP 
and (C) Gal-3 surface levels. HBMECs incubated for 1 h at 4qC with 1:10 dilutions of 
anti-67 LR (Mlu5) (A), 37 LRP (InHLRP) (B) and Gal-3 (mab4033) (C) antibodies. 
Followed by detection with a 1:50 dilution of Goat anti-mouse IgM Alexa Fluor 647 (A), 
Goat anti-rabbit IgG Alexa Fluor 488 (B) and Goat anti-mouse IgG Alexa Fluor 488 (C) 
for 1h at 4qC, and the cells were analysed by flow cytometry. Histogram overlays of 
HBMECs alone (black curves), HBMECs incubated with secondary antibodies alone as 
the negative control (dot curves), and HBMECs incubated with primary and secondary 
antibodies (blue curve), were generated showing intensity of fluorescence on the x-axis 
and number of cells (events) on the y-axis. Fifty thousand cells were counted per 
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experiment, and W0 is the marker region, which indicates the fluorescence from positive 
staining. Percentages indicate the proportion of events within region W0, subtracted from 
secondary antibodies as a background in percentage. 
 
4.2.1.3. Immunofluorescence 
To get more insight in the surface distribution pattern of the Gal-3 and different 
isoforms of 67 LR, immunofluorescence staining was performed on fixed non 
permeabilized HBMECs. Apical membranes staining of 67 LR using Mlu5 and 
Ab711 antibodies showed distinct punctuated staining in HBMECs as shown in 
Figure 4.5. On the other hand, 37 LRP showed more diffuse membrane staining 
(Figure 4.5). Galectin-3 exhibited diffuse and punctate membrane staining using 
the mab4033 antibody (Figure 4.5). Use of other polyclonal and monoclonal 
(Mac-2) anti-Gal-3 antibodies resulted in a similar staining pattern (data not 
shown). To compare the pattern of the surface-expressed receptors in other 
constituents of the BBB, immunofluorescence staining was also performed on a 
human astrocyte cell line. As demonstrated in Figure 4.5, patterns of the Gal-3, 67 
LR and 37 LRP expressions in astrocytes were similar to those observed in 
HBMECs. In addition, positive diffuse staining for the 37 LRP and Gal-3 were 
exhibited in COS7 cells, which was the cell line used later for transfection of 
constructed receptors. Control experiments were performed with secondary 
antibodies alone, to rule out the possibility of a nonspecific fluorescence signal.  
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 Figure 4.5: Immunofluorescence staining of 67 LR, 37 LRP and Gal-3 in 
HBMECs, astrocytes and COS7 cells. Representative confocal microscopic images 
of immunofluorescence labelled HBMECs, astrocytes and COS7 cells, to determine the 
surface localization of 67 LR, 37 LRP and Gal-3. The cells grown on coverslips were 
fixed with 4% paraformaldehyde and stained with; two anti-67 LR (MluC5 and Ab711), 
anti-37 LRP (InHLRP) and anti-Gal-3 (mab4033), and secondary antibody(s); Alexa 
Fluor 647, 680 and 488 antibody. Nuclei are stained with Hoechst 33258. Coverslips 
were mounted using Fluoromount (Sigma) mounting media and images obtained by 
confocal microscope (Zeisis LSM700). Scale bars represent 0.06µm.  
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4.2.2. Construction of 37 LRP and Gal-3 tagged to vYFP 
constructs in mammalian expression vectors  
In order to study surface distribution of 37 LRP and Gal-3 in living cells, the C 
terminus of 37 LRP and Gal-3 were fused to the full length Venus yellow 
fluorescence protein (vYFP). Furthermore, and for subsequent studying of 
receptors homo or heterodimers using the biomolecular fluorescence 
complementation (BiFC) method (described in detail in Chapter 5), the 37 LRP 
and Gal-3 were C terminally tagged with non-Fluorescent BiFC fragments (i.e., 
C-terminus of Venus,vYCL or N-terminus of Venus, vYNL). The cDNAs of 37 
LRP and Gal-3 were amplified using  forward primers designed to add a EcoRI 
restriction site and a Kozak sequence,  prior to the start codon of  37 LRP and 
Gal-3,  and reverse primers remove the stop codon and introduce a XhoI 
restriction site to the 37 LRP and Gal-3, as described earlier in 2.6.1. A 888 bp 
and a 725 bp fragment, encoding cDNA sequences of 37 LRP and Gal-3, 
respectively were successfully amplified by PCR (Figure 4.6A and B). A single 
band with the expected sizes of 0.8 and 0.7 kb was observed for the 37 LRP and 
Gal-3, respectively, by agarose gel electrophoresis. 
 
Figure 4.6: Gel electrophoresis showing amplification of 37 LRP and Gal-3 
fragments. PCR amplification using pET28LR and cDNA sequences of human Gal-3 as 
templates for 37 LRP and Gal-3 gave an expected band at 888 bp and 725bp, 
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respectively. Lanes 1A and B, DNA markers; lanes 2A and 3B, negative control primer 
only without any template; lanes 3A and 4B, PCR product of 37 LRP and Gal-3 
respectively; and Lane 2B, PCR product of Gal-3 using human brain cDNA as a positive 
control.   
The 37 LRP and Gal-3 fragments were purified from the gel and subjected to 
poly-A tailing, then ligated into the pGEM-T easy vector. Ligation products were 
transformed into E. coli JM109 and transformants were cultured into LB agar 
containing ampicillin, IPTG and X-gal. White colonies were selected, which 
indicate successful ligation, and screened by colony PCR (Figure 4.7 A and B). 
Several clones were identified to contain the 37 LRP and Gal-3 inserts by 
observing correct sizes of DNA fragments, corresponding to 37 LRP and Gal-3 
alongside a band amplified with the same primers using 37 LRP and Gal-3 PCR 
purified product as a positive control (Figure 4.7 A and B).  
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Figure 4.7: Colony PCR for pGEM-T 37 LRP and Gal-3 transformants. PCR 
screening for selected white colonies containing pGEM-T 37 LRP (A) and Gal-3 (B) 
transformants. Lanes 1A and B, DNA markers; lanes 2, 3, 4, 5, 6 and 7A and B are 
different selected white colonies containing 37 LRP and Gal-3 fragments, respectively; 
Lanes 10A and B, are positive controls containing 37 LRP and Gal-3 PCR purified 
product as a templates, respectively; and Lanes 9A and B, are negative controls 
containing primers only without any template. 
The 37 LRP and Gal-3 inserts were digested from pGEM-T vector using EcoRI 
and XhoI restriction enzymes which digested the vector into two fragments 
(Figure 4.8 A and B). The resulted digestion products at 3kb, 888 bp and 725 bp 
37 LRP and Gal-3, respectively, which confirmed the successful digestion of the 
pGEM-T vector. 
 
Figure 4.8: Verification of pGEM-T of 37 LRP and Gal-3 constructs. 
Plasmids were prepared from expected transformants and were confirmed by 
EcoRI and XhoI digestion. Lanes 1A and B, DNA markers; lanes 2, 3 and 4A and 
B, Plasmids after EcoR I and XhoI digestion showing linear size at 888bp and 
725bp for the 37 LRP and Gal-3, respectively. 
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The vector pcDNA3.1zeo containing either full length or the C or N terminal 
regions of venus YFP were pre digested with the EcoRI and XhoI enzymes to be 
prepared for subsequent ligation (Figure 4.9).  
 
Figure 4.9: Restriction and digestion confirmation of pcDNA3.1zeo YFP, 
YCL and YNL constructs. pcDNA3.1zeo vector containing vYFP, vYCL and vYNL 
were subjected for  EcoRI and XhoI digestion. Lanes 2, 3 and 4, Plasmids after EcoRI and 
XhoI digestion showing linear size at 5.7kb, 5.5kb and 5.3kb for pcDNA3.1zeo vector 
containing vYFP, vYCL and vYNL, respectively. 
 
Subsequently, the digested and gel extracted Gal-3 and 37 LRP inserts were 
ligated into the N-terminus of: [1] pcDNA3.1zeo vector, containing the full length 
Venus yellow fluorescence protein (vYFP) to generate 37 LRP.vYFP and Gal-
3.vYFP; [2] pcDNA3.1zeo vector containing the N-terminal of Venus yellow 
fluorescence protein (vYNL) to generate 37 LRP.vYNL and Gal-3.vYNL; and [3] 
pcDNA3.1zeo vector containing the C-terminal of Venus yellow fluorescence 
protein (vYCL) to generate 37 LRP.vYCL and Gal-3.vYCL. The ligated products 
were transformed into E. coli JM109 and selected colonies were screened by 
colony PCR (Figure 4.10 A and B). The DNA sequencing of generated constructs 
confirmed successful cloning. For ease of reference, all given names of generated 
constructs are described in Table 2.7. 
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Figure 4.10: Colony PCR for pcDNA3.1 YFP, YCL and YNL 37 LRP and 
Gal-3 trasformants. PCR screening for selected colonies containing 37 LRP (A) and 
Gal-3 (B) fused to vYFP (I), vYNL (II) and vYCL (III) transformants. Lanes 1I, II and 
III, DNA markers; lanes 2, 3, 4 and 5 are different selected white colonies containing 37 
LRP (A) and Gal-3 (B) fragments, respectively cloned into vYFP (I), vYNL (II) and 
vYCL (III); Lanes 7A and B, are positive controls containing 37 LRP and Gal-3 PCR 
purified product as a templates, respectively; and Lanes 6A and B, are negative controls 
containing primers only, without any template. 
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4.2.3. Construction of 37 LRP and Gal-3 in mammalian 
expression vectors containing mCherry 
To visualize both receptors after transfection in eukaryotic cells, the 37 LRP and 
Gal-3 were cloned into another fluorescent protein (mCherry), in addition to 
vYFP to enable their coexpression. The cDNA of mCherry was amplified using 
primers designed to add XhoI and XbaI restriction sites and to remove the start 
codon, as described earlier in 2.6.1. A 711bp fragments encoding cDNA a 
sequence of the mCherry was successfully amplified by PCR (Figure 4.11). A 
single band with the expected size of 0.7kb was observed for the mCherry 
fluorophore, by agarose gel electrophoresis. 
  
Figure 4.11: Amplification of mCherry fragment. PCR amplification using cDNA 
sequences of mCherry as templates gave an expected band at 711 bp. Lane 1, DNA 
marker; lane 2, PCR product of mCherry; and lane 3, negative control primers only 
without any template.  
 
The 37 LRP.vYFP and Gal-3.vYFP vectors were digested with the XhoI and XbaI 
enzymes to remove the vYFP fragment. As shown in Figure 4.12, the vYFP 
fragments were successfully digested from both vectors at 0.7 bp.  
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Figure 4.12: Restriction and digestion of 37 LRP.vYFP and Gal-3.vYFP 
constructs. 37 LRP.vYFP and Gal-3.vYFP were subjected for XhoI and XbaI digestion. 
Lane 1, DNA marker; Lane 2 and 3, Plasmids after XhoI and XbaI digestion showing 
linear sizes at 0.7 kb for vYFP, and 6.4 kb and 6.3kb for pcDNA3.1zeo vector containing 
37 LRP and Gal-3, respectively. 
 
Following this process, digested plasmids containing the 37 LRP and Gal-3 fused 
to pcDNA3.1zeo were extracted from the gel and ligated into the pre digested 
mCherry PCR product. Ligation products were transformed into E.coli JM109 
and selected colonies were screened by colony PCR (Figure 4.13A and B). The 
DNA sequencing confirmed successful cloning and the constructs called 37 LRP 
and Gal-3.mCherry.  
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Figure 4.13: Colony PCR for 37 LRP and Gal-3-mCherry transformants. 
PCR screening for selected colonies containing 37 LRP.mCherry (A) and Gal-3.mCherry 
(B) transformants. Lanes 1A and B, DNA markers; lanes 2, 3 and 4A, and 6, 7 and 8A, 
are different selected containing 37 LRP fragments using primers that amplify mCherry 
and 37 LRP, respectively; Lanes 2 and 3B, and 5 and 6A, are different selected 
containing Gal-3 fragments using primers that amplify mCherry and Gal-3, respectively. 
Lanes 5A and 4B, are negative controls containing mCherry primers only without any 
template. Lanes 9A and 7B, are negative controls containing receptor primers only 
without any template.  
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4.2.4. Expression of fluorescently labelled 37 LRP and Gal-3 
The expression of vYFP-labelled 37 LRP and Gal-3 was investigated by confocal 
microscopy of transiently transfected primary HBMECs. Firstly, HBMECs were 
grown on fibronectin-coated glass cover slips in 12-well plates. Then, cells were 
transfected with different amounts of the 37 LRP and Gal-3.vYFP plasmids (1-
4.5µg) using different amounts of the Trans IT-2020 transfection reagent (0.5-
2.5µl). The Trans IT-2020 transfection reagent was used in this work due to its 
serum compatibility and high efficiency of transfection. Subsequently, the 
expression of vYFP labelled receptors was visualized by confocal microscopy as 
described earlier in Chapter 2. The optimal amount of plasmid DNA was 2µg per 
1µl of transfection reagent in 12 well plates (data not shown), as higher amount of 
plasmids and transfection reagent were cytotoxic and changed the cell 
morphology. Preliminarily, all the optimization experiments were performed 48h 
post-transfection until the amounts of plasmid and transfection reagent were 
optimised. Afterwards, the expression of fluorescently labelled receptors in 
transiently transfected HBMECs were compared between 24 and 48h, after 
transfection by western blot analysis using an anti-GFP antibody. As shown in 
Figure 4.14, a reactive band was detected at 67 kDa in the cell lysates of cells 
transfected with 37 LRP fused to vYFP at 24 and 48h post-transfection, which 
was absent from the lysate of non-transfected cells (Figure 4.14). Surprisingly, a 
band with apparent molecular weight of 67 kDa, larger than predicted molecular 
weight (57 kDa), was also observed in Gal-3.vYFP transfected cells lysates at 24 
and 48h post-transfection. Both receptors showed high expression level at 24h 
post-transfection (Figure 4.14). This demonstrated that 37 LRP and Gal-3 fused to 
vYFP, were successfully expressed in HBMECs and reached highest levels of 
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expression 24h post-transfection. Therefore, all future transfection experiments 
were conducted at 24h post-transfection.  
 
Figure 4.14: Expression of fluorescently labelled 37 LRP and Gal-3 in 
HBMECs at different time points. Whole cell lysates from 37 LRP.vYFP or Gal-
3.vYFP transiently transfected or non-transfected (NT) primary HBMECs were harvested 
under reducing conditions (10% DTT in sample loading buffer) 24h and 48h post-
transfection and immunoblotted with anti-GFP antibody at (1:100) dilution, followed by 
(1:30000) dilution of anti-rabbit conjugated to alkaline phosphatase, and subsequently 
detected by the NBT/BCIP substrate as described in Chapter 2. Western blot analysis 
confirmed higher expression of both constructs at 24h.   
 
The expression of generated constructs was further characterized by transfection 
in COS7 cells (a mammalian cell line), using antibodies to GFP, 37 LRP 
(InHLRP) and Gal-3 (mab4033). COS7 cells were used because of their high 
transfection efficiencies and expression levels. Immunoblotting using anti-GFP 
antibody showed that 37 LRP.vYFP expressed at 67 kDa in a similar fashion to 
HBMECs (Figure 4.15A). In addition, the N and C terminal domains of venus 
YFP fused to 37 LRP were expressed at expected molecular weights of 61 kDa 
and 52 kDa, respectively (Figure 4.15A). However, Gal-3.vYFP was detected at 
24    48 24    48NT
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57 kDa (predicted molecular weight) (Figure 4.15B) which is smaller than 
molecular weight demonstrated in HBMECs. Both Gal-3 tagged to the N and C 
terminal of vYFP were expressed at 50 kDa and 40 kDa, respectively (Figure 
4.15B). Further immunoblotting using InHLRP antibody, detected 37 LRP at 67 
kDa, 61 kDa and 52 kDa, which corresponds to the molecular weight of 37 LRP 
fused to vYFP, vYNL and vYCL, respectively (Figure 4.15C). In addition, 
endogenously expressed 37 LRP was detected in both non-transfected and 
transfected COS7 cells (Figure 4.15C). Similarly, Gal-3 monoclonal antibody 
(mab4033) recognised endogenous Gal-3 and Gal-3 fused to the full and 
fragments of vYFP at the predicted molecular weights, as shown in Figure 4.15D.  
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Figure 4.15: Expression of vYFP, vYNL and vYCL tagged 37 LRP and Gal-3 
in COS7 cells. (A, B, C and D) Whole cell lysates of COS7 cells transiently transfected 
with the indicated constructs, and analyzed 24h post transfection, under reducing 
conditions (10% DTT in sample loading buffer), and subjected to SDS-PAGE. The cell 
lysates were then immunoblotted using  antibodies against GFP (1:100) dilution (A and 
B), 37 LRP (InHLRP) (1:1000) dilution (C) and Gla-3 (mab4033) (1:1000) dilution (D), 
followed by  (1:30000) dilution of anti-rabbit or anti-mouse conjugated to alkaline 
phosphatase, and subsequently detected by NBT/BCIP substrate  as described in Chapter 
2. Lysates of non-transfected (NT) cells were used as negative controls. Western blot 
analysis confirmed the expression of the transfected constructs.  
kDa
A
80
58
46
30
17
BN
T
37
 L
R
P.
v
Y
FP
37
 L
R
P.
v
Y
N
L
37
 L
R
P.
v
Y
CL
80
58
46
30
kDa
Endogenous-
Gal-3
D G
a
l-3
.
v
Y
FP
G
a
l-3
.
v
Y
N
L
G
a
l-3
.
v
Y
CL
N
T
175
80
58
46
kDa
Endogenous-
37 LRP
C 37
 L
R
P.
v
Y
FP
37
 L
R
P.
v
Y
N
L
37
 L
R
P.
v
Y
CL
N
T
80
58
46
30
17
kDa
G
a
l-3
.
v
Y
FP
G
a
l-3
.
v
Y
N
L
G
a
l-3
.
v
Y
CL
N
T
  
154 
 
4.2.5. Sub-cellular localization of fluorescently labelled 37 
LRP and Gal-3  
To visualize the subcellular localization of the vYFP-fused 37 LRP and Gal-3, 
HBMECs, COS7 and N2a cells were transiently transfected and analyzed by 
confocal microscopy. The N2a, mouse neuroblastoma cell line, does not express 
endogenous Gal-3 (Gauczynski et al., 2001) as confirmed by immunoblotting of 
N2a cells lysate using anti-mouse Gal-3(Mac-2) antibody (Figure 4.16). Thus, the 
N2a cells were used for further experiments, described in Chapter 6, to study the 
role of Gal-3 in adhesion and invasion of N. meningitidis.     
 
Figure 4.16: Endogenous expression of Gal-3 in different cell lines.  Whole cell 
lysates of N2a (1), HBMECs (2) and CaCo II (3) were subjected to immunoblotting with 
the anti-Gal-3 (Mac2) antibody at 1: 1000 dilution, followed by 1:30000 dilution of anti-
rat IgG conjugated  to alkaline phosphtase, and subsequently detected by the NBT/BCIP 
substrate,  as described in Chapter 2. 
 
The fluorescently labelled 37 LRP and Gal-3, revealed a punctate pattern of 
expression on the apical membrane and cytoplasm, but not in the nuclei of 
HBMECs (Figure 4.17A). In contrary, the vYFP tagged receptors showed more 
diffuse distribution in the membrane, cytoplasm and nuclei in the COS7 and N2a 
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cells (Figure 4.17A). Furthermore, and to verify surface expression of venus 
labelled 37 LRP and Gal-3, immunofluorescence staining was performed on fixed 
non-permeabilizied N2a cells using an anti-GFP antibody. As shown in Figure 
4.17B, the 37 LRP and Gal-3.vYFP were expressed on the cell surface of non-
permeabilizied N2a cells.  
For further confirmation of the observed distribution of these receptors, COS7 
cells were transfected with 37 LRP.vYFP and Gal-3.vYFP constructs and 
subcellular fractionation carried out, the expression was then examined by 
western blot analysis using the anti-GFP antibody. Both receptors were present in 
the cytoplasmic, membrane, cytoskeleton, soluble and chromatin bound nuclear 
fraction (Figure 4.17C and D). The results of the western blot analysis in 
subcellular localization support the demonstrated distribution of YFP-tagged 
receptors in confocal images.   
 
  
  
156 
 
 
 
COS7  37 LRP. vYFP COS7  Gal-3. vYFP
N2a  Gal-3. vYFPN2a  37 LRP. vYFP
A
HBMECs  Gal-3. vYFPHBMECs 37 LRP. vYFP
37
 L
R
P.
v
Y
FP
venusYFP Anti-GFP(vYFP) Merge
G
al-
3.
v
Y
FP
B
N2a
N2a
  
157 
 
  
Figure 4.17: Subcellular localization of vYFP conjugated 37 LRP and Gal-3. 
Representative confocal microscopic images of (A) HBMECs, COS7 and N2a cells 
transiently transfected with 37 LRP.vYFP or Gal-3.vYFP and 24 h post transfection. The 
cells were fixed with 4% paraformaldehyde and nuclei are stained with Hoechst 33258. 
Scale bars represent 0.15µm, 0.05 and 0.09 µm for HBMECs, COS7 and N2a, 
respectively. (B) Immunofluorescence of fixed non-permeabilized N2a cells, which were 
transfected with the indicated constructs, as mentioned above. The cells were then stained 
with anti-GFP antibody (1: 100), followed by Alexafluor 680 (1:100). Merged images 
indicate co-localization of vYFP tagged receptors on the cell surface of non-
permeabilized N2a cells.  Scale bars 0.05 µm. (C and D) Western blots of COS7, were 
transiently transfected with vYFP tagged 37 LRP and Gal-3, confirming their expression 
in different cellular fractions. Lanes 1C and 2D: untransfected COS7 total cell lysates of 
the cytoplasm, membrane, cytoskeleton, nuclear soluble and chromatin-bound proteins in 
each fraction.  Lanes 2C and 1D: Detection of 37 LRP and Gal-3 expression in different 
subcellular fractions, extracted from tranfected COS7 with 37 LRP vYFP & Gal-3 vYFP, 
respectively, using anti-GFP as described in Chapter 2.  
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4.2.6. Investigation of the role of Cys148 and 163 in 37 LRP 
acylation. 
Acylation (most likely palmitoylation) of 37 LRP is required for the formation of 
67 LR and its targeting to the cell surface (Buto et al., 1998; Landowski et al., 
1995). However, the site of palmitoylation is not yet determined. Palmitoylation 
occurs most commonly on cysteine residues, but also on threonine, serine, and 
lysine. Accordingly, the amino acid sequence of human 37 LRP contains 14 
serine, 23 threonine and 2 cysteine residues, which might be subjected to 
palmitoylation. In the current study, we decided to focus on the two-cysteine 
residues at positions 148 and 163 for further investigation of the 37 LRP 
palmitoylation. 
4.2.6.1. Construction of vYFP-37 LRP and Gal-3 cysteine mutants in 
mammalian expression vectors 
To investigate if one or both of the C-terminal cysteine residues account for the 
palmitoylation of 37 LRP and the subsequent homo or heterodimerization of 67 
LR, constructs were created in which the cysteines, towards the carboxyl terminus 
of 37 LRP, were substituted with alanines and fused to full length C or N termini 
of vYFP. The 37 LRP.C148A, 37 LRP.C163A and 37 LRP.C148/163A fused to 
vYFP, vYNL and vYCL were successfully generated by site directed mutagenesis 
of the 37 LRP, tagged to vYFP, vYNL and vYCL. The mutagenesis protocols 
IROORZHGZHUHEDVHGRQWKH6WUDWDJHQH¶V4XLFN&KDQJHVLWH-directed mutagenesis 
method. A pair of primers, both containing the desired mutations, were designed 
to be complementary to the template DNA (Table 2.5). Following PCR 
mutagenesis, the original non-mutated parental DNA was removed from PCR by 
Dpn I digestion and then transformed into E. coli JM109, and plated on selective 
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LB/ampicillin plates. Plasmids were extracted from the resulting colonies and sent 
for DNA sequencing. As shown in Figure 4.18, the sequencing results confirmed 
the amino acids substitutions. 
   
Figure 4.18: Sequence chromatograms showing substitution of the 37 LRP 
cysteines following site directed mutagenesis. Site directed mutagenesis was 
performed on the 37 LRP.vYFP templates. Automated DNA sequencing confirmed the 
mutation of 37 LRP.C148 (B), 37 LRP.C163 (C) and 37 LRP.C148/163 (D) to alanine. 
Sequencing data were viewed in Chromas lite version 4.02.  
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4.2.6.2. Expression of fluorescently labelled 37 LRP cysteine mutants 
In order to characterize the expression of generated cysteine-substituted 
constructs, 37 LRP.vYFP wild type and cysteine-substituted constructs were 
transfected into COS7, and expression was examined 24h post transfection by 
western blot and flow cytometry. As shown in Figure 4.19A, all 37 LRP cysteine-
substituted constructs (C148, C163 and C148/163A) were expressed and their 
expressions were comparable to 37 LRP wild type, at approximately 67 kDa. 
Then, flow cytometry was used to quantify the expression of each mutant. The 
flow cytometry analysis revealed similar expression of wild type and mutant 
receptors (Figure 4.19B).  
 
Figure 4.19: Expression of fluorescently labelled 37 LRP cysteine substituted 
mutants in COS7. (A) Whole cell lysates of COS7 cells transiently transfected with 
vYFP tagged 37 LRP, 37 LRPC184A, 37 LRPC163A and 37 LRPC163/184A (lane 2,3,4 
and 5, respectively) were subjected to immunoblotting using anti-GFP antibody as 
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described in Chapter 2. Western blot analysis confirmed the expression of receptors 
cysteine mutants at comparable level to the wild type. (B) COS7 cells were transfected 
with constructs as indicated above and Venus fluorescence was analyzed by flow 
cytometry. Results are expressed as percentage of the specific fluorescence signal to the 
value of 37 LRP.vYFP. Bars represent the mean ± SEM of three independent 
experiments. 
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4.2.6.3. Subcellular localization of vYFP-tagged cysteine-substituted 37 
LRP  
To examine the effect of cysteine substitution on subcellular expression patterns 
of these receptors, 37 LRP.vYFP wild type and cysteine substituted constructs 
were transfected into HBMECs and their subcellular localization was examined 
by confocal fluorescence microscopy. As shown in Figure 4.20A, 37 LRP 
cysteine mutants were expressed in HBMECs and their pattern was comparable to 
wild type receptors. All cysteine-substituted mutants showed the punctate cell 
surface distribution on the apical surface of HBMECs. 
For further investigation of the 37 LRP cysteines substitution on subcellular 
distribution of these receptors, wild type and cysteine substituted constructs were 
transfected into COS7 and subcellular fractionation analysis was carried out. 
Similar to wild type 37 LRP, all the Cys mutants were still predominantly present 
in the cytoplasmic, membrane, cytoskeleton, soluble and chromatin bound nuclear 
fraction, suggesting that the replacement of any of the two Cys is not affecting 
normal receptor distribution (Figure 4.20B). 
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 Figure 4.20: Subcellular localization of vYFP labelled 37 LRP and 37 LRP 
cysteine mutants. (A) Representative confocal microscopic images of HBMECs 
transiently transfected with indicated constructs as described in Chapter 2 and 24 hrs post 
transfection. The cells were fixed with 4% paraformaldehyde and nuclei were stained 
with Hoechst 33258. Scale bar 0.1µm. (B) Western blot of COS7 transiently transfected 
with vYFP tagged 37 LRP and 37 LRP cysteine mutants, confirming their expression in 
different cellular fractions. Lanes 1B: untransfected COS7 total cell lysates of 
cytoplasmic, membrane, cytoskeleton, nuclear soluble and chromatin-bound in each 
fraction as described in Chapter 2.  Lanes 2, 3, 4 and 5B:COS7 transfected with vYFP 
tagged LR wild type, LR C148A, LRC163A & LRC148/163A, respectively, and detected 
with anti-GFP as described in Chapter 2.   
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4.3. Discussion: 
The data presented in chapter 3, clearly showed that Gal-3 binds N. meningitidis 
(Figure 3.2), and two meningococcal Gal-3 ligands were identified including; 
PilQ and PilE (Figure 3.9). Interestingly, PilQ is known as an adhesin for 67 
LR/37 LRP (Orihuela et al., 2009). Particularly, the 67 LR originates from homo 
or heterodimerization of its precursor (37 LRP) with Gal-3 (Buto et al., 1998; 
Landowski et al., 1995). Such binding of meningococcal PilQ to both receptors 
raised the question of a possible role for the 67 LR heterodimer with Gal-3 in 
meninigococcal meningitis. To address this question the current chapter studied 
the cell surface distribution and expression pattern of the Gal-3, 67 LR and 37 
LRP.    
Expression of Galectin-3, 67 LR and its precursor in HBMECs were confirmed by 
Western blotting. One band was observed for Gal-3 in the lysate of HBMECs as 
previously described in other endothelial cells (Anna I. Markowska 2010). On the 
other hand, Ab711 antibody detected two bands at molecular weights 
corresponding to mature and precursor forms of 67 LR. These bands were shown 
previously in Western blotting of rat brain endothelial cells (rBCEC), 
immunoblotted with Ab711 antibody (Orihuela et al., 2009).  Furthermore, 
immunoblotting of HBMECs using an antibody generated against purified 
recombinant LR (InHLRP) recognized only a band corresponding to the precursor 
form 37 LRP (Figure 4.3B). This was also demonstrated in a previous study, 
where only the precursor form of the receptor was detected on western blots with 
antibody called W3, which raised against full length 37 LRP (Gauczynski et al., 
2001). Although, 67 LR and 37 LRP share common epitopes (Buto et al., 1998; 
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Landowski et al., 1995), their antibodies appear to have different recognition 
spectra. As some of these antibodies react exclusively with 67 LR or 37 LRP or 
both of them, as observed in a previous study (Baloui et al., 2004).  This suggests 
that these antibodies recognize an epitope exposed differently depending on 
whether the receptor is in a precursor or mature state. Additionally, the 
corresponding epitopes may be exquisitely sensitive to the presence of SDS and 
heat denaturation, discussed in (Baloui et al., 2004; Menard et al., 1997). 
Flow cytometric analysis revealed surface expression of Gal-3 in HBMECs using 
an antibody against the Gal-3 N-terminus (Figure 4.4). This result corroborated 
the surface localisations of Gal-3 in different endothelial cells (Fukushi et al., 
2004; Markowska et al., 2011; Saint-Lu et al., 2012). This localization strongly 
supports the potential role of Gal-3 as a receptor for N. meningitidis in the BBB. 
Because Buto et al (1998) had previously suggested dimerization between Gal-3 
and 37 LRP to form 67 LR, their cell surface localization was also investigated by 
flow cytometry. Both 67 LR and its precursor were located on the surface of 
HBMECs at a comparable level to Gal-3, as revealed by flow cytometry (Figure 
4.4). For detection of 67 LR, the monoclonal antibody, termed Mluc5, was used 
instead of Ab711 because it recognizes only 67 LR not 37 LRP (Martignone et 
al., 1992), while in case of its precursor, InHLRP antibody was utilized.  In line 
with our results, previous studies have shown that 67 LR (Ardini et al., 1998; 
Fujimura et al., 2005) and 37 LRP (Gauczynski et al., 2001; Zuber et al., 2008) 
were expressed on the cell surface of different cells using flow cytometry 
analysis. In all these studies, 37 LRP was detected by using antibodies that 
recognize only 37 LRP in western blot, however, the fact that these antibodies 
might detect 67 LR in flow cytometry cannot be excluded. 
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Immunofluorescence staining showed a diffuse and punctate pattern of staining of 
Galectin-3 on the surface of HBMECs (Figure 4.5A). The punctate staining 
represents a dot-like staining pattern that has been described previously for Gal-3 
in other endothelial cells, human umbilical vein endothelial  cells (HUVECs) 
(Thijssen et al., 2008). This discrepancy in the staining pattern may be related to 
the difference in origins of the endothelial cells used. The current study used 
endothelial cells isolated from the brain instead of umbilical vein. To our 
knowledge, to present, there is no other report in the literature demonstrating the 
staining patterns of Gal-3 in HBMECs exclusively. Because one of the main 
objectives of this study was to investigate 67 LR dimerization status, the 
expression pattern of 67 LR and its precursor on the surface of HBMECs was 
characterized by immunofluorescence staining. Two anti-67 LR antibodies 
(Mluc5 and Ab711) were used to stain 67 LR in HBMECs in order to avoid 
epitope-restricted profiles, which might affect 67 LR antigen behaviour. The 67 
LR showed a punctate staining pattern over the surface of HBMECs using Mluc5 
antibody (Figure 4.5A). This pattern was similar to previously shown for 
HBMECs stained with Mluc5 antibody (Kim et al., 2005). In addition, strong 
punctuate and some diffuse staining at the cell periphery was observed with 
Ab711 antibody staining for HBMECs. The MLuC5 antibody is known to 
identify only the mature receptor 67 LR, but not the 37 LRP, while Ab711 
antibody recognizes the precursor and mature form of 67 LR. With this in mind, it 
appears that the diffuse pattern obtained by Ab711 antibody reflects 37 LRP 
staining.  While the unique punctate staining pattern displayed by Mluc5 and 
Ab711 antibodies represent 67 LR, additionally, a more diffuse pattern of staining 
was obtained with InHLRP antibody (Figure 4.5A). This antibody is assumed to 
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detect the precursor form of the receptor, based on its recognition of 37 LRP only 
in western blot. As a result, these data revealed that 67 LR and its precursor were 
localized at the cell surface of HBMECs in a punctate and diffuse pattern, 
respectively. Taking into consideration that conversion of 37 LRP to 67 LR is as 
yet unclear and will be studied in detail in Chapter 5. It should be noted that 
further work has been done by our group (Dr. Lee Wheldon) showed clearly that 
there were obvious differences in Gal-3, 67 LR and its precursor staining between 
fixed non-permeabilized and permeabilized cells. The Mluc-5 antibody showed 
positive nuclear staining of 67 LR in permeabilized cells. While both 37 LRP and 
Gal-3 displayed more evenly distributed staining in the cytoplasm of 
permeabilized cells when compared with unevenly distributed staining patterns in 
non- permeabilized cells staining. 
For comparison purposes, receptor expression pattern was further characterized in 
primary astrocytes by immunofluorescence staining. The presence of the Gal-3 
and 37 LRP, and its mature form 67 LR, at the plasma membrane of non-
apermeabilizied astrocytes was demonstrated in our study (Figure 4.5B). 
Importantly, astrocytes displayed comparable staining patterns of Gal-3, 67 LR 
and 37 LRP with HBMECs, suggesting a similar repertoire of receptor 
expression. This finding might be an interesting observation with regard to 
meningococcal meningitis, since meningococci elicited significant elevations in 
astrocyte numbers (Astrogliosis) during infection (Chauhan et al., 2008). Hence, 
these receptors might contribute to the potential role of astrocytes in initiation or 
progression of the immune response after pathogen invasion (Chauhan et al., 
2008).   
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For further characterization of receptor subcellular localization and subsequent 
study of their dimerization in chapter 5, 37 LRP and Gal-3 were cloned into the 
full length and N or C terminus of vYFP, respectively. Venus was used owing to 
its fast and efficient maturation and its strong fluorescence intensity as 
demonstrated in previous studies (Robida & Kerppola, 2009; Shyu et al., 2006). 
The expressions of cloned receptors were detected by western blot and confocal 
microscopy. The 37 LRP fused to vYFP expressed at the expected molecular 
weight in HBMECs and COS7 cells (Figure 4.14). These results are in agreement 
with a previous study where 37 LRP tagged C-terminally into EGFP, ECFP and 
DsRed were expressed at similar molecular weight of 37 LRP.vYFP (Nikles et 
al., 2008).  In COS7 cells, the Gal-3.vYFP plasmid expressed protein of the 
expected molecular weight in Western blotting of either GFP and/or Gal-3 (Figure 
4.15), which corroborates previously published data (Nakahara et al., 2006). 
However, in HBMECS the Gal-3 fused to vYFP, expressed at approximately 67 
kDa, which was a slightly higher than expected molecular weight (60 kDa). This 
heterogeneity could be attributed to different post-translational modifications of 
the protein in the primary HBMECs. Confocal microscopic analysis of HBMECs 
transiently transfected with 37 LRP and Gal-3 tagged to vYFP showed punctate 
pattern of expression (Figure 4.17A). Of interest, the observed punctate 
distribution of 37 LRP-vYFP in the surface of HBMECs resembled punctate 
staining of endogenous 67 LR. While the punctate expression of Gal-3-vYFP 
reflects the punctate staining reported for endogenous Gal-3 by our study (Figure 
4.5A) and previous studies (Delacour et al., 2007; Thijssen et al., 2008). In 
addition to punctate staining, some diffuse staining was also observed for 
endogenous Gal-3 in the current study (Figure 4.5A).  This differential pattern 
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may be due to the difference in methods used between direct visualization of 
vYFP expression and indirect immunofluorescence staining. Another possibility 
is that Gal-3 antibody may cross-react with other members of the galectin family, 
which share sequence homology with Gal-3, leading to observed diffuse staining.  
In COS7 cells, which were used in the current study as the transfection host, the 
vYFP labelled 37 LRP and Gal-3 were diffusely distributed in the whole cells as 
shown by confocal microscopy (Figure 4.17A). This pattern supports diffuse 
distribution of endogenous 37 LRP and Gal-3 in the surface of COS7 cells (Figure 
4.5C). In addition, subcellular fractionation analysis independently confirmed the 
confocal microscopy data, and demonstrated expression of Fluorescent tagged 
receptor in the membrane, cytoplasm and nuclear fractions of COS7 cells (Figure 
4.17B). These results are in agreement with a previous study, which showed that 
37 LRP fused to EGFP was expressed in the nuclei, cytoplasm and cell surface of 
transiently transfected BHK cells (Nikles et al., 2008).  The same distribution 
pattern was also observed previously with Gal-3 fused with GFP in COS7 cells 
(Nakahara et al., 2006). Taking into consideration that the present study has 
focused on the receptors located at the cell surface, which confirmed by detection 
of vYFP labelled 37 LRP and Gal-3 in cell membrane fractions of transfected 
COS7 cells.  
One of the main objectives of this study was to investigate the role of Gal-3 in 
meningococcal adhesion and invasion, which will be described in Chapter 6. To 
achieve this aim, N2a cells, which lack the expression of endogenous Gal-3 were 
employed. These cells were extensively used in previous studies to investigate the 
role of 67 LR/37 LRP in prion disease (Gauczynski et al., 2001; Gauczynski et 
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al., 2006). Diffuse expression of vYFP-receptors was demonstrated in N2a cells 
and their surface localization was confirmed by immunofluorescence staining 
(Figure 1.17B).  Such pattern reflects immunofluorescence staining of 
endogenous and overexpressed 37 LRP in N2a cells as shown by a previous study 
(Gauczynski et al., 2001). Importantly, the observed surface localization of Gal-
3.vYFP in N2a cells verifies their suitability as model to study role of Gal-3 in 
adhesion and invasion of N. meningitidis.  
It is known that 67 LR is formed by homo or hetero-dimerization of the acylated 
37 LRP (mainly palmitoylated), which is required for cell surface delivery of 67 
LR. Therefore, cysteines at position 148 and 163 of 37 LRP.vYFP were 
substituted to alanines, to investigate if this substitution will affect targeting of 67 
LR to the cell surface. In HBMECs, mutant constructs showed the same punctate 
distribution pattern of native receptors (Figure 4.20A). Based on western blot and 
flow cytometry analysis there was no significant difference in molecular weight 
and cellular expression between native receptor and mutants in COS7. Cellular 
fractionation coupled with Western blotting illustrated that the localization of 
cysteine mutants was indistinguishable from wild type 37 LRP (Figure 4.20B). 
These results collectively revealed that the substitution of the selected cysteine 
does not affect receptor expression, cell surface targeting and localization. It 
might be interesting to detect 67 LR surface expression in cells transfected with 
native and cysteine mutants using the Mluc5 antibody in flow cytometry. 
Therefore, future studies on these cysteine-substituted constructs are 
recommended.  
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Based on the experimental data presented herein, expression and surface 
localization of the endogenous Gal-3, 67 LR and its precursor form 37 LRP in 
primary HBMECs were verified by western blotting, flow cytometry and 
immunofluorescence staining. A similar pattern of receptor expression was 
observed in astrocytes. Furthermore, expression of vYFP labelled receptors 
revealed a punctate staining pattern in HBMEC, and a diffuse pattern in COS7 
and N2a cells. Additionally, their surface expression were confirmed, indicating 
that tagging of 37 LRP and Gal-3 with vYFP did not affect their surface 
localization.  Finally, substitution of the two-cysteine residues to alanines within 
the C-terminal of 37 LRP, which is thought to be involved in acylation, showed 
no noticeable differences in membrane localization between native and mutants 
receptors, suggesting involvement of other amino acid residues in 67 LR 
acylation.  
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5. Chapter 5: Laminin Receptor dimerization 
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5.1. Introduction: 
Previous studies have suggested that 67 LR is a heterodimer derived from 
dimerization of 37 LRP and Galectin-3 (Gal-3) (Castronovo et al., 1992; Simona 
Butò, 1998). Both Gal-3 and 67 LR are non-integrin laminin binding proteins. 
Gal-3 ELQGV WR ȕ-galactosides and the poly-N-acetyl-lactosamine residues of 
laminin, while 67 LR binds laminin into two binding sites: the YIGSR, a short 
VHTXHQFHRIWKHȕFKDLQDQGSHSWLGH* (Nelson et al., 2008). Moreover, Gal-3 is 
found in the cytoplasm and nucleus as 37 LRP, and on the cell surface as 67 LR, 
and excreted extracellularly by unknown mechanisms (Barondes et al., 1994b; 
Nelson et al., 2008).  
Among evidences that support heterodimerization of 67 LR with Gal-3 is the fact 
that 67 LR can be eluted from a laminin affinity column by lactose, galactose and 
N-acetyllactoseamine (Castronovo et al., 1992). Additionally, Laminin 
recognition by 67 LR is lactose dependent since treatment of laminin with endo-
ȕ-galactosidase enzyme, which disrupts linear type 2 poly-N-acetyl lactoseamine, 
abolishes its binding with 67 LR and Gal-3 (Castronovo et al., 1992). As a result, 
recognition of laminin by 67 LR and Gal-3 is depending on the N-
acetyllactoseamine moiety (Castronovo et al., 1992). Immunoblotting of human 
carcinoma cell extract, which proved to express 67 LR and 37 LRP, using a 
polyclonal antibody directed against Gal-3, recognized a band at 67 kDa, which is 
the same size of mature 67 LR, but not at 37 kDa (Simona Butò, 1998). 
Furthermore, antibodies generated against other lectins, such as HLBP14 (human 
laminin binding protein 14), also detect lactose eluted 67 LR and Gal-3 laminin 
binding proteins in Western blotting (Castronovo et al., 1992). In conclusion, all 
these findings indicate that 37 LRP might form heterodimers with other acylated 
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proteins carrying the Gal-3 epitope, and produce the mature receptor form 67 LR 
(Figure 5.1).  
On the contrary to heterodimerization theory, amino-acid compositions of 67LR 
were found to be identical to 37 LRP, suggesting a homodimer (Landowski et al., 
1995). Another study showed that both 67 LR and 37 LRP co-exist on the surface 
of N2a cells, a cell which does not express Gal-3 (Gauczynski et al., 2001). That 
revealed Gal-3 or any other lectin is not obligate for surface expression of 67 LR. 
Therefore, so far the issue of 67 LR dimerization is not yet determined. A general 
scheme for the mechanisms of cell surface distribution of different forms of LR 
and Gal-3 is illustrated in Fig. 5.1. 
 
Figure 5.1: Speculations of the 67 LR dimerization status.  The 67 LR would be 
obtained by the association between the 37LRP and Gal-3 or 37 LRP and 37 LRP 
 Buto et al 1998
 Castronovo et. al. 1992
 Kapatova et al.  1996
Cytoplasm
Cell surface 
Nucleus
37 LRP
 Landowski et. al. 1995
 Gauczynski, et al. 2001
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forming 67 LR hetero or homodimers, respectively. Reproduced from (Menard et al., 
1997). 
In addition, Gal-3 exists as a monomer in solution (Morris et al., 2004). In the 
absence of Gal-3 glycan ligands, it can form homodimer and self associates via its 
CRD (Yang et al., 1998) (Figure 5.2) and a cysteine at position 186 was shown to 
be required for such homodimerization in murine Gal-3 (Woo et al., 1991).  
Whereas, in the presence of glycan ligands, Gal-3 can multimerize upto a 
pentamer, through its N-terminus (Barondes et al., 1994b) (Figure 5.2).  Binding 
of Gal-3 to specific ligands mediate its cellular action. 
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Figure 5.2. Schematic representations of the monomeric structure of Gal-3 and 
Gal-3 dimerization, through its CRD, in the absence of binding ligands and 
polymerization, and through its N-terminal domain in the presence of 
carbohydrate binding ligands. The figure was adopted from (Newlaczyl & Yu, 
2011). 
Advanced non-invasive fluorescent-based approaches have been used recently to 
study protein-protein interactions, such as receptor dimerization, in living cells. 
These approaches include bimolecular fluorescence complementation (BiFC) 
(Kerppola, 2008; Shyu et al., 2006) and fluorescence resonance energy transfer 
(FRET) (Miyawaki et al., 1997). BiFC was utilized in the current study to 
C-terminal CRD 
domain
N-terminal domain
PGAYPG(x)1-4
Ligand
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investigate 67 LR dimerization status in mammalian cells. The principle of BiFC 
is based on the generation of a fluorescent signal from two separate non-
fluorescent fragments, which are brought together by the association of two 
potential interacting proteins fused to the fragments (Hu et al., 2002; Kerppola, 
2008) (Figure 5.2A). An in vitro study has shown that the development of BiFC is 
a two steps process (Hu et al., 2002). In the first step, the N and C terminal 
domains of the fluorescent protein fragments refold into the ß-barrel structure 
when brought into close proximity. This step can be disturbed by untagged 
competitors only initially after the association begins, revealing rapid (half time 1 
min) and irreversible properties of the association step (Figure 5.2A). The second 
step is chromophore maturation, which involves slow autocatalytic oxidation 
reaction, to generate fluorescent a BiFC complex with a half-life of approximately 
50 min (Hu et al., 2002). This step is the rate limiting step for detection of BiFC.  
Until now, more than 200 protein-protein interaction have been visualized 
successfully by the BiFC approach (Kerppola, 2006). This owes to the capability 
of this method to visualize and determine subcellular distribution of interacting 
proteins in living cells without invasive immunostaining (Kerppola, 2006; 
Kerppola, 2008). Additionally, the complementation of fluorescent fragments in 
the BiFC method, result in the production of new fluorescence, which is simple to 
detect and analyse (Kerppola, 2006; Kerppola, 2008). However, BiFC has some 
limitations: the irreversible complementation of the fluorescent fragments, the 
intrinsic ability of the fluorescents fragments to associate under certain condition, 
and the time required for fluorophore maturation (Hu et al., 2002; Kerppola, 
2008). These limitations should be taken into consideration when designing any 
BiFC experiment. 
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Two distinctive positions in GFP variants have been used to split intact proteins. 
The two positions of fragmentation represent amino acid residues 155 and 173 
(Figure 5.2B). In Hu. et al 2002 study, fragment of EYFP were used to develop 
the BiFC method. However, these fragments require preincubation at 30°C to 
visualize the BiFC signal.  To overcome this limitation, several fragments of GFP 
variants were used to develop new BiFC fragments. Among these variants, 
Venus, a known YFP mutant (Figure 5.2B), which is characterized by fast 
maturation at 37°C and  bright fluorescence as described in Chapter 4 (Nagai et 
al., 2002). Interestingly, fragments of Venus, truncated at either residue 155 or 
173, were shown to enhance the efficiency of BiFC complementation, and allow 
experiments in mammalian cells to be performed under physiological conditions 
(Shyu et al., 2006). Other fragments of different fluorescent proteins, such as 
CFP, GFP and mCherry have been identified and used in BiFC (Rose et al., 
2010).  
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Figure 5.2: Principle of bimolecular fluorescence complementation. (A) 
Schematic diagram showing the interaction between two potential interacting proteins 
fused to N-terminal and C-terminal fluorescent protein fragments (N and C, respectively).  
The potential interacting proteins can associate and dissociate reversibly until the 
fluorescent protein fragments refold to form a fluorescent protein. This is followed by 
subsequent maturation of the chromophore, over a longer time period, to generate the 
fluorescent BiFC complex. Adapted and modified from (Hu et al., 2002; Rose et al., 
2010). (B) A schematic view of the green fluorescent protein (GFP) and two of its 
variants (EYFP and Venus YFP). The positions of splitting in fluorescent proteins are 
indicated with scissors symbols. Adapted and modified from (Shyu et al., 2006). (C) A 
schematic diagram showing the structure of Aequorea fluorescent protein, which is 
1 min
N CC N CC N CC N CC
60 min
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B
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FRPSRVHGRIȕVWUDQGV7KHarrows reveal the most common position of truncation to 
produce the non-fluorescent half fragments. Adapted and modified from (Rose et al., 
2010).  
 
The aim of this chapter was to investigate homo- and hetero-dimerization among 
the 37 LRP and Gal-3 to form mature 67 LR in mammalian cells using 
immunofluorescence, coexpression of receptors tagged with the mCherry or 
vYFP, ELISA and BiFC confocal microscopy and flow cytometry. This chapter 
also aimed to explore whether substitution of the Gal-3 cysteine residue, which is 
required for Gal-3 homodimer formation, affects Gal-3 dimerization with 37 LRP, 
using BiFC. Moreover, other cysteine residues in 37 LRP, which were thought to 
be involved in acylation, were substituted into alanine and further examined for 
their ability to form BiFC signal comparable to native receptors.  
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5.2. Results: 
5.2.1. Colocalization of laminin receptor and Galectin-3 
5.2.1.1. Immunofluorescence  
Homo and heterodimerization of 67 LR was suggested by previous studies (Buto 
et al., 1998; Castronovo et al., 1992; Gauczynski et al., 2001; Landowski et al., 
1995). Therefore, double immunofluorescence staining of non-permeabilized cells 
was used to examine the colocalization of 67 LR, 37 LRP and Gal-3. As shown in 
Figure 5.3A,  a merged image of the common punctate staining of 67 LR using 
Mlu5 antibody (red) and  the diffuse staining of 37 LRP using InHLRP antibody 
(green) revealed co-localization of 67 LR with 37 LRP in HBMECs and 
astrocytes. Interestingly, the merged images of the red fluorescent signal 
corresponding to either 67 LR or 37 LRP and green fluorescent signal (Gal-3) 
showed a strong co-localization (yellow) of Gal-3 with 67 LR in HBMECs and 
astrocytes (Figure 5.3B) or 37 LRP (Figure 5.3C ) in HBMECs, astrocytes and 
COS7 cells.  
 
 
 
 
 
 
 
  
182 
 
 
 
37LRP (InHLRP)
67 LR (MluC5)
67 LR (MluC5) & 37LRP (InHLRP)
HBMECs
A
37LRP (InHLRP)
67 LR (MluC5)
67 LR (MluC5) & 
37LRP (InHLRP)
Astrocyte
  
183 
 
 
Gal3 (mab4033)  
& 67 LR (Mluc5)
Gal-3 (mab4033 )
67 LR (Ab711)
67 LR (Ab711)
Gal-3 (mab4033)
67 LR (Ab711) & Gal-3 (Mab4033)
B
HBMECs
Astrocyte
  
184 
 
 
Gal3
(mab4033) 
37 LRP (InHLRP)
HBMECs
Gal3 (mab4033) & 
37 LRP (InHLRP)
37 LRP (InHLRP) & 
Gal-3 (mab4033)
37 LRP (InHLRP) 
Gal-3
(mab4033)
C
Astrocyte
  
185 
 
 
 
Figure 5.3: Double immunofluorescence staining shows colocalization of 67 
LR with 37 LRP and 67 LR/37 LRP with Galectin-3 in HBMECs, astrocyte 
and COS7. Representative confocal microscopic images of immunofluorescence double 
labelled HBMECs, or astrocytes, or COS7 cells, to determine receptor surface co-
localization. The cells grown on coverslips were fixed with 4% paraformaldehyde and 
co-stained with anti-67 LR (MluC5) and anti-37 LRP (InHLRP) (A), anti-67 LR (Ab711) 
and anti-Gal-3 (mab4033) (B), or anti-37 LRP (InHLRP) and anti-Gal-3 (mab4033) (C) 
and secondary antibody(s); Alexa Fluor 647 ,680 and 488 antibodies. Areas of overlap 
appear yellow in the merged images, illustrating co-localization of 67 LR with 37 LRP 
(A), 67 LR and with Gal-3 (B), and 37 LRP with Gal-3 (C). Nuclei are stained with 
Hoechst 33258, and appear blue.  Scale bars represent 0.09µm (HBMECs), 0.2µm 
(Astrocytes) and 0.05µm (COS7 cells).  
Gal-3 (mab4033)
37 LRP (InHLRP) 
37 LRP (InHLRP) & 
Gal-3 (Mab4033)
COS 7
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5.2.1.2. Coexpression of fluorescently tagged receptors  
Double immunofluorescence staining suggests colocalization of 67 LR with its 
precursor (37 LRP) and Gal-3. To further characterize their colocalization, 
receptors were fused C-terminally to mCherry (monomeric red fluorescent 
protein, RFP), as described in Chapter 4, to enable their coexpression with vYFP 
tagged receptors. The expression of generated constructs was examined by 
Western blot analysis using an anti-mCherry antibody. Western blotting of COS7 
cells, transiently  transfected with 37 LRP or Gal-3 fused to mCherry, yielded 
bands of 67 and 60 kDa, representing the sum of the molecular weights of the 
receptor and fused fluorescent protein (Figure 5.4). Cotransfection of 37 
LRP.vYFP and 37 LRP.mCherry or Gal-3.mCherry resulted in a colocalization in 
the nuclear, cytoplasmic compartments and on the cell surface (Figure 5.5A and 
B). As a positive control, Gal-3.mCherry and Gal-3.vYFP were coexpressed, 
since earlier studies have shown Gal-3 dimerization (Nieminen et al., 2007; Woo 
et al., 1991). In addition, distribution of Gal-3.vYFP and Gal-3.mCherry almost 
completely overlapped (Figure 5.5C). 
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Figure 5.4: Immunoblot analysis indicates expression of 37 LRP and 
Galectin-3 fused to mCherry. Whole cell lysates of COS7 cells, transiently 
transfected with the indicated constructs, as described in Chapter 2, and subjected to 
SDS-PAGE. The cell lysates were then immunoblotted using anti-mCherry rabbit 
polyclonal antibody at a 1:1000 dilution followed by a 1:30000 dilution of anti-rabbit 
conjugated to alkaline phosphtase, and subsequently detected by the NBT/BCIP substrate 
as described in Chapter 2. Western blot analysis confirmed the expression of the 
transfected constructs.  
 
 
Figure 5.5: Colocalization of the 37 LRP.vYFP with mCherry coupled 37 
LRP and Galectin-3. Representative confocal microscopic images of COS7 cells 
COS7  Gal-3. mCherryCOS7  37 LRP. vYFP Merged
COS7  Gal-3. vYFP COS7  Gal-3. mCherry Merged
COS7  LR. mCherryCOS7  37 LRP. vYFP Merged
Hoechst
Hoechst
Hoechst
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C
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transiently cotransfected with 37 LRP.vYFP and 37 LRP.mCherry (A) or 37 LRP.vYFP 
and Gal-3.mCherry (C) or Gal-3.vYFP and Gal-3.mCherry (B), and  24h post 
transfection the cells were fixed with 4% paraformaldehyde and nuclei stained with 
Hoechst, as described in Chapter 2. Scale bars represent 0.15µm. 
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5.2.1.3. ELISA 
Immunofluorescence and cotransfection data indicated that 37 LRP colocalize 
with Gal-3 (Figures 5.3 and 5), which supports previous ELISA results (Figures 
3.8). In order to determine which part of Gal-3 interacts with 37 LRP, either Gal-3 
full molecule or its CRD, was immobilized on an ELISA plate and 37 LRP 
binding activity was assessed. As shown in Figure 5.6, recombinant LR bound to 
the CRD significantly (p= 0.0004) when compared with the negative control 
(BSA), with a level comparable to that determined for the rLR interaction with 
the Gal-3 full molecule. This result suggests that the CRD of Gal-3 mediates the 
majority of the Gal-3 interaction with 37 LRP. 
rLR
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Figure 5.6: Interaction of rLR and rGal-3. Specific binding of recombinant 
purified LR with immobilized rGal-3 full molecule and rCRD coated ELISA plates. 
BSA-coated wells were considered as a negative control, and the mean value obtained 
from rLR-BSA coated wells was subtracted from rGal-3 and rCRD coated wells. The 
data represent the mean (OD) at wavelength of 405 nm ± SEM (error bars) of a sample 
tested in triplicate. Experiments were repeated three times, with consistent results. 
Asterisks indicate the significant binding of purified proteins to rLR compared with BSA. 
6WXGHQW¶VW- test; ***P < 0.001). 
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5.2.1.4. BiFC (Biomolecular fluorescence complementation) 
The bimolecular fluorescence complementation (BiFC) approach was used to 
characterize the possible homo- and heterodimerization of 37 LRP and Gal-3. To 
this end, the C terminus of the 37 LRP and Gal-3 was fused to the N-terminal or 
C-terminal fragment of the Venus YFP, a derivative of YFP (Nagai et al., 2002) 
as described in Chapter 4, and then transfected into HBMECs, N2a and COS7 
cells. The overall strategy of BiFC was outlined in Figure 5.7. Interestingly, 
Venus fluorescence was detected, indicating successful complementation of YFP 
(cYFP) and formation of BiFC complex by confocal microscopy. This result 
demonstrated the formation of both 67 LR homodimer (Figure 5.8A and B) and 
37 LRP and Gal-3 heterodimers (Figure 5.8A and B) in HBMECs and N2a. BiFC 
complexes showed a punctate distribution on the apical surface of HBMECs 
(Figure 5.8A) and smooth uniform distribution in N2a cells (Figure 5.8B). As a 
previous study showed Gal-3 dimerization (Woo et al., 1991), Venus fragments 
(YNL or YCL) fused to the C-terminal region of Gal-3 were cotransfected into 
HBMECs and N2a cells for further characterization of observed BiFC complexes, 
above. As represented in Figure 4B, Gal-3 was able to form homodimers and 
produce a comparable signal to that produced from 67 LR homo and heterodimers 
in N2a (Figure 5.8B). However, in HBMECs no BiFC signal was detected (Figure 
5.8A).  
The subcellular distribution of YFP-complemented receptors was not apparently 
different from that observed with receptors labelled with full length vYFP (Figure 
4.17A). When cells were transfected with single constructs containing receptors 
fused to either C or N fragments of YFP, no fluorescence was observed, as the 
YFP fragments by their own are not fluorescent (Figure 5.8A and B).  
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To confirm construct surface expression, N2a cells, transiently transfected or co-
transfected with Venus fragments tagged into receptors, were immunostained 
with antibodies specific for GFP-tag, confirming their expression (Figure 5.8B). 
Each Venus fragment fused to a receptor was expressed successfully and no 
comparable fluorescence signal to complemented fragments was detected in the 
Venus channel, as expected (Figure 5.8B). Furthermore, the receptor dimerization 
was additionally analyzed by flow cytometry. As primary HBMECs are relatively 
difficult to transfect, thus, COS7 cells, transiently transfected or cotransfected 
with receptors fused to Venus full length and its fragments, and 24h post 
transfection, were subjected to flow cytometry. As expected, the BiFC signal was 
detected for the interaction of 37 LRP.vYNL/37 LRP.vYCL, 37 LRP.vYNL/Gal-
3.vYCL and vice versa, whereas only a very low background fluorescence was 
observed for sole 37 LRP.vYNL and 37 LRP.vYCL, Gal-3.vYCL and Gal-
3.vYNL (Figure 5.8B). Taken together, the results revealed the formation of 37 
LRP and Gal-3 as a homo- and/or hetero- dimer receptor in the HBMECs, N2a 
and COS7 cells.  
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Figure 5.7: Biomolecular fluorescence complementation (BiFC) strategy used 
in this project. (A) Typical Gal-3 and 37 LRP structure. The C terminals of 37 LRP 
and Gal-3 were fused to the N-terminus of vYFP (N) and the C-terminus of vYFP (C) 
and receptors interaction will lead to BiFC complementation and vYFP generation.  Two 
models were tested for possible interactions between 37 LRP and 37 LRP (A.), 37 LRP 
and Gal-3(C.), whereas model (B.) Gal-3 and Gal-3 was used as a positive control for the 
BiFC method. 
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Figure 5.8: Detection of 37 LRP and Galectin-3 dimerization using BiFC and 
flow cytometry.  Representative confocal microscopic images of the primary HBMECs 
(A) or N2a (B) transiently co-transfected with indicated construct and 24 hrs post 
transfection the cells were fixed with 4% paraformaldehyde and nuclei stained with 
Hoechst (A) or anti-GFP antibody (1: 100) followed by Alexafluor 680 (1:100) (B). 
Fluorescence was detected in cells co-expressing 37 LRP.vYNL and 37 LRP.vYCL, or 
Gal-3.vYCL and Gal-3.vYNL, revealing successful complementation of Venus fragments 
(A and B). No fluorescence was detected in cells transfected with either half of Venus 
fused to 37 LRP or Gal-3 (A and B). Immunostaining of N2a cells that were transfected 
with the same previous constructs using anti-GFP, confirms the cell surface expression of 
receptors tagged into Venus fragments (B). Scale bars represent 0.15 µm and 0.09 µm for 
HBMECs and N2a, respectively. (C) Flow cytometry revealed 37 LRP & Gal-3 
dimerization. COS7 cells were transfected with constructs as indicated above and Venus 
fluorescence was analyzed by flow cytometry as described in Chapter 2. Results are 
expressed as percentage of the specific fluorescence signal to the value of 37 LRP.vYFP 
and Gal-3.vYFP. Bars represent the mean ± SE of three independent experiments. 
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5.2.2. Colocalization of 37 LRP and Galectin-3 dimers with 
InHLRP antibody  
Previous immunostaining of Venus full length and its fragments, fused to Gal-3 
and 37 LRP, using the anti-GFP antibody, confirm the expression and surface 
localization of transfected constructs in N2a cells (Figure 5.8B).  Both 67 LR and 
37 LRP are expressed endogenously on the surface of N2a cells, confirming a 
previous study (Gauczynski et al., 2001). To examine whether BiFC complexes 
formed by 37 LRP and Gal-3 were co-localized with endogenous 37 LRP, the 
distribution of BiFC complexes was compared with anti-37 LRP 
immunofluorescence. Firstly, the immunofluorescence of endogenous 37 LRP, in 
non-transfected fixed non-permeabilizied N2a cells, was carried out using both 
the InHLRP antibody. The 37 LRP showed diffuse membrane staining on the 
surface of N2a cells (Figure 5.9). 
  
Figure 5.9: Immunofluorescence staining of 37 LRP in N2a cells. 
Representative confocal microscopic images of immunofluorescence labelled N2a cells 
to detect localization of 37 LRP. The cells grown on coverslips were fixed with 4% 
paraformaldehyde and stained with anti-37 LRP (InHLRP), and secondary antibody:  
AlexaFluor 680. Nuclei were stained with Hoechst 33258. Scale bar represents 0.05µm.  
 
InHLRP
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Then, N2a cells were transiently transfected with 37 LRP fused to vYFP or 
cotransfected with receptors fused to Venus fragments and stained with the 
InHLRP antibody. 37 LRP homo- and hetero- dimers with Gal-3 were colocalized 
with diffuse staining of 37 LRP (Figure 5.10). 
 
Figure 5.10:  Distribution of 37 LRP and Gal-3 BiFC complexes and anti-37 
LRP immunofluorescence. Representative confocal microscopic images of N2a 
transiently co-transfected with indicated constructs, as described in Chapter 2, and 24 h 
post transfection. The cells were fixed with 4% paraformaldehyde and stained with anti-
37 LRP (InHLRP) followed by Alexa Fluor 680 and nuclei stained with Hoechst. 
Transfection of 37 LRP.vYFP served as the control.  
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5.2.3. Investigation of Galectin-3 and 37 LRP dimerization  
As our data revealed that 37 LRP and Gal-3 forms homo and heterodimers in 
cells, we were interested in how these receptors formed dimers.  Galectin-3 has 
one cysteine residue in the C-terminus (Figure 5.11), which was shown to be 
required for dimerization of murine Gal-3 (Woo et al., 1991). Therefore, the 
homologous cysteine in human Gal-3 at position 173 was further investigated in 
this study, for its role in Gal-3 homo and heterodimerization with 37 LRP. 
 
Figure 5.11: The conservation of cysteine residues in the CRD of Galectin-3 
among different species. Reproduced from (Herrmann et al., 1993). 
 
5.2.3.1. Construction of Galectin-3 cysteine mutants in 
mammalian expression vectors 
 To examine if the cysteine of human Gal-3 is also required for Gal-3 
homodimerization, and furthermore, heterodimerization with 37 LRP, mutants 
were created in which the cysteine toward the carboxyl terminus of Gal-3 was 
substituted with alanine and fused to the full length, N or C-terminal ends of 
vYFP. The Gal-3.C173A tagged to vYFP, vYNL and vYCL were successfully 
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generated by site directed mutagenesis as described in Chapter 2 and 4 (Figure 
5.12).  
 
Figure 5.12: Sequence chromatograms showing substitution of the Galectin-3 
cysteine residue following site directed mutagenesis. Site directed mutagenesis 
was performed on the Gal-3 fused to vYFP, vYNL and vYCL templates. Automated 
DNA sequencing confirmed the mutation of Gal-3.C173 to alanine (B). Sequencing data 
were viewed in Chromas lite version 4.02.  
 
5.2.3.2. Expression of fluorescently labelled Galectin-3 cysteine 
mutants 
To examine the expression of generated constructs Western blot analysis of cell 
lysates from transfected COS7 cells were performed using anti-GFP antibody. As 
shown in Figure 5.13, a band of approximately 60 kDa was detected in Western 
blots of cells transfected with plasmids encoding Gal-3.C173AvYFP plasmid 
Gal-3 native sequence
Gal-3C173A mutant sequence
N      R      R V       I      V      C     N      T      K       L      D    
N      R      R V       I      V       A N      T      K       L      D    
A
B
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(Figure 5.13A, lane 3).  The Gal-3 cysteine substituted construct expressed at the 
same molecular weight of native Gal-3.vYFP construct (Figure 5.13A, lane 2) and 
no significant difference between their expression level was observed, as 
indicated by flow cytometry analysis (Figure 5.13B). In addition, the BiFC 
fragments fused to Gal-3 cysteine substituted were expressed at the expected 
molecular weights (Figure 5.13A, lanes 4 and 5).   
 
Figure 5.13: Expression of fluorescently labelled Galectin-3 cysteine 
substituted mutants in COS7 cells. (A) Whole cell lysates of COS7 cells transiently 
transfected with indicated constructs as described in Chapter 2, and immunoblotted with 
anti-GFP antibody,  confirming  expression of Gal-3 cysteine substituted constructs at the 
expected molecular weight. (B) COS7 cells were transfected with constructs as indicated 
above and Venus fluorescence was analyzed by flow cytometry as described Chapter 2. 
The flow cytometry data revealed no significant difference between Gal-3 native and 
cysteine mutant in the levels of expression. 
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5.2.3.3. Subcellular localization of vYFP-tagged cysteine-substituted 
Galectin-3 
To examine the effect of cysteine substitution on subcellular expression patterns 
of the Gal-3 wild type and cysteine substituted constructs were transfected into 
HBMECs and subcellular localization was examined 24h post transfection by 
confocal fluorescence microscopy. As shown in Figure 5.14A, the Gal-3 cysteine 
mutant was expressed in a punctate staining pattern, comparable to the staining 
pattern of wild type receptors in HBMECs. In addition, subcellular fractionation 
of the Gal-3 Cys mutant gave the same distribution pattern of the Gal-3 wild type 
in COS7 cells (Figure 5.14B). However, the Gal-3 Cys mutant cytoskeleton 
extract showed an extra band, which was lacking in the wild type (Figure 5.14B, 
cytoskeleton fraction lane: 3). 
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Figure 5.14: Subcellular localization of vYFP labelled Galectin-3 cysteine 
mutants. (A) Representative confocal microscopic images of HBMECs transiently 
transfected with indicated constructs as described in Chapter 2, showing similar punctate 
expression of  Gal-3 and its cysteine substituted mutant. Scale bar represents 0.1µm. (B) 
Western blot of COS7 transiently transfected with vYFP tagged Gal-3 and Gal-3 cysteine 
mutant, confirming their expression in different cellular fractions. Lane 2B: untransfected 
COS7 cell total cell lysate of cytoplasmic, membrane, nuclear soluble, chromatin-bound 
and cytoskeleton in each fraction as described in Chapter 2.  Lanes 1 and 3: COS7 cells 
transfected with vYFP tagged Gal-3 wild type and Gal-3C173A, respectively, and 
detected with anti-GFP, as described in Chapter 2.    
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5.2.3.4. The impact of cysteine 173 substitution on 37 LRP and 
Galectin-3 heterodimerization 
Next, the effect of Gal-3 Cys 173 mutation on the homo- and hetero-dimerization 
of Gal-3 and 37 LRP was investigated by flow cytometry. This substitution  led to 
significant reduction in Gal-3 homodimerization as revealed by reduced BiFC 
signal in COS7 cells  cotransfected with the Gal3.C173A vYNL and Gal3.C173A 
vYCL mutant, when compared with wild type homodimer (p=0.029, Figure 
5.15B). Concomitantly, the heterodimer form consisting of the wild-type 37 LRP 
and Gal-3 mutant receptor, showed a significant reduction in signal (p=0.025, 
Figure 5.15A). Using different heterodimer combinations of 37 LRP and Gal-3 
mutant also demonstrated a significant reduction in signal (p=0.006, Figure 
5.15A).  
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Figure 5.15: Galectin-3 cysteine-173 affects homo- and hetero-dimerization. 
Flow cytometry analysis of COS7 cells transfected with indicated constructs and 
24h post transfection. The Venus fluorescence was analyzed by flow cytometry.  
Substitution of Gal-3 cysteine 173 to alanine significantly reduced its homo- (B) 
and hetro-dimerization with 37 LRP (A). Results are expressed as percentage of 
the specific fluorescence signal to the value of 37 LRP.vYFP and Gal-3.vYFP, as 
described in Chapter 2. Bars represent the mean ± SE of three independent 
experiments. 6WXGHQW¶Vt- test; **P < 0.01, *P < 0.05). 
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5.2.4. Substitution of 37 LRP cysteines 148 and 163 does not 
abolish 37 LRP and Gal-3 dimerization  
Furthermore, 67 LR has been demonstrated previously to be acylated (Buto et al., 
1998). As described earlier in the previous chapter, two cysteine residues (C148, 
C163) in the C- terminus of 37 LRP, were substituted to alanine to investigate if 
these cysteines accounted for total acylation (palmitoylation) of 67 LR. According 
to cellular fractionation results, there were no effects on 37 LRP cellular 
localization. To further investigate if the substitutions (C148A, C163A) may 
effect 37 LRP homodimerization, mutants were created, in which the cysteines 
toward the carboxyl terminus of 37 LRP were substituted with alanines and fused 
into Venus fragments. To examine the expression of generated constructs, 
Western blot analysis of cell lysates from transfected COS7 cells were performed 
using the anti-GFP antibody. As shown in Figure 5.16, LRC148A and C163A 
fused to the Venus fragments were expressed at the expected molecular weight.  
 
Figure 5.16: Immunoblot analysis for expression of cysteine substituted 37 
LRP fused to Venus fragments. Whole cell lysates of COS7 cells transiently 
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transfected with the indicated constructs and immunoblotted with anti-GFP antibody as 
described in Chapter 2, confirming their expression at the expected molecular weight.  
 
Subsequently, the homo and heterodimerization of 37 LRP and Gal-3, was 
analyzed by flow cytometry. Mutation of C148A and C163A does not affect 37 
LRP homo- or hetero-dimer formation, as confirmed by flow cytometry (Figure 
5.17). 
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Figure 5.17: Substitution of cysteines 148 and 163 of 37 LRP do not affect 37 
LRP homo- or hetero- dimerization. Flow cytometric analysis of COS7 cells 
transfected with the indicated constructs and the Venus fluorescence was analyzed by 
flow cytometry as described in Chapter 2.  Substitution of 37 LRP cysteines 148 and 163 
into alanine does not significantly affect its homo or hetrodimerization with Gal-3.  
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5.3. Discussion: 
Previous studies have predicted the existence of 67 LR as a homo- (Gauczynski et 
al., 2001; Landowski et al., 1995) or hetero- dimer with Gal-3 (Buto et al., 1998; 
Castronovo et al., 1992) on the cell surface. The emerging roles of 67 LR and 
Gal-3 in CNS infections, including bacterial meningitis (Bellac et al., 2007; 
Orihuela et al., 2009) necessitate further understanding of their configuration in 
the BBB. Therefore, this chapter was designed to focus on the investigation of the 
67 LR dimerization status, employing several approaches.  
In terms of infection, the surface localization of 67 LR, whether as homo- or 
hetero- dimer is a prerequisite  for initiation of N. meningitidis adhesion to the 
BBB (Orihuela et al., 2009). The data of the previous chapter confirmed that 67 
LR, 37 LRP and Gal-3 are located on the surface of HBMECs and astrocytes, as 
BBB components, and other mammalian cells (COS7 and N2a). In light of these 
data, we first sought to further characterize the surface distribution of the 67 LR 
homodimer and/or heterodimers, using dual immunofluorescence staining. In the 
present work, the dual immunofluorescence staining revealed co-localization of 
endogenously expressed 67 LR with its precursor, and both of these proteins with 
Gal-3 on the surface of HBMECs, astrocytes and COS7 cells. Because the Mluc5 
antibody specifically recognizes the 67 LR, but not the precursor form, it was 
used instead of the Ab711 antibody to detect the co-localization of 67 LR with 37 
LRP. While InHLRP antibody recognized only the 37 LRP form by Western blot 
analysis as shown previously in Figure 4.3. Thus, the observed staining pattern of 
67 LR with 37 LRP on the apical surface of HBMECs and astrocytes indicates 
distinct populations of 67 LR and 37 LRP (Figure 5.3A). Whilst 37LRP still 
exhibited a more diffuse staining pattern, often polarised and with an apparent 
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inverse correlation to the degree of 67 LR staining, 67 LR staining was punctate. 
There was some colocalization of the two receptor populations on the cell surface 
(Figure 5.3A, yellow colour). In this context, it should be noted that the present 
colocalization images of 67 LR and its precursor are visual-based and therefore 
highly prone to bias. Therefore, quantitative analysis of colocalization of 67 LR 
with 37 LRP within cell body and specific sub-cellular structure, named laminin 
rrich structures (LRS), was conducted in our laboratory (Oral communication 
with Dr. Lee Wheldon). This data revealed minimal colocalization of 37 LRP and 
67 LR in areas of the cell devoid of LRS (14 ± 1.6%), comparing with a 
significantly increased colocalization at LRS (48.5 ± 2.2%) (Dr. Lee Wheldon, 
unpublished data). Importantly, the proportion of 37 LRP-associated 67 LR or 67 
LR-associated 37 LRP was not significantly different on the cell body (14 ± 1.6% 
compared to 12 ± 2.1%, respectively) (Dr. Lee Wheldon, unpublished data). 
Notably, whilst many cells exhibited both 37 LRP and 67 LR surface staining, 
cells that were particularly enriched for one receptor displayed reduced levels of 
the other (Dr. Lee Wheldon, unpublished data).  This apparent inverse correlation 
was subsequently confirmed by direct comparison of mean fluorescence intensity 
measurements of both 37 LRP and 67 LR on the same cell (Dr. Lee Wheldon, 
unpublished data). This suggests existence of 67 LR as 37 LRP homodimer, 
which corroborates findings of a previous study, where the amino acid 
composition of 67 LR was found to be identical to 37 LRP (Landowski et al., 
1995). Another study suggests that the homodimerization of 67 LR, based on the 
detection of 67 LR and 37 LRP at the plasma membrane fractions of N2a cells, by 
Western blot analysis (Gauczynski et al., 2001) using a monoclonal antibody, 
which recognizes both 37 LRP and 67 LR. However, N2a cells lack expression of 
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endogenous Gal-3 (Gauczynski et al., 2001). Interestingly, the current study 
found that Gal-3 was colocalized predominantly with 37 LRP on the apical 
surface of HBMECs, astrocytes and COS7 cells, which endogenously express 
Gal-3 (Figure 5.3C). Similar results were obtained with second rat monoclonal 
(Mac-2) and goat polyclonal (AF1154) antibodies to Gal-3 (data not shown). In 
addition to 37 LRP, clear colocalization was observed between Gal-3 and Ab711 
polyclonal antibody against 67 LR (Figure 5.3B). Measuring the co-localization 
coefficient of 37 LRP and Gal-3 showed that approximately half of the surface-
localized 37 LRP associated with Gal-3 on the cell (50 ± 5.9%) or at LRS (62.6 ± 
6.9%) (Dr. Lee Wheldon, unpublished data). Such colocalization between Gal-3 
and 67 LR was further charcterizied using Mluc-5 antibdy, which is known to 
detect only 67 LR (Oral communication with Dr. Lee Wheldon). Both 
monoclonal (mab4033) and polyclonal (AF1154) Gal-3 antibodies demonstrated 
an almost perfect (>90%) co-localization with 67 LR stained with Mluc-5 
antibody. In contrast, minimal colocalization was demonstrated between 
monoclonal (Mac-2) Gal-3 antibody and 67 LR stained with Mluc-5 antibody on 
the cell (9.4 ± 2.1%) or at LRS (6.1 ± 1.3%) (Dr. Lee Wheldon, unpublished 
data). A previous study has shown that the antibody against Gal-3 can detect 67 
LR on immunoblots of detergent cell extracts (Buto et al., 1998). In addition, 67 
LR can be eluted from a laminin affinity column using lactose and N-
acetyllactoseamine, a known ligand for Gal-3 (Castronovo et al., 1992). All these 
studies support our finding of observed colocalization of Gal-3 with 67 LR and its 
precursor.  
Further investigation for the association of 37 LRP-37 LRP and 37 LRP-Gal-3 to 
form 67 LR homo- or hetero-dimer respectively, was performed using receptors 
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labelled with a different spectral fluorescent protein. This approach allows 
visualization of the interaction between fluorescently tagged 37 LRP and Gal-3 in 
different cellular compartments, providing a number of findings that cannot be 
detected by immunofluorescence staining. This approach was used before to 
characterize the subcellular localization of 37 LRP and a prion protein (Nikles et 
al., 2008). The vYFP and mCherry are well-characterized spectral variants of 
GFP and RFP, respectively, and have been used for dual imaging of two different 
receptors. The subcellular localization of each receptor, fused to vYFP and other 
fluorescent proteins, was observed in Chapter 4 (Figure 4.16) and previous reports 
(Nakahara et al., 2006; Nikles et al., 2008), respectively. This study showed that 
the 37 LRP.vYFP colocalized with 37 LRP.mCherry and Gal-3.mCherry when 
both receptors were coexpressed in a cell (Figure 5.5A and B), suggesting that 37 
LRP formed homo- and hetero-dimers with Gal-3, and reflecting dual 
immunofluorescence staining of endogenous receptors (Figure 5.2C). Such 
pattern of almost complete overlapping of coexpressed receptors in COS7 cells 
were expected, since both 37 LRP and Gal-3 are located in the nucleus, cytoplasm 
and the cell surface. In addition, whether or not, the obtained colocalization signal 
only represent homo- or hetero- dimer forms of 67 LR, cannot be concluded from 
this experiment. This is because 37 LRP and Gal-3 are multifunctional proteins 
that interact with many cellular proteins (Dumic et al., 2006; Nelson et al., 2008). 
However, the main limitation of this approach was the ability to produce adequate 
transfection efficiency, which would lead to expression of the protein at varying 
ratios. Thus, subpopulation of cells, expressing one of two constructs were found. 
To overcome the limitations of dual immunofluorescence staining and fusion of 
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receptors to fluorescent proteins, a specific method to detect receptor dimerization 
called BiFC was used.  
In our study, the BiFC approach was used as an applicable method for direct 
visualization of receptor dimerization and their subcellular localization in many 
types of cells, under physiological conditions (Hu et al., 2002; Kerppola, 2006). 
Interestingly, and for the first time, we have shown by BiFC that 67 LR exists in 
homo- and hetero- dimer forms with Gal-3 in different mammalian cells, 
indicating cell type independent interactions. In HBMECs, the pattern of BiFC 
expression was unique, as fluorescence resulting from complementation of 67 LR 
homo- and hetero- dimers, was punctate throughout the apical surface and 
excluded from the nuclei (Figure 5.8A). In contrast to HBMECs, BiFC complexes 
exhibited more diffuse distribution throughout the cells in N2a cells (Figure 
5.8B). This pattern of distribution mirrored that of 37 LRP and Gal-3 fused to 
full-length vYFP, as shown in Chapter 4 (Figure 4.17). Taking into consideration 
that the BiFC signal observed may represent receptors that interact with each 
other directly, as homo or heterodimers, and/or they are present in the same 
complex. A previous study has shown that both 67 LR and 37 LRP are distributed 
on the surface of N2a cells (Gauczynski et al., 2001). The surface localization of 
67 LR homo- and hetero-dimers fused to BiFC fragments in N2a cells in our 
study, was confirmed by immunostaining of the GFP tag (Figure 5.8B). It was 
clearly shown that the surface expression pattern of BiFC complexes were 
comparable to wild type receptors fused to vYFP (Figure 4.17B). This indicates 
that fusion of Venus fragments does not disturb receptor cell surface localization. 
Moreover, co-staining with the 37 LRP antibody revealed partial colocalization of 
the 67 LR dimers with receptor precursor (Figure 5.10). 
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Utilizing flow cytometry, as a more quantitative method to detect BiFC signal, 
showed successful complementation of receptor BiFC fragments, confirming the 
confocal microscopy results. In both flow cytometry and confocal microscopy, 
the fluorescence intensity of the BiFC signal is lower than the fluorescence 
resulting from 37 LRP and Gal-3 fused to vYFP (Figure 4.17) in N2a and COS7 
cells. This was expected since the BiFC signal, resulting from receptor 
complementation, is not comparable to the signal result from receptors fused to 
full length fluorescent protein.  
The ability of Gal-3 to homodimerize (Woo et al., 1991) and oligmerize 
(Nieminen et al., 2007) make it a suitable positive control for the BiFC 
experiment. In agreement with these studies, Gal-3 homodimers were successfully 
obtained by the BiFC method in COS7 and N2a cells, but unexpectedly, not in 
HBMECs (Figure 5.8 A, B and C). The failure of Gal-3 to homodimerize in 
HBMECs is not easily explained.  
The fluorescent protein fragments have the tendency to associate under certain 
condition. Usually to validate specificity of BiFC signal, association between 
unrelated protein and one of the genuine interacting proteins are investigated. 
However, multifunctionality and numerous interactions of 37 LRP and Gal-3 with 
different cellular proteins and receptors render choosing of other proteins, as a 
negative control, unfavourable. Based on a previous study, cysteine residue at 
position 186 of murine Gal-3 was found to be responsible for Gal-3 homodimer 
formation (Woo et al., 1991). Therefore, in this study, a single cysteine residue 
(Cys173) at the CRD of human Gal-3 was substituted into alanine and fused to 
Venus fragments to validate BiFC signal using flow cytometry. In agreement with 
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another report (Woo et al., 1991) using the BiFC method, this substitution 
abolished Gal-3 homodimerization (Figure 5.15B), validating our BiFC approach. 
Interestingly, such substitutions also significantly affect Gal-3 heterodimerization 
with 37 LRP (Figure 5.15A). Mutation of the sole cysteine (C173A), within the 
CRD of human Gal-3, did not interfere with the subcellular distribution of Gal-3 
as shown by subcellular fractionation analysis (Figure 5.14). Of interest, this 
cysteine is highly conserved among species  (Woo et al., 1991). Woo et al and co-
workers (1991), suggested that the covalent disulfide bond mediates Gal-3 
dimerization. However, in the current study, Gal-3 is still able to dimerize with 37 
LRP cysteine substituted constructs, which rules out the possibility that 67 LR 
heterodimers were formed by disulfide bonds between Gal-3 Cys173 and 37 LRP 
Cys148 or Cys163. This is consistent with other studies that have shown that the 
67 LR is not sensitive to reducing agents (Fujimura et al., 2012; Landowski et al., 
1995).  
Another study has suggested that the C-terminal region of 37 LRP  is involved in 
the formation of 67 LR, due to its high conservation among vertebrates (Menard 
1997). Also, the mutation of Gal-3 cysteine 173, which is located in the CRD of 
Gal-3, significantly reduced its heterodimerization with 37 LRP. In addition, in 
vitro binding assays revealed that rLR bound Gal-3 full molecule and its CRD 
significantly, and with almost similar affinity (Figure 5.6). Collectively, these 
findings led to assumption that the heterodimerization appears to be mediated by 
the C-terminals of both 37 LRP and Gal-3. Although Gal-3 CRD is involved in 
the 67 LR heterodimer formation, there is no evidence for 67 LR glycosylation 
(Castronovo et al., 1991a; Landowski et al., 1995), suggesting a protein-protein 
interaction between 37 LRP and Gal-3. This assumption is supported by the fact 
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that Gal-3 CRD is known to interact with several intracellular non glycosylated 
proteins in a carbohydrate-independent manner (Bawumia et al., 2003; Shimura et 
al., 2004; Shimura et al., 2005). It is therefore likely that the 37 LRP associates 
with Gal-3 in the cytoplasm, and is then targeted to the cell surface by acylation, 
as suggested by previous studies (Buto et al., 1998).  
Among reported intracellular interacting partners for Gal-3 is active K-Ras (Elad-
Sfadia et al., 2004). The K-ras is an important member of the Ras family, which 
play an important role in the control of signaling cascades that regulate cell 
proliferation, differentiation, survival, and death. Interactions of Gal-3 with active 
K-ras was found to be farnesyl-dependent since immunoprecipitation of Gal-3 
was decreased significantly in the lysate of unfarnesylated K-Ras (C185S) (Elad-
Sfadia et al., 2004). Farensylation is a type of lipid modification, where 15-carbon 
farnesyl isoprenoid is added to the thiol group of the cysteine residue, by the 
enzyme protein farnesyltransferase (FTase).  A further report has identified a 
hydrophobic pocket in Gal-3 CRD that is predicted to accommodate the farnesyl 
group of K-Ras (Ashery et al., 2006). Importantly, this pocket is crucial to 
mediate K-Ras.GTP nanocluster formation and signal output (Shalom-Feuerstein 
et al., 2008). Thus, it is possible that 37 LRP becomes acylated in the cytoplasm 
and interacts with Gal-3 via its CRD hydrophobic pocket, in a manner similar to 
the interaction of Gal-3 with active K-Ras. Interestingly, the Gal-3 cysteine 173 
was one of the amino acids that have been identified within the hydrophobic 
pocket that adapt farensyl binding. Such existence of this cysteine within this 
pocket may participate in the heterodimerization of Gal-3 with 37 LRP, since the 
disulfide bond theory was not applicable.  
  
215 
 
In summary, the data presented in this chapter provide new insights into an 
understanding of 67 LR dimerization status. Double immunofluorescence staining 
and coexpression of the fluorescent fusion receptors confirm colocalization of 
endogenously and transiently transfected receptors. Importantly, and using the 
BiFC method, presence of 67 LR as homo or heterodimers is demonstrated by 
confocal microscopy and flow cytometry. Of interest, the cysteine residue 173 of 
Gal-3 is involved in the formation of Gal-3 and 37 LRP heterodimers.  
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6. Chapter 6: Laminin Receptor and Galectin-3 expression 
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6.1. Introduction: 
Because of the potential role that Gal-3 recently played in CNS infection, 
including meniningitis, and in light of our data that Gal-3 dimerized with 37 LRP 
to form 67 LR, this chapter focuses on studying the role of Gal-3 in 
meningococcal adhesion and invasion, and furthermore investigates Gal-3 and 37 
LRP expression in response to meningococci and meningococcal 67 LR/37 LRP 
ligands.  
After attachment of meningococci to brain endothelial cells, which is mediated by 
meningococcal T4p and several other adhesins, including PorA and PilQ 
(described in detail in Chapter 3), two mechanisms that have been suggested to be 
used by N. meningitidis to cross brain endothelial cells: transcellular transport 
(Nassif et al., 2002) and paracellular entry via opened tight junction (Coureuil et 
al., 2009). Recently, an in vitro study has shown that N. meningitidis can be 
internalized within vacuoles in human brain microvascular endothelial cells 
(Nikulin et al., 2006). Also, N. meningitidis has been found to recruit polarity 
complex and disrupt the intercellular junctions of brain endothelial cells, enabling 
meningococcal passage via a paracellular route (Coureuil et al., 2009). This 
resulted from the activation RI WKH ȕ2-DGUHQHUJLF UHFHSWRUȕ-arrestin signalling 
pathway by the T4p (described in detail in Chapter 1). 
N. meningitidis is an obligate human pathogen, and this characteristic hinders 
development of animal models. However, this has been circumvented by 
development of transgenic mice. Among these transgenic mice one expresses 
human CD46, a proposed receptor for meningococcal T4p (Johansson et al., 
2003). These mice were shown to be susceptible to meningococcal disease after 
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intranasal challenge, revealing enhanced interaction between T4p and the murine 
nasopharynx (Johansson et al., 2003). Thus, these models provide an efficient tool 
for studying bacterial pathogenesis and evaluating vaccine efficacy. In the present 
study, mice expressing CD46 will be used to investigate role of Gal-3 and 67 
LR/37 LRP in meningococcal disease. 
Galectin-3 expression has been reported by previous studies to be upregulated in 
human meningothelial cells challenged with meningococcal secreted proteins 
(MSP) (Robinson et al., 2004), in experimental pneumococcal meningitis (Bellac 
et al., 2007; Coimbra et al., 2006) and other CNS infections (De Giusti et al., 
2011; Mok et al., 2007). In addition, several other pathogens also induce Gal-3 
expression, including: Helicobacter pylori, human immunodeficiency virus 
(HIV), and Trypanosoma cruzi (Fowler et al., 2006; Schroder et al., 1995; Vray et 
al., 2004). On the other hand, expression of 67 LR has been found to be increased 
in pneumococcal meningitis (Orihuela et al., 2009). Moreover, upregulation of 67 
LR expressions in response to CNF1-expressing E. coli K1 was shown recently in 
HBMECs (Kim et al., 2005). In this context, expression of both 67 LR and Gal-3 
is induced by host cell exposure to inflammatory cytokine, such as TNFD and 
INF-Ȗ (Jeon et al., 2010; Orihuela et al., 2009). Based on these reports, it is 
possible that the recently identified meningococcal laminin receptor ligands will 
affect the expression of 67 LR and its associated surface molecules, including 
Gal-3, to promote bacterial internalization. 
The identified meningococcal LR adhesins were outer membrane proteins PorA 
and PilQ (Orihuela et al., 2009). PorA is a 47 kDa meningococcal outer 
membrane protein (OMP), and forms trimeric cation-selective pores that allow the 
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traffic of water-soluble nutrients of up to 600 Da in size. Based on topology 
models, the protein is predicted to traverse the outer membrane via 16 E-sheets 
that create eight extracellular loops (van den Elsen et al., 1999). Two of these 
loops (loops 1 and 4) are strongly immunogenic and able to provoke bactericidal 
antibodies (van den Elsen et al., 1999). Preliminary data showed that loop 4 of 
rPorA is essential for LR binding (N. Abouseada, personal communication). The 
other meningococcal LR ligand, PilQ, is an antigenically conserved 82 kDa OMP 
that is fundamental for type IV pilus expression. It has a doughnut-like 
appearance with an apparent cavity (Frye et al., 2006) and forms a large (960 
kDa) homododecamer complex which is capable of generating bactericidal 
antibodies.  
Therefore, the focuses of this chapter were to assess the role of Gal-3 in 
meningococcal adhesion and invasion, to investigate whether the meningococci 
will affect 67 LR/37 LRP and Gal-3 expression in infected mice, and to examine 
if meningococcal LR ligands will induce 67 LR and Gal-3 expression in 
HBMECs.  
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6.2. Results: 
6.2.1. Enhanced invasion of MC58 in Galectin-3 expressed 
N2a cells 
N2a (mice neuroblastoma) cells, a cell line that does not express endogenous Gal-
3 as demonstrated previously by immunoblotting (Figure 4.16), were used to 
examine the role of Gal-3 in meningococcal adhesion and invasion. To achieve 
this, first, cells were transfected with human Gal-3 containing plasmid vector and 
its expression and surface localization was verified by immunoblotting and 
immunofluorescence staining. The expression of vYFP-tagged Gal-3 in 
transfected cells was confirmed by immunoblotting, as shown in Figure 6.1A. In 
addition, as demonstrated in Figure 6.1B, strong positive staining was observed 
with anti-Gal-3 (Mac-2) antibody in the cell surface of transfected cells only. 
Further, immunofluorescence analysis of Gal-3.vYFP transfected non-
permeabilized N2a cells employing 37 LRP antibody showed that Gal-3 and 37 
LRP colocalize on the surface of these cells (Figure 6.1B). 
Then, cell association assay was performed to compare the adhesive and invasive 
capacity of MC58 to Gal-3 transfected and non-transfected N2a cells. 
Interestingly, the number of internalized (Figure 6.1C) but not associated bacteria 
(data not shown) significantly increased (p = 0.005) in Gal-3 transfected cells 
when compared with untransfected cells. To exclude the possibility that the 
enhanced invasion was due to transfection, control empty vector was transfected 
into N2a cells. As shown in Figure 6.1C, there is no significant difference 
between meningococcal invasion in the empty vector-transfected and non-
transfected cells, excluding the possibility that enhanced invasion was due to 
transfection. 
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Figure 6.1: Galectin-3 expression enhances MC58 invasion of N2a cells. N2a 
cells were transiently transfected with plasmid containing Gal-3.vYFP, and one day after 
transfection the expression of recombinant protein was determined by Western blotting 
(A) from total cell lysates using anti-GFP antibody as described in Chapter 2. Surface 
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localization of Gal-vYFP in transfected cells was confirmed by immunofluorescence 
staining of non-permeabilized cells using anti-Gal-3 (Mac-2) antibody (B) and its co-
localization with endogenous 37 LRP using anti-37 LRP (InHLRP) antibody as described 
in Chapter 2. Scale bars are shown. (C) MC58 invasion to N2a cells expressing Gal-3 
was performed. The transfected and non-transfected N2a cells were infected with MC58 
for 2h at an MOI (multiplicity of infection) of 300 and incubated at 37ºC. For invasion 
assay, the cells were cultured for an additional 30min with 100 µg/ml gentamycin to kill 
any extracellular bacteria. Gal-3 transient expression enhanced the invasion of MC58 into 
N2a cells as compared with those of transfected with empty vector and non-transfected 
cells. Each value is the mean ± SEM of nine samples compiled from three independent 
experiments. Asterisks indicate the significant increase of MC58 invasion into Gal-3 
transfected cell when compared with empty vector transfected and non-transfected cells 
(NT), respectively6WXGHQW¶Vt- test; **p < 0.01,*** p < 0.001.) 
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6.2.2. Study of the expression of Gal-3 and 37 LRP in CD46 
brain tissues of mice infected with MC58 
Previous studies showed increased expression of Gal-3 and 67 LR in 
pneumococcal meningitis (PM) and other infections. To determine the expression 
of 37 LRP and Gal-3, and further confirm their colocalization in CD46 brain 
tissues of MC58 infected mice, double immunofluorescence staining for 37 LRP 
and Gal-3 was performed. As shown in Figure 6.2A, both 37 LRP (green) and 
Gal-3 (red) are expressed and colocalized (yellow) in the brains of both MC58 
infected and non-infected mice. As displayed in Figure 6.2B and C, Gal-3 and 37 
LRP expression showed significantly greater fluorescence intensity in infected 
mice when compared with the non-infected group (p = 0.0001). These results 
were consistent with results from the visualization under the fluorescence 
microscope in Figure 6.2A.  
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 Figure 6.2: Up-regulation of 37 LRP and Galectin-3 expression in the brain 
of MC58 infected mice. (A) Sections of brain tissues were stained for 37 LRP (green) 
and Gal-3 (red) in MC58 infected and non-infected mice. Merge images indicate co-
localization (yellow) of the 37 LRP and Gal-3 in the brain. Scale bars 0.06µm. (B and C) 
immunofluorescence intensity for Gal-3 (B) and 37 LRP (C) were measured in the brains 
of four randomly chosen MC58 infected and another four uninfected mice. Fluorescence 
intensity was greatest for 37 LRP and Gal-3 in infected mice when compared with non-
infected (6WXGHQW¶VWWHVW; ***p < 0.001). Data are presented as mean ± SEM of eighty-
four values taken randomly from each of four mice (twenty-one values / mouse) of each 
group. Quantification of fluorescence intensity by ImageJ software.  
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6.2.3. Meningococcal 37 LRP/67 LR ligands recruit 67 LR and Gal-3 to 
surface of HBMECs  
To examine the effect of meningococcal 37 LRP/67 LR adhesins on the surface 
level of 67 LR and Gal-3, HBMECs were treated with different 37 LRP/67 LR-
binding bacterial proteins or PBS as negative control for 2h and the surface level 
of 67 LR and Gal-3 were measured by flow cytometry. As represented in Figure 
6.3A and B, the surface level of both 67 LR and Gal-3 was increased in cells 
treated with rPilQ, Loop 4 of PorA and, more prominently, rPorA protein, when 
compared with PBS treated cells. 
 
Figure 6.3: Detection of 67 LR and Galectin-3 surface level in response to 
meningococcal LR ligands using flow cytometry. HBMECs were analyzed for (A) 
67 LR and (B) Gal-3 surface levels after incubation with 20µg/ml of different bacterial 
proteins rPorA (pink curve), loop4 of PorA (turquoise curve) and rPilQ (green curve) or 
PBS (blue curve). The 67 LR and Gal-3 surface levels were detected using the anti-67 LR 
(Mlu5) and anti-Gal-3 (mab4033) antibodies, followed by appropriate secondary 
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antibodies as described in Chapter 2. Histogram overlays of HBMECs alone (black 
curves), HBMECs incubated with secondary antibodies alone as negative control (dot 
curves), and HBMECs incubated with primary and secondary antibodies pre-treated with 
PBS (blue curve) or different bacterial proteins, including rPorA (pink curve), loop4 of 
PorA (torques curve) and rPilQ (green curve), were generated as described in Chapter 2, 
revealing induction of 67 LR (A) and Gal-3 (B) in HBMECs treated with different 
bacterial proteins. Experiments were repeated three times, with consistent results. 
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6.2.4. Detection of 37 LRP transcription in response to bacterial ligands 
To investigate the effect of meningococcal LR ligands on the transcriptional level 
of 37 LRP/67 LR in HBMECs, qPCR was carried out.  
6.2.4.1. Purity of the RNA samples 
Total RNA was extracted from monolayer of HBMECs induced for 24h with 
different bacterial proteins (rPorA, rPilQ and loop 4 of PorA) or PBS as a 
negative control. Quality of extracted RNA was examined by measuring the 
OD260/280 ratio, and all samples fell within a ratio of 1.8 to 2. The purity of 
extracted RNA was further confirmed by PCR. LR specific primers which 
amplify 888 bp from genomic sequence were used in PCR using 1µg of RNA 
from all samples. No detectable PCR product was obtained, which confirmed the 
purity of RNA (Figure 6.4, lanes 1-4). A positive control (Figure 6.4, lanes 5 and 
6) produced the expected band at 888bp, and no band was obtained in the 
negative control (Figure 6.4, lane 7) which ensures primer specificity and 
successful PCR reaction. 
 
Figure 6.4: Assessment of extracted RNA purity by PCR. RNA of HBMECs 
treated with PBS (lane 1), (20µg/ml) of rPorA (lane 2), Loop 4 of PorA (lane 3) and 
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rPilQ (lane 4). PCR product of 37 LRP and human cDNA (lanes 5 and 6) respectively as 
positive controls. Negative control primer only without any template (lane 7).   
 
6.2.4.2. cDNA 
cDNA to be used in qPCR analysis was prepared by RT-PCR of RNA extracted 
from untreated and treated HBMECs. As shown in Figure 6.5, all cDNA samples 
produce 37 LRP/67 LR at the expected size (888 bp).  
 
Figure 6.5: RT-PCR for extracted RNA. cDNA synthesised from RNA of 
HBMECs treated with PBS (lane 1), (20µg/ml) of rPorA (lane 2), Loop 4 of PorA (lane 
3) and rPilQ (lane 4). PCR product of 37 LRP (lane 5). Negative control primer only 
without any template (lane 7).   
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6.2.4.3. Optimization of qPCR 37 LRP DQGȕ-actin primer 
concentrations  
To use the prepared cDNA in qPCR, specific primers should be designed to 
amplify only short fragments ranging from 50 to 120 bp for 37 LRP DQGȕ-actin. 
Primers were designed to amplify 98bp and 55bp of 37 LRP DQG ȕ-actin, 
respectively. The primer concentrations were optimized using different ratios of 
the primers in a series of experiments. Figures 6.6A and B showed the 
amplification plot (cycle threshold, CT versus fluorescence, Rn) of 37 LRP (gene 
of interest) and ȕ-actin (endogenous gene) respectively for all primer ratios used. 
The CT is defined as the amplification cycle number in which the curve crosses a 
specified threshold. The Rn is the normalized fluorescence signals which are 
generated in the reaction. The mixture of 3µM forward and 9µM reverse primer 
produce an amplification plot with both the lowest cycle threshold (CT) value and 
highest fluorescence (Rn). As a result, all experiments were done using 3µM of 
forward and 9µM of reverse primer for both 37 LRP DQGȕ-actin. 
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Figure 6.6: Optimization of 37 LRP DQG ȕ-actin primers concentration. 
3ULPHU FRQFHQWUDWLRQ GHSHQGHQW DPSOLILFDWLRQ SORWV RI  /53 $ DQG ȕ-actin (B). 
Forward and reverse primers were examined at different concentrations (0.5-9 µM) using 
fL[HG  QJO RI +%0(&V F'1$ IRU  /53 DQG ȕ-actin. The amplification blot 
indicated that the 3µM of forward and 9µM of reverse primer were the optimal primer 
FRQFHQWUDWLRQVIRU/53$DQGȕ-actin (B). 
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6.2.4.4. Standard curves of 37 LRP DQGȕ-actin 
To calculate relative transcriptional levels of the genes of interest using the delta 
GHOWD&7ǻǻ&7PHWKRG(Livak & Schmittgen, 2001), the reaction efficiency of 
PCR was calculated. HBMEC cDNA was used as a template to perform standard 
curves for 37 LRP DQG ȕ-actin in order to examine the PCR efficiency and 
linearity of template amplification. As shown in Figure 6.7, the slope of standard 
curves was -3.229 and -3.258 for 37 LRP and B-actin respectively, revealing 
100% efficient PCR amplification; the efficiency was calculated according to the 
following equation: (   ʊ VORSH ʊ  [  )LJXUH  GHPRQVWUDWHG a 
linear correlation between the cDNA and CT values. Moreover, the correlation 
coefficients were 0.994 and 0.999 for 37 LRP and B-actin respectively, 
confirming the accuracy of the amplification efficiency. 
 
 
  
Figure 6.7: Standard curves for 37 LRP and ȕ-actin to evaluate efficiency of 
qPCR. Standard curves were established for 37 LRP (blue diamond) and B-actin (red 
square) using log cDNA against CT values. Each point represents the mean of triplicate 
values for each 37 LRP and ȕ-actin.  
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6.2.4.5.  Validation of 2¯ ǻǻ&7method 
There are different methods for analysis of relative quantification of gene 
expression, such as the GHOWD GHOWD F\FOH WKUHVKROG ǻǻ&7 PHWKRG (Livak & 
Schmittgen, 2001). This method can be used when the amplification efficiencies 
of the target and reference are approximately equal. Assessment of the 
DPSOLILFDWLRQ HIILFLHQF\ FDQ EH PHDVXUHG E\ VWXG\LQJ ¨&7 &7 7DUJHW±CT 
(Endogenous)) changes with different dilutions of cDNA. Identical efficiencies of 
the target (37 LRP DQG UHIHUHQFH JHQH ȕ-actin) are indicated by slope values 
close to zero. $VDUHVXOWWKH¨&7&737 LRP±CT B-actin) was calculated and 
plotted versus log cDNA as represented in Figure 6.8. The slope of the line is 
WKXVWKHǻǻ&7PHWKRGFDQEHXVHGWRDQDO\]HWKHGDWD 
 
)LJXUH  9DOLGDWLRQ RI  Āǻǻ&7 PHWKRG 7KH¨&7&737 LRP±CT B-actin) 
was calculated and plotted versus log cDNA of HBMECs. The data fit using linear 
regression analysis (no=3). 
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6.2.4.6. Relative 37 LRP gene expression in HBMECs treated with LR 
binding bacterial protein 
Quantitative PCR (qPCR) was utilized to examine the effect of meningococcal 
LR ligands on the transcription level of 37 LRP. To achieve that, monolayers of 
HBMECs were incubated for 24h with different bacterial proteins (rPorA, rPilQ 
and loop 4 of PorA) or PBS as a negative control. Then, total RNA was extracted 
from treated HBMECs and RNA was reverse-transcribed and qPCR used. The 
ratios of gene expression levels were calculated using the ǻǻ&7PHWKRG(Livak & 
Schmittgen, 2001). The data were normalised against ȕ-actin. As shown in Figure 
6.9, Loop4 of PorA and rPilQ induces 37 LRP expression significantly more than 
PBS (p<0.0001). Recombinant PorA increases 37 LRP expression but to a lesser 
extent than loop 4 synthetic peptide and rPilQ. Although there was a trend for an 
increase in 37 LRP expression with treatment with rPorA, the difference was not 
statistically significant (p = 0.1507). 
PBS rPorA Loop 4 rPilQ
-0.1
0.0
0.1
0.2
0.3
0.4
***
***
Re
lat
iv
e 
ex
pr
es
sio
n
 
o
f  
37
 
LR
P
 
Figure 6.9: Changes in 37 LRP gene expression in the induced HBMECs. 
HBMECs monolayer was treated with 20µg/ml of rPorA, Loop 4 of PorA and rPilQ or 
PBS for 24h. Total RNA was extracted and subjected to relative quantification (RQ) 
using the ǻǻ&7PHWKRGThe qPCR was used to check 37 LRP expression and a log of 
RQ was plotted using ȕ-actin as an endogenous control and PBS sample as a calibrator. 
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Each value is the mean ± SEM of nine samples compiled from three independent 
experiments. 6WXGHQW¶Vt-test; ***p < 0.001). 
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6.3. Discussion: 
The heterodimerization of 37 LRP with Gal-3 to form 67 LR (Chapter 5) and in 
vitro binding of N. meningitidis to Gal-3 (Chapter 3) were encouraging to study 
the potential role of Gal-3 in meningococcal adhesion and invasion in this 
chapter. Interestingly, transient expression of Gal-3 significantly increased MC58 
invasion into N2a cells (Figure 6.1C). This is in accordance with a previous study 
which showed that transfection of Gal-3 enhances H. pylori adhesion to Cos-1 
cells, which naturally express low levels of Gal-3, when compared with non-
transfected cells (Fowler et al., 2006). A recent study has reported the recruitment 
of Gal-3 into vacuole disrupted by an invasive pathogen (Paz et al., 2010). Other 
Galectins, such as Gal-1, increase HIV infectivity by enhancing viral adhesion 
(Mercier et al., 2008; St-Pierre et al., 2011). Also Gal-1 promotes adhesion of 
Trichomonas vaginalis to cervical epithelium (Okumura et al., 2008). Thus, the 
increase in meningococcal invasion mediated by Gal-3 suggests that Gal-3 might 
enhance meningococcal infection. How Gal-3 contributes in N. meninigitidis 
invasion and the underlying mechanism is not yet clear. It will be interesting to 
investigate such a mechanism in future studies.  
Since Gal-3 heterodimerizes with 37 LRP to form 67 LR (described in Chapter 5), 
involving Gal-3 cysteine 173, there might be a cooperative mechanism between 
these receptors¶ heterodimers in meningococcal infection. In an attempt to 
investigate if the obtained increase in meningococcal entry to N2a cells was 
related to 67 LR heterodimer in addition to Gal-3 itself, Gal-3 C173A mutant, 
which does not dimerize with 37 LRP, was transfected into N2a cells, and the 
capability of meningococci to adhere to and invade N2a cells was measured. The 
meningococcal adhesion and invasion into N2a cells was comparable between 
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Gal-3 wild type and cysteine substituted construct (data not shown). These results 
signify the role of Gal-3 in meningococcal invasion, even if its cysteine has been 
substituted. Taking into consideration that N2a cells lack the endogenous 
expression of Gal-3, therefore, the behaviour of these receptors¶ dimers in other 
cells expressing both receptors, such as HBMECs, could show specific functions.  
An interesting finding of the current study was the upregulation of Gal-3 and 37 
LRP expression in response to N. meningitidis in the brain of CD46 expressing 
mice (Figure 6.2A and B). In agreement with this result, previous studies have 
demonstrated increased expression of Gal-3 in in human meningothelial cells 
exposed to secreted proteins from meningococci (Robinson et al., 2004). In 
another study reported by Bellac et al. (2007), expression of Gal-3 was found to 
be increased in the cortex and hippocampus of pneumococcal meningitis-infected 
rat, which corroborates our finding (Figure 6.2). In addition to bacterial 
meningitis, other CNS infections, such as prion (Mok et al., 2007) and Junín virus 
(JUNV) encephalitis (De Giusti et al., 2011) was associated with upregulation in 
Gal-3 expression. In the context of bacterial meningitis, all illustrated studies have 
related the increased Gal-3 expression and its role in neuroinflammation and also 
anti-apoptotic activity. However, results of several other studies have suggested 
that Gal-3-pathogen interactions might mediate pathogen adhesion and thus 
promote infection (Cerliani et al., 2011). For example, adhesion of H. pylori to 
the gastric epithelial cells increases expression and secretion of Gal-3, which has 
been suggested to enhance infection (Fowler et al., 2006). Another relevant study 
has reported that the increased expression of Gal-3 has promoted adhesion of T. 
cruzi to host cells (Kleshchenko et al., 2004). With this in mind, the possibility 
that the upregulation of Gal-3 expression might enhance meningococcal infection 
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by mediating more bacterial entry is strongly recommended, specifically when 
considering our finding that Gal-3 promoted meningococcal invasion into N2a 
cells (Figure 6.1).  
The demonstrated increased expression of 37 LRP in meningococcal infected 
mice (Figure 6.2) corroborates Orihuela, Mahdavi et al. (2009) study which 
showed that the expression of 67 LR is upregulated in mice challenged with 
pneumococci by immunohistochemical staining of 67 LR in lung and brain of 
infected mice. Furthermore, CNF1 expressing E. coli .EXWQRWǻcnf1 mutant, 
increased the total amount of 67 LR as evidenced by Western blot analysis and 
immunofluorescence staining of 67 LR in HBMECs (Kim et al., 2005). In 
Orihuela and Mahdavi et al. (2009) study, the upregulation of 67 LR expression 
on the surface of host cells was found to be required for bacterial adherence. This 
was further supported by previous reporWV¶ILQGLQJVZKLFKGHPRQVWUDWHGthat high 
density of CEACAM expression is required for cellular invasion of N. 
meningitidis in an Opa-CEACAM dependent manner, even in capsulated 
organisms (Griffiths et al., 2007; Rowe et al., 2007). Thus, increased expression 
of 37 LRP in the brain of N. meningitidis infected mice might induce 
meningococcal adhesion.   
Flow cytometery analysis showed that the recruitment of 67 LR and Gal-3 to the 
cell surface of HBMECs was increased in response to meningococcal 37 LRP/67 
LR ligands, including rPilQ, rPorA and Loop 4 of PorA, when compared with 
PBS (Figures 6.3A and B). The purpose of this experiment was detailed 
investigation for the effect of each meningococcal 37 LRP/67 LR adhesin on the 
surface level of 67 LR and its dimer Gal-3 in vitro. The observed increase in 67 
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LR surface level was reported by previous studies which showed that the 
incubation of human melanoma cells with laminin induces 67 LR and its 
precursor expression on the cell surface (Romanov et al., 1994; Romanov et al., 
1995). Romanov et al. (1995) study has further reported that the laminin 
induction of 67 LR and 37 LRP expression was blocked by cycloheximide 
(protein synthesis inhibitor), revealing that the induction was depenent on protein 
synthesis (Romanov et al., 1995). Of interest, meningococcal 37 LRP/67 LR 
ligands also increased the recruitment of Gal-3 to the surface of HBMECs (Figure 
6.3B). Since PilQ was one of the identified meningococcal-Gal-3 adhesins, 
therefore, induction of Gal-3 surface level in response to its ligand was 
anticipated. Upregulation of Gal-3 expression in response to several pathogens 
was reported previously (Bellac et al., 2007; De Giusti et al., 2011; Fowler et al., 
2006; Mok et al., 2007). It should be noted that most of theses studies do not 
differentiate between surface and intracellular Gal-3. However, a recent study 
showed that the S. mansoni soluble egg antigens (SEA) induced surface 
expression of Gal-3 on CD+ T cells (Zaccone et al., 2009). This antigen was 
demonstrated previously to bind Gal-3 via its N-acetyl-lactosamine residues (van 
den Berg et al., 2004). Not only pathogen ligands but also several host cellular 
ligands were found to induce Gal-3 surface expression. In this context, Greco et 
al¶V (2004) study has reported that an increased expression of Gal-3 on the 
surface of cells from adenoma patients was accompanied by an increase of its 
ligand (90k) in blood plasma of those patients (Greco et al., 2004). This increase 
in Gal-3 surface expression and its ligand (90k) plasma level was suggested to be 
used as a marker for differentiation between non-malignant and malignant colon 
cancers. On the other hand, surprisingly, Gal-3 surface level was increased also 
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upon treatment of HBMECs with other meningococcal LR adhesins, rPorA and 
its loop 4 peptide. Since PorA was not identified in the current study as Gal-3 
adhesin (discussed in Chapter 3), it is possible that the observed increase in Gal-3 
surface level in response to LR bacterial ligands (rPorA and its loop 4 peptide) 
might be because of the association of Gal-3 with 37 LRP to form 67 LR. 
Importantly, rPorA induced the most robust increase in surface 67 LR and Gal-3 
levels. Meningococcal major porin PorA has immunogenic and adjuvant 
properties as reported by previous studies. One of these studies has found that 
recombinant PorA (rPorA) induced dendtritc cell (DC) maturation, which was 
reflected by reduced receptor-mediated endocytosis (Al-Bader T, 2004). It also 
increased production of the chemokine IL-8, RANTES, macrophage 
inflammatory protein-1 alpha and beta (MIP-ĮDQGȕDQGDXJPHQWHGH[SUHVVLRQ
of CD40, CD54, CD80, CD86 and the major histocompatibility complex class II 
molecules, indicating T cell activation (Al-Bader T, 2004). However, in terms of 
meningococcal adhesion only recently PorA was identified as bacterial ligand for 
67 LR, as mentioned earlier. As a result, the observed increased of 67 LR and 
Gal-3 surface levels in response to meningococcal adhesins could increase the 
strength of bacterial adhesion and leads to increased cellular invasion by 
meningococci, as increased CECAM receptor density helps to overcome the 
inhibitory effects of bacterial capsule and increased bacterial entry into the cells 
(Bradley et al., 2005; Griffiths et al., 2007; Rowe et al., 2007; Virji et al., 1992). 
Whether the observed recruitment of receptors to the cell surface in response to 
bacterial proteins resulted from increased receptor transport or de novo synthesis 
cannot be concluded from the current study. It would be interesting in a future 
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study to examine the influence of protein synthesis inhibitor on the recruitment of 
67 LR and Gal-3 to cell surface after stimulation with meningococcal ligands.  
Furthermore, in the present study, qPCR was used to examine whether the 
bacterial proteins will affect gene expression of 37 LRP in HBMECs. The qPCR 
results revealed that the gene expression of 37 LRP in HBMECs is increased in 
response to loop4 peptide of PorA, rPilQ and, to a lesser extent, rPorA (Figure 
6.9). Loop 4 synthetic peptide was employed in the qPCR to avoid possible LPS 
contamination which might associate with purification of recombinant outer 
membrane proteins (rPorA and rPilQ). This peptide contains a terminal cysteine 
residue at each end to form a bridge between the peptide ends to simulate the loop 
structure. The significant increase of 37 LRP expression as a result of loop 4 was 
an interesting finding as loop 4 appears to be essential for rPorA-LR binding 
(Abouseada, 2009). In addition, loop 4 of PorA has been shown to elicit 
bactericidal antibodies which provide protection against infection (Saukkonen et 
al., 1989). The significant potentiation of 37 LRP expression by loop 4 peptide 
more than whole rPorA might be because rPorA is purified under denaturing 
conditions, so protein conformation including surface exposure of loop 4 will be 
changed and differs from the native trimer form of the protein, while loop 4 
peptide contains a terminal cysteine residue at each end to form a bridge between 
the peptide ends to stimulate loop structure. This could explain reduced influence 
of rPorA when compared with its loop 4 peptide in term of 37 LRP expression. 
Another 37 LRP/67 LR meningococcal adhesin rPilQ (82 kDa) significantly 
increased 37 LRP expression more than rPorA, but not loop 4. Another relevant 
study has shown that the TNF-Į LQFUHDVHV 67 LR expression in a rat brain 
capillary endothelial cell (rBCEC6) at protein level (Orihuela et al., 2009). This 
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was evident by immunoblotting of rBCEC6 lysates using Ab711 antibody which 
detects the mature (67 LR) and precursor (37 LRP) forms of the receptor and 
showed gradual increase in the expression level of 67 LR and its precursor in 
response to TNF-Į(Orihuela et al., 2009). Therefore, it will be useful to study 37 
LRP/67 LR expression at the protein level by Western blotting in a future study. 
In the context of bacterial meningitis, meningococcal porin and secretin (PilQ) are 
considered the second bacterial ligands after E. coli K1 CNF (Kim et al., 2005) 
that induce 67 LR gene expression on HBMECs. Interestingly, both PorA and 
PilQ are outer membrane proteins and strong vaccine candidates (D. Halliwell, 
2004; Jan T. Poolman, 2006; Vermont et al., 2003). It is noteworthy that both 
rPorA and rPilQ were also shown previously to induce transient increases in 
calcium release in HBMECs using confocal microscopy (Abouseada, 2009). In 
addition, meningococci are known to release outer membrane vesicles (OMVs) or 
blebs in vivo during infection, which play an important role in immune evasion 
and inflammation (Devoe & Gilchrist, 1973). Blebs are formed by circular pieces 
of the outer membrane carrying a number of different OMPs and LOSs. This 
feature was used to develop a vaccine against meningococci serogroup B where 
outer membrane proteins presented in LOS depleted OMVs (Fredriksen et al., 
1991). More interestingly, 37 LRP/67 LR meningococcal adhesins are 
constituents of OMVs or blebs (Post et al., 2005) which might act as additional 
microbial signal that induce 67 LR expression in vivo, taking into consideration 
that these OMVs have been shown to correlate with severity of the 
meningococcal disease (Brandtzaeg et al., 1992b).  
It is noteworthy that the 67 LR exists as a homo- and heterodimer with Gal-3, so 
it is possible that the upregulation of 37 LRP/ 67 LR expression in response to 
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meningococcal LR ligands might be not mediated solely by receptor homodimers, 
but also heterodimers form with Gal-3. Attempts were made to study the 
expression of Gal-3 in response to meningococcal LR ligands, but the available 
time did not allow further optimization for qPCR. 
In conclusion, the results presented in this chapter revealed that expression of 
Gal-3 enhanced meningococcal invasion into N2a cells. Both 37 LRP and Gal-3 
expression were upregulated in response to N. meningitidis infection in the 
meninges of CD46 expressing mice. Furthermore, incubation of HBMECs with 
purified proteins of meningococcal LR ligands increased the recruitment of 67 LR 
and Gal-3 to cell surface and increased gene expression of 37 LRP at the mRNA 
level. 
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7. Chapter 7: General discussion  
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7.1. General Discussion  
 
N. meningitidis remains the leading cause of meningitis and septicaemia 
worldwide (Harrison et al., 2009). The incidence of meningococcal disease ranges 
from 0.5 to 1000 cases per 100, 000 of the population each year,  in the sporadic 
outbreaks observed across Europe and during epidemics in the meningitis belt in 
sub-Saharan Africa, respectively (Hill et al., 2010; Stephens et al., 2007). Of the 
estimated 1.2 million cases of invasive meningococcal disease, 135,000 deaths are 
thought to occur annually worldwide, even with antibiotic treatment (WHO, 
2001); furthermore, patients who survive meningococcal disease suffer from 
long-term neurological complications, such as epilepsy, neurological damage and 
deafness (Dawson et al., 1999; Grimwood et al., 2000). Meningococcal vaccines 
were thus introduced, in an attempt to control and prevent the disease. The 
introduction of conjugated vaccines against meningococcal serogroup C to routine 
immunization in different countries has led to a dramatic decline in the incidence 
of the disease and the asymptomatic carriage caused by serogroup C (Gasparini & 
Panatto, 2011). In many countries, quadrivalent vaccines have been used for years 
in the prevention of meningococcal disease caused by serogroups A, C, Y and W-
135 (Tan et al., 2010); however, as yet, there are no vaccines that are broadly 
effective against serogroup B meningococci, which is the predominant cause of 
meningococcal disease in developed countries (Harrison et al., 2009). This is due 
to similarities between the serogroup B polysaccharide capsule and the human 
neurological antigen. As a result, the immunogenicity of the meningococcal 
serogroup B capsule is poor in humans and its use in the development of vaccines 
has thus been avoided, in order to prevent the development of potential 
  
245 
 
autoimmune disease. Despite the availability of a preventative vaccine against 
some serogroups and the sensitivity of the organisms to several antibiotics, N. 
meningitidis remains a major threat to human health. Alternative approaches in 
the prevention of meningococcal disease are thus required and this necessitates a 
greater understanding of the host-pathogen interaction, which may also enable 
new vaccine and therapeutic strategies.  
N. meningitidis is a highly-invasive Gram-negative bacterium that is capable of 
causing outbreaks of meningitis, septicaemia and septicaemic shock, which can 
kill within hours of the appearance of symptoms. In order to approach the 
meninges from the nasopharynx, the meningococci must cross two cellular 
barriers: firstly, the epithelial cell barrier in the nasopharynx and, secondly, the 
endothelial barrier in the brain. In this context, Neisseria meningitidis uses 
numerous adhesins and secreted virulence factors to interact with the various host 
cell receptors that mediate bacterial adhesion and invasion of human cells 
(Orihuela et al., 2009; Unkmeir et al., 2002; Virji et al., 1994). These adhesins act 
in a sequential manner and in concert, resulting in high avidity interactions, which 
are often a prelude to cellular invasion and tissue penetration (Virji, 2009). Some 
of these adhesins have been identified to target multiple host receptors (Virji, 
2009).  
In terms of the host receptors, 37 LRP/67 LR has recently been identified by a 
researchers in our group as being targeted by meningococcal PorA and PilQ, 
pneumococcal CbpA and OmpP2 of H. influenza (Orihuela et al., 2009). These 
pathogens are the most common cause of bacterial meningitis and it has been 
suggested that their interactions with 37 LRP/67 LR underlie their CNS tropism 
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(Orihuela et al., 2009). Interestingly, of the three strains of meningitis bacteria, N. 
meningitidis is the only one with two 37 LRP/67 LR-binding surface adhesins: 
this may reflect the importance of, and the affinity required for, this binding. Of 
interest is the fact that the identified meningococcal ligands for 37 LRP/67 LR 
have been utilised as a strategy in the  development of vaccines (St. Jude 
Children's Research Hospital, 2008; University of Nottingham, 2009). This 
strategy is based on the interruption of the interaction of these pathogens with 37 
LRP/67 LR, through the administration of polypeptides mimicking the binding 
proteins expressed on the surface of these pathogens (St. Jude Children's Research 
Hospital, 2008; University of Nottingham, 2009). Another bacteria that causes 
meningitis, Escherichia coli K1, also targets the same receptor via its cytotoxic 
necrotising factor 1 (CNF1) (Chung et al., 2003): the interaction of CNF1 with 37 
LRP/67 LR induces the E. coli K1 invasion of endothelial cells in the human 
brain (Kim et al., 2005). Recently, pharmacological agents (etoposide) were 
shown to prevent the invasion of HBMECs by E. coli K1 and this significantly 
decreased the development of meningitis in experimental mice (Zhu et al., 2010). 
Interestingly, a reduction in the expression of 37 LRP/67 LR is the mechanism 
that underlies the preventive effect of etoposide on E. coli K1 invasion (Zhu et 
al., 2010).  
The 37 LRP/67 LR is a non-integrin laminin receptor, which is expressed in 
different cells, including brain endothelial cells, and acts as a receptor for a 
versatile range of neurotropic pathogens (Menard et al., 1997; Nelson et al., 
2008). A number of previous studies have suggested that the homodimerization of 
the receptor precursor (37 LRP) or the heterodimerization of this precursor with 
an interesting partner Galectin-3 (Gal-3) forms the mature 67 LR (Buto et al., 
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1998; Castronovo, 1993; Landowski et al., 1995); however, the dimerization 
status of 37 LRP/67 LR is not yet clear. The significance of 37 LRP/67 LR as a 
therapeutic target in bacterial meningitis, including meningococcal disease, and 
its potential contribution to meningococcal CNS tropism necessitates further 
characterisation of the dimerization status of the receptor, which was one of the 
major aims addressed by the current study. 
The potential dimerization of 37 LRP/67 LR with Galectin-3 is of particular 
interest: this is because Galectin-3 is a multi-talented lectin that interacts with 
several pathogens and is involved in their pathogenesis through its functions in 
innate immunity or as pathogen receptor. In addition, the role of Galectin-3 in 
CNS infections, such as prion disease, encephalomyelitis and pneumococcal 
meningitis (PM), has emerged recently (Bellac et al., 2007; Coimbra et al., 2006; 
Mok et al., 2007; Reichert & Rotshenker, 1999). Recently, Galectin-3 has been 
shown to bind N. meningitidis and this interaction has been shown to require an 
intact LOS (Quattroni et al., 2012). Although Quattroni et al (2012) study has 
shown that the presence of lactose leads to the inhibition of Gal-3 binding, some 
remaining binding was also observed; thus, the fact that other meningococcal 
ligand(s) also imply in bacterial binding with Gal-3 cannot be excluded. The aim 
of this study was to determine the non-LOS meningococcal surface molecules that 
mediate bacterial binding with Gal-3, using a lactose liganded form of Gal-3.  
In the current study, the binding of the lactose liganded Gal-3 with N. 
meningitidis was demonstrated and the majority of this binding was largely 
attributed to the N-terminal domain of Galectin-3. Some binding was also 
exhibited by the CRD of Gal-3, but was markedly less than the N-terminal 
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domain. Notably, several meningococcal clinical isolates were able to bind Gal-3 
in differential binding densities, regardless of their serogroups and geographical 
distribution. Quattroni et al. (2012) undertook an immunohistochemical analysis 
of tissue from patients with meningococcal infection and this revealed the 
colocalisation of meningococci with Gal-3. The observed in-vivo colocalisation 
suggests the binding of Gal-3 with N. meningitidis which was further confirmed 
by in-vitro binding assay, using flow cytometry and fixed-label meningococci 
(Quattroni et al., 2012). A comparison of the full molecule of the Gal-3 and its 
CRD demonstrated that the Gal-3 full molecule is required for meningococcal 
binding (Quattroni et al., 2012). Despite the use of lactose liganded Gal-3 in the 
current study, the findings of our research are in accordance with the findings of 
Quattroni & Li et al (2012) study. However, the observed binding of Gal-3 CRD 
to meningococci in the current study was more apparent in our study than in 
Quattroni et al study.  
Quattroni et al. (2012) demonstrated that the binding of meningococci with Gal3 
can be inhibited by very high doses of lactose (100mM). In addition, deletion 
mutants lacking various LOS-related glycosyltransferase genes (IgtA, IgtB, Isi1, 
icsB and galE) significantly reduce meningococcal ability to bind Gal3 (Quattroni 
et al., 2012). Thus, Quattroni et al (2012) concluded that the binding of 
meningococci with Galectin-3 is dependent on intact LOS. In the current study, 
the non inhibitable binding of meningococci with Gal-3 in the presence of 
increasing concentrations of lactose, up to 150mM, was observed: this was due to 
the fact that the Gal-3 used in the current study is lactose liganded. Such a result 
does not neglect the involvement of meningococcal LOS in Gal-3 binding, as the 
lactose-liganding did not necessarily block all LOS-carbohydrate binding sites on 
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Gal3. Because meningococcal LOS has extended lactose (e.g. LacNAc), which 
have five times a higher affinity for Gal3 than lactose (Agrwal et al., 1993; Sato 
& Hughes, 1992; Seetharaman et al., 1998). In addition, conformational changes 
in Gal3 after the initial interaction can potentially increase affinity, possibly via 
the involvement of the N-terminal domain of Gal3 and its CDR (Agrwal et al., 
1993). This was verified by the very low but nevertheless significant Gal3 binding 
exhibited in this study by the lgtf mutant, which produces a truncated LOS 
molecule lacking chain containing LacNAc moiety.  
Galectin-3 is widely distributed in various cellular compartments (nuclei, 
cytoplasm, cell surface and extracellular) and thus bacteria can take advantage of 
this molecule through the engagement of different bacterial ligands at various 
stages of infection. For example, bacterial surface adhesins may use cell surface 
Gal-3 to adhere or invade and other secreted bacterial proteins may utilise 
intracellular Gal-3 (for example, in their nuclear shuttling) and extracellular Gal-
3, in order to activate the innate immune system. Thus, despite the reported 
involvement of LOS in the interaction of Gal-3 with meninigococci, the 
contribution of other non-LOS meningococcal ligands cannot be ruled out.  
In the current study, a retagging approach was used, in order to identify non-LOS 
meningococcal-Gal-3 ligands. Two bacterial ligands were identified: the secretin 
PilQ and its associated pilin molecule PilE. The contribution of these adhesins to 
the recognition of the meningococci by Gal-3 was confirmed via observed 
significant reduction in the binding of corresponding mutants to Gal-3.   
PilQ is a conserved secretin that is fundamental for pilus extrusion and is naturally 
expressed at very high levels (Martin et al., 1993). It is interesting to note that PilQ 
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is already identified as an adhesin for 37 LRP/67 LR (Orihuela et al., 2009). In 
previous studies, it has been suggested that PilQ could be a potential vaccine 
candidate (D. Halliwell, 2004; Jan T. Poolman, 2006); indeed, a recent study 
demonstrated that the sera from mice, when immunised with a purified rPilQ 
fragment (406-770), was strongly bactericidal against N. meningitidis serogroups 
A and B (Haghi et al., 2012). PilQ is not glycosylated; thus, its binding with Gal-
3 appears to be mediated through a protein-protein interaction. This binding 
pattern is consistent with the carbohydrate independent binding of another lectin 
(namely, mannose binding lectin (MBL)) with non-glycosylated meningococcal 
outer membrane proteins Opa and PorB (Estabrook et al., 2004). The 
identification of PilQ as an adhesin for Gal-3 represents the second non-LOS 
bacterial ligand, after P. mirabilis fimbriae (Altman et al., 2001).  
PilE is the major subunit that forms the shaft of the pilus fiber (Craig et al., 2006), 
a hair-like structure that is extruded to the external surface via the PilQ (Martin et 
al., 1993). The fiber rapidly extends for several micrometres from the bacterial 
surface, in order to initiate contact with the host cells, before retracting (twitching 
motility). The pilus has long been considered a primary adhesion factor (Pelicic, 
2008; Pujol et al., 1997; Virji et al., 1991) and plays a major role in maintaining 
adherence to endothelial cells under high-flow conditions (Mikaty et al., 2009). 
This and the twitching motility are thought to help the organism crawl until it 
comes into intimate contact with the host cells, where other bacterial surface 
adhesins and their corresponding receptors interact. Furthermore, anti-(PilE) pilin 
antibodies have been detected in patients infected with N. meningitidis confirming 
the immunogenicity of PilE (Poolman et al., 1983). However, the high level of 
antigenic variability detected between PilE proteins hinders the development of a 
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pilus-based vaccine (Svanborg Eden et al., 1983). Interestingly, a recent study 
found that the major pilin genes are highly conserved within N. meningitidis 
disease isolates, representing ST-8 and ST-11 clonal complexes (Cehovin et al., 
2010), suggesting the reconsideration of pilus as a vaccine candidate.  
The adhesin properties of pilus are believed to be mediated by the PilC protein at 
its tip and the numerous post-translational modifications, including O-
glycosylation, at its shaft (PilE subunits) (Banerjee & Ghosh, 2003). Identified 
types of O-linked glycans in N. meningitidis include Gal-ȕ-Gal-Į-DATDH 
(DATDH represents 2, 4-diacetamido-2, 4, 6-trideoxyhexose) (Stimson et al., 
1995), Gal-ȕ -Gal-Į -GATDH (GATDH represents 2-glyceramido-4-
acetamido-2, 4, 6-trideoxyhexose) (Chamot-Rooke et al., 2007).  Gal-Į
3GlcNAc is also present in the N. meningitidis strain 8013SB (Marceau et al., 
1998). These glycans are synthesised in the cytoplasm by the sequential action of 
pglD, pglC and PglB (for DATDH) or PglB2 (for GATDH), then flipped into the 
periplasmic space by pglF flippase and block transferred onto Ser63 of PilE by 
the pilin glycosylation ligase PglL (Power et al., 2006). In the current study, the 
mutagenesis of pglL, pglC and pglLC radically reduced the binding of 
meningococci to Gal3, indicating that the glycosylation of PilE has a clear role in 
this binding.  
The involvement of PilE O-glycan in the interaction of Gal-3 with meningococci 
may justify the observed binding of the CRD. A question that must be raised is 
why, in Quattroni et als¶ (2012) study, was the binding of CRD with 
meningococci markedly less than in our study? This may have been due to the 
fact that we used a lactose-bound form of the CRD, which might have changed 
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the conformation of the molecule and increased its binding affinity. This 
explanation is supported by a previous NMR study on liganded Gal-3, which 
showed that the carbohydrate binding site was found to be more open in the 
bound state (Umemoto et al., 2003). Given the fact that the CRD of Gal-3 has an 
extended carbohydrate site, which enables it to accommodate complex glycan 
binding (Seetharaman et al., 1998), it is possible that the extended spectrum of the 
CRD also enables the accommodation of the binding of PilE O-glycans. However, 
it should be noted that, in addition to the CRD of Gal-3, the N-terminal domain is 
also implicated in the various interactions of Gal-3 with glycans. A mutagenesis 
analysis of Gal-3 supported the contribution of Tyr102 and some adjacent 
residues in carbohydrate binding (Barboni et al., 2000). In addition, the 
multimerisation of the N-terminal, in terms of the interaction of the CRD and the 
glycoconjugate, led to the formation of Gal-3 pentamers, facilitating increasingly 
diverse interactions with several glycoconjugated ligands (referred to as positive 
co-operativity). This was best exemplified in the demonstrated inhibition of H. 
pylori 26695 LPS binding to gastric epithelial cells (by antibodies) against the N-
terminal part of Gal-3 (Fowler et al., 2006). Thus, it could be that both the CRD 
and the N-terminal domain of Gal-3 participate in the interaction of Gal-3 with 
glycosylated pilin.  
Current observations of Gal-3 binding to the glycosylated meningococcal 
molecule (PilE)  in addition to LOS (Quattroni et al., 2012) will assist future 
studies (as the majority of studies regarding the bacterial interactions of Gal-3- 
have focused particularly (and, in some instances, solely) on LPS). In this context, 
a member of other host lectins, such as the C-type lectin receptor (MGL), was 
shown to bind distinct LOS glycoforms and the N-linked glycoproteins of 
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Campylobacter jejuni (van Sorge et al., 2009). This corroborates our findings, 
suggesting the potential ability of host lectins (including Galectin-3) to recognize 
multiple glycosylated ligands within the same pathogen. It should be noted that 
the pgl genes encode an N-linked protein glycosylation system share features with 
lipopolysaccharide (LPS) O-antigen biosynthesis (Alaimo et al., 2006; van Sorge 
et al., 2009). While in meningococci, the Pgl enzymes are not involved in 
meningococcal LOS biosynthesis and their mutation has no effect on the structure 
or function of the LOS (Power et al., 2000; Power et al., 2006). It is noteworthy 
that neisserial pglL (O-Otase) contains a Wzy_C motif, which is conserved in all 
O-OTases, but it is also found in WaaL ligases, which catalyze the transfer of the 
O antigen to the lipid A core of bacterial LPS. However, the meningococci 
bacteria produces LOS rather than LPS, as it lacks O-antigen repeat and therefore 
excludes the involvement of pglL in the biosynthesis of LOS (Preston et al., 
1996). This provides more specificity to the observed reduction in the binding of 
Gal-3 with pglL, pglC and pglLC mutants, to be attributed only to O-glycans 
decorating PilE. Interestingly, a careful examination of the mutants used in 
4XDWWURQLHWDOV¶ VWXG\UHYHDOHGWKDWRQHRI/26PXWDQWVGHPRQVWUDWHGD
marked reduction in Gal-3 binding (the galE mutant, which expressed galactose-
deficient LOS (Robertson et al., 1993) and galactose deficient PilE glycan) 
(Stimson et al., 1995). This further confirms the contribution of glycosylated PilE, 
in terms of the binding of Gal-3 with meningococci.   
The glycosylation of pilin is suggested to be one of  the bacterial virulence factors 
that may aid the development of the P. aureginosa infection (Smedley et al., 
2005). As a mutation of the pilO gene analogue of the N. meningitidis pglL gene, 
this leads to a reduction in bacterial twitching motility and decreases the survival 
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of the bacteria in the environment of the lungs (Smedley et al., 2005). It has also 
been observed that strains of  P. aeruginosa producing glycosylated pilin were 
commonly found amongst clinical isolates, particularly those isolated from 
sputum, revealing the involvement of pilin glycans in the pathogenesis of P. 
aeruginosa (Smedley et al., 2005). In terms of Niesseria meningitidis, it has been 
suggested that pilin glycosylation influences bacterial cellular adhesion (Stimson 
et al., 1995; Virji et al., 1993b): such an influence might be mediated in part 
through meningococcal glycosylated pilin interacting with Galectin-3. It would be 
interesting if future studies could examine the effect of pglL, pglC and pglLC 
mutations on bacterial adhesion and the invasion of host cells in-vivo, as pilin 
glycosylation in the closely-related bacteria N. gonorrhoeae has recently been 
shown to imply bacterial invasion into host cells (Jennings et al.). A further post-
translational modification of meningococcal pilin, phosphoglycerol at serine 93, 
was recently shown to enable bacterial migration across host cells and 
dissemination to other hosts (Chamot-Rooke et al., 2011). It thus appears that 
various post-translational modifications of PilE contribute to meningococcal 
pathogenesis, in various aspects.   
For the first time, the current study provides evidence for the existence of 67 LR 
as a homo- and hetero dimer with Gal-3. The dimerization of 37 LRP with itself 
and with Gal3 to form 67 LR homo and heterodimer respectively has long been 
suggested (Buto et al., 1998; Castronovo, 1993; Landowski et al., 1995). 
However, the majority of these studies used biochemical approaches, which 
require detergent cell lysis and thus affect native receptor-receptor interaction. To 
avoid this disadvantage, the BiFC approach has been used in this study, in order 
to enable the direct visualisation of receptor interactions non-invasively 
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(Kerppola, 2008). The expression pattern of the 67 LR homo- and hetro- dimers 
formed by the complementation of the 37 LRP and Gal-3 fused to BiFC 
fragments clearly reflects the punctuate staining of endogenous 67 LR and Gal-3 
in HBMECs respectively. It should be noted that the endogenous staining of Gal-
3 in the HBMECs also showed some diffuse staining. The punctate staining of the 
endogenous 67 LR in HBMECs was revealed by two antibodies; namely, the 
Mluc5 and Ab711 antibodies. The Mluc5 antibody is anti-mouse and thus we 
could not use it, with regards to the dual fluorescence staining and the Gal-3 
antibodies (mab4033 and Mac-2) that arose in mice and rats respectively, due to 
the observed cross-reactivity. Instead, the Ab711 antibody, which is anti-rabbit, 
was co-stained with anti-Gal-3 (mab4033), revealing the marked extent of 
colocalization. Also in the current study, the dual immunofluorescence staining of 
67 LR and its precursor was performed, using the Mluc5 and InHLRP antibodies 
respectively. Colocalization between the punctate staining of 67 LR and the 
diffuse staining of its precursor was noted in the specific cellular compartment 
only: whether Ab711 and Mluc5 antibodies detect the heterodimer form of 67 LR, 
in addition to the homodimer, is not clear. Indeed, the BiFC signals of the dimers 
of both receptors demonstrated a punctate pattern and each form of receptor dimer 
appeared to have a distinct cellular distribution. In order to clearly distinguish the 
cellular distribution of the populations of each receptor, it would be useful if the 
multi-colour BiFC approach was considered in future investigations. In contrast to 
the punctate pattern, the receptor¶s homo- and hetero- dimer BiFC complexes 
were expressed in a diffuse pattern in COS7 and N2a cells, which represented the 
endogenous staining of 37 LRP and Gal-3. Unlike HBMECs, immunoFluorscence 
staining using the anti-67 LR antibodies revealed the existence of such a pattern 
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in the astrocytes, but not in the COS7 and N2a cells. This might be due to the fact 
that these cells are not maintained in substrate (fibronectin) like HBMECs and the 
67 LR expression was down-regulated in a plastic tissue-culture flask.  
Recently, a unique interaction between dectin-1(a C-type lectin) and Gal-3 has 
been shown to function in the proinflammatory response of macrophages to 
pathogenic fungi (Esteban et al., 2011). Dectin-1 recognises the ȕ-glucan of the 
fungal cell wall of most fungi, while Gal-3 binds to the ȕ-1,2 oligomannans from 
the cell wall of certain fungi. In RAW 264.7 macrophages, which express Gal-3 
but express little dectin-1, there was no induction of TNF-¢  after fungal 
exposure. When the expression of dectin-1 is increased, RAW 264.7 macrophages 
show a significant TNF-Į UHVSRQVH, upon exposure to both pathogenic and non 
pathogenic fungi (Esteban et al., 2011): this indicates that the presence of dectin-1 
is required for TNF-Į LQGXFWLRQ :KHQ WKH OHYHOV RI *DO-3 are reduced by 
silencing, the RAW 264.7 macrophage fails to generate the dectin-1-driven TNF-
Į UHVSRQVH DIWHU H[SRVXUH WR the pathogenic fungi C. albicans. In contrast, the 
TNF-ĮUHVSRQVHZDVQRWDIIHFWHG, in terms of the RAW 264.7 macrophage being 
challenged with the non-pathogenic fungi S. cerevisiae after Gal-3 silencing 
(Esteban et al., 2011). Thus, the Gal-3 acts in concert with dectin-1, in order to 
modulate the TNF-ĮUHVSRQVHRI the macrophage, in terms of the recognition of 
pathogenic fungi (Esteban et al., 2011). Moreover, the association of Gal-3 with 
TLR2 displays a similar role and modulates the TLR2-driven inflammatory 
response (Jouault et al., 2006). In this regard, the current findings, in terms of the 
heterodimerization between 37 LRP/67 LR and Gal-3, are strongly supported by 
the binding of PilQ for both. Thus, 37 LRP/67 LR and Gal3 may closely 
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collaborate in binding to a common target molecule or, conversely, the 
meningococcus has evolved to exploit both molecules,  adding affinity to the cell-
cell adhesion, facilitating host cell invasion and/or triggering downstream host-
cell signalling. In this context, the engagement of the PilQ-associated pilin 
molecule, PilE, adds another interesting and more dynamic molecule to the 
adhesion-receptor complex.  
Taking into consideration the notion that 37 LRP/67 LR and Gal3 are broadly 
distributed in different cellular compartments, their collaborative interaction 
against the meningococcus or its ligands may not end at interactions with the cell 
surface (Dumic et al., 2006; Nelson et al., 2008). The two molecules play a joint 
role in tissue-specific adhesion and in the signalling, internalisation and 
modulation of host cell responses. 37 LRP/67 LR and Gal3 are both over-
expressed in various cancer cells and Gal3 is a regulator of a broad range of 
cancer cell growths, transformations, apoptosis, angiogenesis, adhesions, 
invasions and metastases  (Nelson et al., 2008; Newlaczyl & Yu, 2011).   
In this study, further investigation of Gal-3 and 37 LRP dimer formation revealed 
that, like the murine Gal3 cys186 (Woo et al., 1991), the only cysteine residue 
present in human Gal3 (cys173) is critical for both homo- and hetero-
dimerization, whereas neither of the two cystienes on 37LR (cys148 and cys163) 
are required for dimerization. The impact of the mutation of Gal3 (cys173) on the 
dimerization of Gal-3 with 37LRP/ 67 LR might be of consequence, in terms of 
the role of this dimer in normal physiological and pathological conditions. Such 
consequences were not addressed in the current study and it would be interesting 
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if future studies considered these. In Woo HWDOV¶ (1991) study, the substitution of 
Gal-3 (cys173) did not affect the binding of the receptor with laminin.  
It is well-recognised that 37 LRP/67 LR is subjected to acylation (mainly 
palmitoylation), which commonly occurs in cysteine residues, in being delivered 
to the cell surface (Buto et al., 1998; Landowski et al., 1995). In the current study, 
the mutations of the previously-mentioned cystiene residues of 37LR (cys148 and 
cys163) do not affect receptor targeting to the cell surface and this was revealed 
through two findings: the distribution of cysteine-substituted receptors was 
comparable to the wild-type receptor in the membrane fractions of transfected 
COS7 cells and the punctate expression of cysteine-substituted receptors was 
comparable to the wild type receptors in transfected HBMECs. Given the fact that 
palmitoylation is a reversible process, it is possible that the experimental setting 
used in the current study does not provide an adequate time frame, in terms of 
detecting any differences between the cysteine-substituted and wild-type 
receptors. As mentioned above, further examination of the role of 37LR (cys148 
and cys163) in the homo- or hetero- dimerization of 67 LR, using BiFC, revealed 
that these cysteine residues are not involved in the dimerization of receptors. In 
agreement with our findings, research conducted by Fujimura et al. (2012) found 
that the amount of 67 LR was not affected by the presence or absence of the 
reducing agent. All these results collectively confirm that a Cys residue-mediated 
disulfide bond is not involved in the formation of the cell-membrane 67LR, 
although it is possible that these two cysteines are involved in protein 
stabilisation. With regards to the acylation of 67 LR, it appears that other amino 
acid residues are involved in the acylation of 37 LRP/ 67 LR. It is interesting to 
note that Buto et al. (1998) observed an inhibition or decrease in the formation of 
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67 LR by the fatty acid synthetase inhibitor, cerulenin. Thus, future study is 
essential, in terms of clarifying the role of acylation in the dimerization of 67 LR, 
through investigating the effects of cerulenin on the complementation of receptors 
fused to BiFC fragments.  
In Quattroni et al (2012) study has showed that the exogenously added Gal-3 
increases meningococcal adhesion to monocyte and THP-1 cells without any 
effect on bacterial internalisation. They also established that the full-length LOS 
is required for such an increase in bacterial adhesion, as the adhesion of the LOS 
mutants to these cells was not affected by the exogenously-added Gal-3 
(Quattroni et al., 2012). However, the perincubation of meningococci with Gal-3 
did not affect their association with epithelial cells (Quattroni et al., 2012). The 
focus of Quattroni et alV¶ (2012) study was the effects of exogenous Gal-3 on 
bacterial adhesion, as the secretion of Gal-3 is known to be stimulated in response 
to bacterial infection. However, a particular interest of the current study was to 
examine the contribution of the cell surface Gal-3, rather than the secreted form, 
in terms of meningococcal adhesion and invasion. In order to achieve this, N2a 
cells were chosen, due to their lack of endogenous Gal-3 expression (Gauczynski 
et al., 2001). N2a cells were transfected with Gal-3 containing plasmid and the 
surface localisation of Gal-3 in transfected cells was confirmed  
immunofluorescence staining. Interestingly, the transient expression of Gal-3 
significantly increased the invasion of MC58, but not adhesion to N2a cells: this 
finding suggests that N. meningitidis may use Gal-3 as a mechanism of host 
invasion. Such promotion of meningococcal invasion, mediated by Gal-3, 
strongly suggests that Gal-3 may enhance meningococcal infection. Several 
studies have suggested that Galectin-3-pathogen interactions may enhance 
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infection by mediating microbial cellular adhesion. In this context, Galectin-3 
may facilitate H. pylori infection, through allowing bacterial adhesion to the 
gastric epithelium (Cerliani et al., 2011; Fowler et al., 2006). Other galectins, 
such as Gal-1, increase HIV infectivity by promoting viral adhesion (Mercier et 
al., 2008; St-Pierre et al., 2011). Gal-1 also enhances the adhesion of trichomonas 
vaginalis to the cervical epithelium (Okumura et al., 2008). How Gal-3 
contributes to N. meninigitidis invasion and the underlying mechanism is not yet 
clear and it would be both beneficial and interesting to investigate this in future 
studies. 
Meningococci T4P initiates bacterial adhesion to host cells, using an as yet 
unknown receptor, followed by the activation and recruitment of different host 
receptors and bacterial adhesins and invasins mediating cell signaling events: this 
leads to the formation of cortical plaque and subsequent bacterial entry. Although 
pilus-mediated signalling results in the formation of apparently similar cortical 
plaque in epithelial and endothelial cells, the signalling pathways are strikingly 
different in both models (Lecuyer et al., 2012). For example, it has been found 
that the recruitment of tight junctional proteins in response to N. meningitidis 
T4p-mediated adhesion is restricted to endothelial cells, but not epithelial cells 
(Lecuyer et al., 2012). In other instance, unlike brain endothelial cells, 
meningococcal adhesion to epithelial cells did not recruit or activate WKH ȕ-
DGUHQHUJLF UHFHSWRUȕ-arrestin pathway. Considering the discrepancies of T4p-
mediated signalling in epithelial and endothelial cells, the observed finding of the 
Gal-3-mediated enhanced invasion of meningococci into N2a cells may be more 
significant in relevant cells (endothelial or epithelial cells) and Gal-3 may also 
contribute to bacterial adhesion. Although Quattroni et al (2012) study did not 
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report any significant role of exogenously-added Gal-3, in terms of 
meningococcal adhesion to epithelial cells, the current study demonstrated a 
distinct punctuate expression of Gal-3 and both dimers of 67 LR on the apical 
surface of brain endothelial cells. This pattern suggests the localisation of 
receptors within membrane microdomains referred to as lipid rafts. Lipid rafts are 
discrete plasma membrane domains that contain high levels of cholesterol, 
gangliosides, glycosphingolipids, GPI anchored proteins and many acylated & 
palmitolyated proteins (Simons & Toomre, 2000). Accordingly, lipid rafts and 
their components act as a concentrating domain for cell signalling molecules 
(Anderson, 1998). Both Galectin-3 and 67 LR have been shown to be located in 
lipid rafts in various cell lines (Foster et al., 2003; Fujimura et al., 2005; Hsu et 
al., 2009; Osterhues et al., 2006). In this context, meningococcal minor pilin PilV 
has been shown to induce the recruitment of cholesterol, in the formation of 
cortical plaques. These lipid rafts enable N. meninigitidis to induce the action of 
polymerisation, in order to form projections at the apical aspect of cells that 
protect bacteria from shear stress (Mikaty et al., 2009; Trivedi et al., 2011). The 
depletion of the concentration of cholesterol in the plasma membrane by MßCD 
(methyl-ß-cyclodextrin), which inhibits the formation of lipid rafts, decreases the 
recruitment of those cellular components of the cortical plaque under the bacterial 
microcolonies and renders meningococcal microcolonies sensitive to shear stress 
(Mikaty et al., 2009). It is thus possible that both Gal-3 and 67 LR (either homo- 
or hetero- dimers) are located in the lipid raft domain and such localisation may 
have an impact, in terms of meningococcal infection. An investigation of this 
possibility would make interesting future research. 
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One of the most intriguing findings of this study was the upregulation of the Gal-
3 and 37 LRP expressions, in response to meningococcal infection in the brains of 
CD46-expressing mice. Increased expression of Gal-3 was also observed in the 
spleen tissue of mice challenged with N. meningitidis and in the spleen tissue of 
patients infected with meningococcal meningitis (Quattroni et al., 2012). In terms 
of pneumococcal meningitis, the expression of Gal-3 was shown to be 
upregulated in the brain of infected rats (Bellac et al., 2007). In addition, the 
expression of 67 LR was increased in the lungs and brains of mice infected with 
pneumococcal meningitis (Orihuela et al., 2009). In vitro, it has been suggested 
that the upregulation of 67 LR increases bacterial adhesion (Orihuela et al., 2009). 
All these findings corroborate the demonstrated increased expression of Gal-3 and 
37 LRP in meningococcal- infected mice in the current study. Whether this 
increase in receptor expression promotes meningococcal infection or not is 
unclear and cannot be concluded from the current findings. In regards to this, Gal-
3 deficient mice have been found to have significantly lower levels of 
bacteraemia after exposure to N.meningitidis, when compared to wild-type mice, 
(Quattroni et al., 2012). This indicates that Gal-3 promotes bacteraemic 
meningococcal disease and various conclusions have been suggested, in order to 
explain this effect (Quattroni et al., 2012). For example, the observed increased 
association of Gal-3 to macrophages and monocytes in-vitro could lead to 
enhanced meningococcal survival by allowing an escape from phagocytosis, 
promoting bacterial dissemination or affecting the activity of phagocytes 
(Quattroni et al., 2012). Other studies have highlighted the increased expression 
of Gal-3 in response to infection and the fact that this is due to its role in 
neuroinflammation and its anti-apoptotic activity (Bellac et al., 2007). It will be 
  
263 
 
useful to investigate the level of bacteremia, survival and Gal-3 expression in the 
brains of Ga-3 deficient mice, after challenging with pilE, pilQ and pglLC 
meningococcal mutants, and compare the results with those of wild-type mice. 
Such an experiment will be useful in clarifying the contribution of the binding of 
Gal-3 with non-LOS meningococcal ligands, in terms of meningococcal 
pathogenesis.  
The current study showed the ability of the purified proteins corresponding to 
meningococcal 37 LRP/67 LR ligands (rPorA, loop 4 of PorA and rPilQ) in 
recruiting 67 LR and Gal-3 to the surface of HBMECs. Interestingly, among these 
proteins, rPorA produced the most prominent effect on the surface level of both 
receptors. PorA is a known ligand for 37 LRP/67 LR, but not for Gal-3; it thus 
appears that such recruitment of Gal-3 to cell surfaces, in response to rPorA, is 
mediated through 37 LRP/67 LR dimers with Gal-3. Although rPorA and its loop 
4 bound Gal-3 in ELISA, meningococcal PorA mutant bound Gal-3 in 
comparable level to wild type bacteria. In addition, the retagging approach did not 
identify PorA as potential ligands. Despite this, the possibility that Gal-3, in its 67 
LR heterodimer form, interacts directly with meningococcal PilE and PilQ and 
indirectly with PorA (due to the close association between Gal-3 and 37 LRP) 
cannot be excluded. PilQ also recruits Gal-3 to the cell surface to a greater extent 
than loop 4 of PorA: this was expected, as PilQ is one of the Gal-3-
meningococcal ligands. The use of recombinant PilE and other non-LOS 
meningococcal Gal-3-ligands was avoided in the current study and this was due to 
the fact that PilE is subjected to different posttranslational modifications; thus, 
when expressed in a foreign host (E. coli), it would inevitably lose its natural 
post-translational modification and the results may not be easily interpretable. In 
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the case of 67 LR, PorA and its loop 4 recruit 67 LR to the cell surface more than 
PilQ. It was of interest that loop 4 of PorA appears to be essential in the binding 
of meningococcal PorA with 37 LRP/67 LR (Abouseada, 2009). Whether the 
inducible recruitment of bacterial proteins to a cell-surface 67 LR and Gal-3 
resulted from recycling or de novo synthesis of the receptor is not yet known. 
Kim et al (2005) study has demonstrated that the expression of 67 LR is 
upregulated in response to CNF1-expressing E. coli K1 in HBMECs (Kim et al., 
2005). In addition, the expression of 67 LR has been found to increase in the 
lungs and brains of mice infected with pneumococcal meningitis (Orihuela et al., 
2009). The current study also demonstrated the upregulation of the expression of 
37 LRP in the brains of mice infected with N. meningitidis. In these studies, the 
whole bacteria was used and receptor expression was studied through either 
immunofluorescence staining or western blot analysis, or both. Thus, the current 
study has evaluated the effects of various purified bacterial proteins (rPorA, loop 
4 of PorA and rPilQ), rather than whole bacteria, in the gene expression of 37 
LRP. In order to achieve this, HBMECs were treated with these proteins for 24 
hours and the 37 LRP gene expression was examined by qPCR. The qPCR data 
revealed increases in the 37 LRP gene expression in HBMECs treated with loop 4 
of PorA, rPilQ and, to a lesser extent, rPorA, when compared with PBS-treated 
cells. These results suggest that meningococcal porin (PorA) and secretin (PilQ) 
are considered the second bacterial ligands after E. coli K1 CNF (Kim et al., 
2005), which induces the expression of the 37 LRP gene on HBMECs. The 
capability of these proteins to induce receptor expression in-vitro may have an 
impact on future studies investigating cell-signalling pathways mediated by 
meningococcal interaction with 37 LRP/67 LR. Attempts were made to study the 
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expression of Gal-3 in response to meningococcal ligands, but time restrictions 
prevented the further optimisation of qPCR. It would be interesting if future 
studies considered the examination of the protein levels of receptors in cells 
challenged with these meningococcal proteins. 
The prevention of meningococcal interaction with Gal-3 as the host receptor may 
help in the prevention or treatment of meningococcal meningitis. The 
determination of the specific epitope that mediates meningococcal PilE and PilQ 
binding with Gal-3 will facilitate the synthesis of their corresponding peptides, 
which could be used to prevent receptor-ligand interaction. In addition, the 
mutation of amino acids residues within the predicted binding sites of PilQ and 
PilE provide yet another therapeutic strategy. Note that N. meningitidis PilE is 
subject to antigenic variation, while PilQ is highly conserved. 
One of the goals in the treatment of meningococcal disease is the prevention of 
the damage caused by the host inflammatory response (Somand & Meurer, 2009): 
the resulting inflammation from bacterial meningitis is responsible for significant 
negative outcomes, despite antimicrobial treatment (Somand & Meurer, 2009). 
Various clinical trials have been conducted, in order to investigate the use of anti-
inflammatory drugs such as steroids, particularly dexamethasone, in the treatment 
of bacterial meningitis. Most of the studies supported the use of dexamethasone, 
at least in adults. Indeed, reduction in hearing loss, neurological sequelae and 
mortality have been observed in patients treated with dexamethasone, as an 
adjunct to antibiotics (van de Beek et al., 2007). Other recent studies conducted in 
Sub-Saharan Africa, however, revealed that the administration of dexamethasone 
was not efficacious (Molyneux et al., 2002; Scarborough et al., 2007). These 
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studies were conducted in areas where there was a high prevalence of HIV and 
thus it is not clear yet if these studies also apply to developed nations (Somand & 
Meurer, 2009). In adults, it is recommended that dexamethasone is administered 
before or concurrent with an initial dose of antibiotics and is continued every 6 
hours for 4 days (Fitch & van de Beek, 2007; Tunkel et al., 2004). Given the 
important role of Gal-3 in inflammation during infection, a recent study has found 
that the intranasal delivery of a plasmid encoding Gal-3 inhibited chronic airway 
inflammation and remodelling in the murine model of ovalbumin (OVA)-induced 
asthma (Lopez et al., 2006). It was also demonstrated how the peribronchial 
inflammatory cells and bronchoalveolar lavage fluid from OVA-challenged mice 
expressed significantly higher levels of Gal-3 than control mice (Zuberi et al., 
2004): these results may indicate differences in the effects of endogenous versus 
exogenously delivered Gal-3 (Henderson & Sethi, 2009). In term of 
meningococcal disease, the intranasal administration of Gal-3 may be used as an 
adjuvant therapy with antibiotic treatment, in order to provide relief from 
inflammation and improve treatment outcomes.  
In conclusion, Gal3 plays an obvious role in the meningococcal-host cell 
interaction; however, such interaction is complex and requires careful 
investigation.  In response to bacterial invasion, the host cell expresses Gal3, 
possibly to limit bacterial adhesion (secreted Gal3), suppress self-damaging, 
exaggerated inflammatory responses or even to induce host-cell apoptosis.  
Conversely, the organism may induce the over-expression of Gal3, in order to 
exploit it for the purpose of enhanced adhesion and invasion and to suppress 
detrimental pro-inflammatory responses and prolong its own survival. Either way, 
a better understanding of this interaction will help in the design of novel 
  
267 
 
preventative and/or therapeutic strategies in the battle against invasive 
meningococcal disease.   
7.2. Future direction 
Although this study has identified that PilE and PilQ as non-LOS meningococcal 
Gal-3 ligands, future experiments should be performed to show their relevance in 
vivo. A potentially useful approach may be to compare Gal-3 expression in CD46 
H[SUHVVLQJPLFHLQIHFWHGZLWKǻPilQ ǻPilEDQGǻPglLC with those infected with 
wild type meningococci. Survival and level of bacteremia in those infected mice 
can be also investigated in future study. Future work should also aim to clarify the 
mechanism(s) of Gal-3 contribution in meningococcal invasion. This could be 
investigated by Gal-3 silencing in relevant cell line such as HBMECs, followed 
by subsequent investigation of meningococcal capacity to adhere or invade these 
cells. Importantly, future studies should also aim to investigate the relevant of the 
Gal-3 and 37 LRP dimerization in normal physiological and pathological 
conditions such as, meningococcal meningitis by using silencing strategy.
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Appendix B. Formula of commonly used buffers and solutions 
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Sodium dodecyl sulfate (SDS)-resolving buffer; (18.18 g Tris base, 2 ml 20% SDS, 
100 µl 10% NaN3) add deionised water (dH2O) up to 100 ml, pH at 8.8. 
SDS-stacking buffer; (6.06 g Tris base, 2 ml 20% SDS, 100 µl 10% NaN3) add 
dH2O up to 100 ml, pH at 6.8. 
SDS running buffer (10 x); (30.3 g Tris base, 144 g Glycine, 1 ml 10% NaN3, 10 g 
SDS (1%), made up to 1000 ml with dH2O, mix well. 
SDS-sample buffer (5 x); 0.62 M Tris-Cl (pH 6.8), 5% SDS, 25% glycerol, 12.5% 
meracaptoethanol, 0.002% Bromophenol blue, or 7.8125 ml (2 M) Tris-Cl, 1.25 g 
6'6POJO\FHUROPOȕ-meracaptoethanol, tip of pipette Bromophenol 
blue, made up to 25 ml with dH2O. 
SDS-sample buffer (1 x); 2.72 g Tris, 25 ml of 20% SDS, 50% glycerol, 12.5% 
meracaptoethanol, 0.002% Bromophenol blue and add dH2O up to 100 ml, pH at 
6.8. 
SDS-sample buffer (2 x); 100mM Tris HCL PH 6.8, 2% SDS, 10% glycerol, 10% 
DTT, 0.10% Bromophenol blue and add dH2O up to 10 ml, pH at 6.8. 
Resolving (separating) gel; 2.5 ml SDS-resolving buffer, 2.52 ml Acrylamide/Bis-
$FU\ODPLGHPOG+2ȝO6DWXUDWHG$PPRQLXPSHUVXOIDWH$36DQG
ȝO7HWUDPHWK\OHWK\OHQHGLDPLQH7(0('. 
Stacking gel; 1.25 ml SDS-stacking buffer, 0.75 ml Acrylamide/Bis-Acrylamide (30%), 
3 ml dH2O, 8 ȝO$36DQG1ȝO7(0(' 
Semi-dry blotting buffer; 5.82 g Tris base, 2.93 g Glycine, 3.75ml 10% SDS, 200 ml 
methanol and make up to 1000 ml with dH2O. 
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Phosphate buffered saline solution (PBS); prepared by dissolving 1 tablet of Phosphate 
buffered saline (Dulbaco A, Oxoid) in 100 ml dH2O and autoclave, this gives sodium 
chloride 0.16 mol, potassium chloride 0.003 mol, disodium hydrogen phosphate 0.008 
mol and potassium dihydrogen phosphate 0.001 mol with a pH value of 7.3. 
BSA; (Albumin from bovine serum, Sigma A3912) as lyophilized powder (M W ca. 66 
kDa) was prepared in sterile PBS according to the concentration needed. 
Buffers for protein purification; 28.2 g Urea, 0.83 g NaH2PO4, 0.07 g Tris base, 60 ml 
dH2O, mix, adjusts the pH, buffer B at pH 8.0, buffer C at pH 6.3 and buffer E at pH 4.3. 
LB (Luria-Bertani) broth; Tryptone 10 g, Yeast extract 5 g and Sodium chloride 10 g 
for 1000 ml dH2O. 
LB (Luria-Bertani) agar; Tryptone 10 g, Yeast extract 5 g, Sodium chloride 10g, 
Microbial tested agar 15 g for 1000 ml of dH2O, pH 7.0 ± 0.2 at 25°C. 
IPTG (Isopropyl-ȕ-D thiogalactopyranoside); (FW 238.8) for 1 M solution, 0.23 g of 
IPTG dissolve in 1 ml dH2O, sterilize by filtration and store at -20ȗ. 
LB agar with Amp/IPTG/X-gal; LB agar at 50ȗȝJPO-$PSLFLOOLQȝJPO-1 
,37*DQGȝJPO-1 X-JDOPL[DQGSRXUP0,37*DQGȝJPO-1 X-gal). 
DNA loading dye (6x); 10 mM Tris-HCl (pH 7.6), 0.03% bromophenol blue, 0.03% 
xylene cyanol FF, 60% glycerol, 60 mM ethylenediamine tetraacetic acid (EDTA). 
TAE buffer (Tris-Acetate-EDTA buffer, 1x); 40 mM Tris base, 40 mM Acetic acid 
and 1 mM EDTA. 
TBS-T (Tris Buffered Saline-Tween, 1 x); 10mM Tris/HCl, pH 7.4, 75mM NaCl, 
0.05% Tween-20 (v/v) 
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Transformation Solution (TS); LB broth with 10% (wt/vol) PEG 8000 + 5% (vol/vol) 
DMSO  
+ 50 mM (MgCl2) at a final pH of 6.5. 
TAE buffer (50 × stock); 242 g Tris base (life technologies), 57.1 ml glacial 
acetic acid (Fisher chemicals) 100 ml 500 mM EDTA (pH 8.0) made up to 1 L 
with dH2O. 
Agarose gel; 1.0 % agarose was prepared by dissolving 1 g of agarose powder 
(sigma), 2ml 50 × TAE buffer and made up to 100 ml with dH2O; melt and add 5 
µl ethidium bromide (10 mg/ml). 
Antibiotics; Antibiotics were purchased from Sigma-Aldrich UK, prepared 
according to the PDQXIDFWXUHU¶V UHFRPPHQGDWLRQV VWHULOL]HG E\ ILOWUDWLRQ DQG
store at 4°C. 
Ampicillin (100 mg ml-1 stock solution prepared in dH2O) 
Kanamycin (50 mg ml-1 stock solution prepared in dH2O) 
Streptomycin (50 mg ml-1 stock solution prepared in dH2O) 
Erythromycin (100 mg ml-1 stock solution prepared in ethanol) 
 
